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Executive summary
The availability since 1990 of commercial assays to test for infection with the hepatitis C virus (HCV) enabled
investigation of its epidemiology to begin in earnest. Current serological assays do not distinguish between
incident and old infections, or whether infections acquired have resolved or remain to cause ongoing liver
damage. Measurement of markers in the serum does not necessarily reflect what is occurring in the liver.
Moreover, the costs associated with tests such as quantitative polymerase chain reaction (PCR), genotyping and
serotyping, in addition to the need to avoid repeated invasive liver biopsies, means that our knowledge at this
early stage of investigation of the epidemic is imperfect. This report of the epidemiology of HCV summarises the
state of knowledge to the end of 1998. The report is based upon extensive literature reviews of the world medical
literature and the compilation of a research register that identifies Australian studies completed or in progress
and the ideas which researchers and practitioners involved in HCV have identified as areas where information is
deficient.
The hepatitis C virus in Australia
Although there are Australian data on the prevalence and incidence of HCV in some specific populations,
including those at high risk of infection, there are no reliable data on its prevalence in the general population. It
has been estimated that there are already about 143,000 Australian residents currently chronically infected with
HCV, and that around 11,000 new infections are acquired each year among injecting drug users (IDUs). These
figures are based upon extrapolations of small surveys and make several assumptions. We have poor data about
participation in particular activities associated with transmission or about the average risk of transmission per
event.
Transmission of hepatitis C virus
Injecting drug use
The major group in which transmission of HCV is ongoing is IDUs. The strongest predictor of risk among IDUs
is duration of injecting: opiate as opposed to stimulant use has also been associated consistently with a higher
prevalence of infection. Other predictors such as association with prison history or with methadone maintenance
may reflect the extent (frequency, degree of control) of drug usage. Further efforts to increase the availability
and use of sterile injecting equipment and to promote basic hygiene among IDUs are necessary, especially in
situations of extreme risk such as prisons and IDUs among marginalised groups such as Aboriginal and
Vietnamese-speaking people.
Blood or blood products
A history of receiving blood products before the beginning of blood-donor screening is likely to account for a
substantial proportion of HCV-infected individuals who are not IDUs. This is particularly likely to have affected
regular recipients of fractionated plasma derivatives such as people with haemophilia who received Factor VIII
before heat treatment procedures were implemented. Transmission of HCV in blood products received in
Australia is now, and will continue to be, rare.x
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Tattooing and skin penetration
Tattooing and skin penetration procedures such as ear piercing and acupuncture could potentially transmit HCV,
in the same way as has been well documented to occur with the hepatitis B virus (HBV). Tattooing occurs with
greater frequency among those who inject drugs, and the disclosure of illicit injecting may be incomplete.
However, there are studies that demonstrate an increase in the prevalence of HCV among tattooed individuals
who deny ever having injected drugs. There is evidence from surveys of skin penetration premises in some States
in Australia that infection control in skin penetration and tattooing premises is substandard. Relevant education
in infection control of tattooists and skin penetration operators and those who oversee the registration of
premises is an identified need. National guidelines and standardised information would help reduce the
confusion and conflicting advice that skin penetration operators receive.
Health care settings
Transmission of HCV in health care settings has been identified as an important mode of transmission in some
countries other than Australia, including Japan. Well-documented outbreaks of nosocomial transmission have
occurred among patients with immunosuppressive conditions who have frequent venepuncture or access to veins.
The need for proper cleaning and sterilisation of all instruments entering sterile body sites is obvious and the
exhortation to health care workers (HCWs) to regularly and thoroughly wash their hands needs constant re-
emphasis.
The risk of occupational transmission of HCV to HCWs has been investigated through cross-sectional
prevalence studies, surveillance of HCWs following needlestick injury from positive source patients and in
cohorts of hospital staff negative for HCV antibody on enrolment. Such data suggest that the risk of transmission
of HCV through percutaneous injury is higher than for human immunodeficiency virus (HIV) but lower than for
HBV. Predictably, risk of acquiring HCV occupationally is related to frequency of blood contact, volume of
blood involved, prevalence of HCV in the patient population and probably the level of viraemia.
Sexual, household and vertical transmission
Increasingly, evidence suggests that the risk of HCV transmission through sexual contact or through ordinary
household contact is very low. Mother-to-child transmission is known to occur, risk increasing with level of
viraemia as measured by quantitative HCV-RNA PCR or with maternal coinfection with HIV. Unanswered
questions in relation to mother-to-child transmission include whether Caesarean section lowers the risk of
transmission, and the role of breast feeding in transmission, although in both cases any influence is likely to be
small.
Coinfection with HIV, stage of chronic liver disease (CLD) and level of viraemia may be important determinants
of the efficiency of transmission in all circumstances.
Natural history of hepatitis C virus infection
A major gap in our knowledge about HCV concerns the natural history of infection. Such knowledge is critical
to resource allocation and development of cost-effective strategies for prevention and treatment.xi
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Acute HCV infection is generally anicteric and relatively asymptomatic, making it difficult to determine when
infection occurred. Surrogate markers of potential for exposure (eg year of first injection or blood transfusion)
may be used, but are inevitably subject to error: personal risk factors may be unknown or denied. Of people
infected with HCV, most will fail to eliminate it, and estimates of those who develop chronic HCV infection vary
between 50 and 90 per cent. We lack information on the extent to which those who clear the virus can extinguish
their antibody response, and what proportion progressively clear the virus over time.
Follow-up of transfusion-associated cases of HCV infection indicate that the average time taken to develop
cirrhosis is about 20 years, but the time range over which liver disease develops is wide. Some reports describe
carriers of HCV RNA who have developed minimal liver damage or chronic persistent hepatitis (CPH) that has
not progressed over decades, prompting speculation about whether a healthy carrier state exists. More rapid
progression is also common, and histological assessment of liver biopsies suggests that among those with
persistent viraemia, few have livers that are histologically normal, even when serum alanine aminotransferase
(ALT) levels are normal. HCV disease is often slowly progressive and potentially results in severe liver disease,
but the features of the virus or host which mediate the effect are unknown. Much better information is needed
about which patients are prone to develop cirrhosis and which are likely to have an indolent course. Among the
factors that may influence or reflect the severity of disease are: the route by which infection was acquired, patient
age, viral genotype (including multiple infections,  viral load, coinfections (HIV, HBV), environmental cofactors
(alcohol, nutrition), duration of infection, and host immune factors.
Although there is some evidence that certain genotypes may be associated with a worse prognosis, clinical trials
suggest that those patients who are most likely to respond to interferon (IFN) are those who are less likely to
progress to advanced disease. Pooled information from randomised trials of IFN therapy demonstrate a complete
response rate (in terms of normalised ALT levels) to standard regimes (3 MU for 6 months) of about 50 per cent,
with a sustained response rate of 20 per cent. Preliminary evidence suggests that treatment with higher doses of
IFN or for longer duration may provide greater and more sustained response rates. Many patients experience side
effects from IFN treatment and are unable to tolerate treatment. Whether current therapies favourably alter the
natural history of chronic HCV infection to reduce morbidity and mortality is a critical and yet to be answered
question.
Our current understanding of the rate at which people can and do progress through the stages of HCV disease is
poor. HCV infection can progress through CLD and ultimately result in hepatocellular carcinoma (HCC). Given
that disease progression may be multifactorial, the extent to which viral hepatitis viruses contribute to the
development of CLD and HCC in Australia is unknown. In order to assess the importance of these chronic
hepatotrophic viruses, we need to obtain good baseline data on the prevalence of HCV in the cases of HCC and
ensure that such information continues to be collected. The incidence of HCC probably will increase in coming
decades as the effect of chronic infection in those infected as a result of IDU becomes evident.xiii
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Preface
It was not until 1988 that the HCV was first identified, although its existence had been suspected for some time.
Even before this identification, the role of a virus other than hepatitis A (HAV) or HBV in the causation of post
transfusion hepatitis and of long-term liver disease was clear. With the availability of assays for the presence of
viral genetic material and for antibody to the virus, investigation of the epidemiology of HCV could begin in
earnest.
Early studies confirmed that HCV was blood borne, showing high prevalences among recipients of blood and
blood products and among IDUs. Screening of blood donors for antibody to HCV decreased the rate of
posttransfusion viral hepatitis to negligible levels. However, increasing evidence of continuing transmission of
HCV among IDUs at high rates poses challenges for control of the epidemic, as IDUs make up the major core
group for HCV in western communities. As well, the natural history of chronic HCV infection remains ill-
defined, posing problems for development of sensible approaches to treatment and evaluation of the efficacy of
treatment approaches.
In this context it is difficult to formulate policy decisions about resource allocation or program development.
There is, therefore, a need to review both the current understanding of HCV epidemiology and current directions
of research into that epidemiology so that informed decisions can be made about the need and directions for
further research, and to enable appropriate and necessary policy and program decisions to be made. To this end,
this review was commissioned by the Commonwealth Department of Health and Family Services in November
1995. We present a review of the epidemiology of HCV.
Methods
Literature reviews were carried out to identify published articles relating to HCV and the particular topic of
interest through MEDLINE searches for the period from January 1990 through August 1996. Further reports
were identified from bibliographies of published articles, from reports of conference proceedings, and from
abstracts, reports and articles submitted by researchers as part of the review of current research into the
epidemiology of HCV in Australia. A further update was carried out in March 1999 to bring the literature review
up to the end of 1998.xiv
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1 Virology - consequences of
infection
The hepatitis C virus (HCV) is a single-stranded positive-sense RNA virus closely related to the Flaviviruses. Its
entire genome has been mapped and the structural proteins are derived from the 5′ end of the genome, and non-
structural proteins from the 3′ end.
1.1 Virus replication and interaction with host cellular processes
The HCV replication cycle begins with entry into cells, such as hepatocytes and leucocytes, possibly through
interaction with cells possessing Fc receptors (Branch 1996). With HCV, the rate of viral protein synthesis seems
to be partly regulated by positive and negative translational control elements in the 5' untranslated region of the
mRNA. Cellular and viral proteins may switch these RNA control elements on and off. Since HCV is a positive
sense RNA virus, encapsulated viral RNA has the correct anatomy to serve in three ways: as a messenger RNA
which is translated into viral proteins; as a replication intermediate that is copied into a negative strand; and as a
genomic RNA packaged into a virion. RNA signals may be used by HCV to apportion the positive strand
population, balancing the need for replication intermediates with the need for RNAs to be packaged into virions,
and therefore helping to regulate the rate of replication.
Anti-viral activities of the systemic immune system and anti-viral factors produced within the virus-infected cell
also strongly influence the rate of viral multiplication. The HCV replication complex has the potential to form
double-stranded RNA, a potent activator of intracellular anti-viral defence pathways and interferon (IFN). Branch
(1996) thus argues that through a combination of regulatory pathways built into the virus, intracellular anti-viral
responses and the actions of the immune system, HCV is suppressed following acute infection. Chronic HCV
infection results from the battle between anti-viral responses and HCV replication and mutation. Because of the
immune response, during chronic infection the levels of HCV RNAs and proteins in the liver are very low, almost
undetectable, although the liver is constantly bathed in blood containing HCV. However, HCV generally persists
despite the immune response, presumably despite a low rate of replication and perhaps reflecting the ability to
infect and perhaps disarm the immune system.
1.2 Immune response to hepatitis C virus infection
There is evidence from in vivo studies that at least some neutralising antibody responses occur, and that they are
highly strain specific, allowing other strains to emerge and perpetuate infection in the face of measurable
neutralisation. Thus, host responses are generally unable to contain the emergence of neutralisation-resistant
variants (Farci et al 1994). There is also evidence from chimpanzee models and multiply-transfused thalassaemia
patients that there is no protective response against either heterologous or homologous rechallenge (Farci et al
1992; Lai et al 1994).2
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1.3 Effects of genetic diversity of the hepatitis C virus
Considerable genetic variation exists in different isolates of HCV. This appears to be the result of frequent
mutation during the somewhat imprecise replication process typical of RNA viruses. The genetic variation is
classified as being of two main types: quasispecies and genotypes.
1.3.1 Quasispecies
‘Quasispecies’ refers to the genetic heterogeneity of the HCV population within an infected individual, that is, the
population of HCV genomes is present as a group of closely related, yet heterogenous, sequences. Homologous
viral populations have been observed at the start of infection, with sequence heterogeneity developing some years
later.
It is uncertain whether the observed genetic drift reflects inherent viral evolution or whether immune selection
drives the sequence variability and antigenic variation of the amino terminus of E2/NS1.This ability to change
sequence may be a mechanism by which HCV escapes immune surveillance and establishes persistent infection in
the host. Thus, under immune pressure the virus might mutate rapidly and exist simultaneously as a series of
related but immunologically distinct variants (Alter 1995a). Although mutations occur throughout the HCV
genome, most occur in a relatively short, hypervariable segment of the E2/NS1 domain (Weiner et al 1991).
Naito et al (1995) examined the relationship between nucleotide complexity and diversity of hypervariable region
1 and various stages of the carrier states using polymerase chain reaction (PCR)-SSCP (single strand
conformational polymorphism). There were no significant differences in the number of SSCP bands among the
stages of HCV infection: normal alanine aminotransferase (ALT) (20); chronic hepatitis with elevated ALT (50);
cirrhosis (22); hepatocellular carcinoma (HCC) (24). The authors’ findings suggest that the quasispecies
complexity of the hypervariable region is independent of the stage of chronic HCV infection. Koizumi et al
(1995) examined the same question in a smaller number of patients (42 total) and reported contradictory findings:
the percentage of patients with a single band was 41 in chronic active hepatitis (CAH), 22 in cirrhosis, and 0 in
HCC. If these findings are correct, then they support the diversity of HCV quasispecies becoming more complex
as the disease stage progresses. Honda et al (1993) examined 28 patients with liver disease of varying severity for
nucleotide diversity spanning the region from the core to envelope. Intrapatient variation in nucleotides increased
significantly with severity of liver disease, except in cirrhosis complicated by HCC. Histological findings
correlated most with quasispecies diversity, not time from infection. The authors conjecture that replication of
HCV is more active in patients with severe liver disease, and an error-prone RNA polymerase causes mutation
during replication. Kurosaki et al (1995a) examined four patients for SSCP patterns and reported that the
population of quasispecies changed during the course of chronic infection, more so where transaminase levels
were high. They argue that the population of quasispecies changes during the course of infection.
Sakamoto et al (1995) examined nucleotide sequences of the hypervariable region of HCV genomes obtained
from plasma and liver tissue of eight patients with chronic HCV infection. Comparison of the SSCP patterns
revealed that the number, mobility, and density of bands were the same between the plasma and the liver. The
authors concluded that the population and the diversity of HCV quasispecies as detected by the hypervariable
region sequence are the same between the plasma and the liver despite rapid mutations, indicating that rapid
changes in the population of HCV quasispecies also occur in the liver.
1.3.2 Genotypes
Heterogeneity of genomes is observed among different HCV isolates - a result of the accumulation of mutations
during evolution of the viruses. This diversity has led to its classification into ‘genotypes’, based upon genetic
relatedness. Although each genotype was initially thought to have a distinct geographical location [HCV type I
being3
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the major genotype in the United States of America (USA) and Europe, and types II, III and IV being reported
initially only from Japan], it is now clear that different genotypes are distributed worldwide (Takada et al 1993).
No well-defined culture system or classification based upon clinical manifestations has yet been identified for
these variants.
These genetic variations are important as they may have an effect on clinical outcome, on response to treatment,
on diagnostic testing and on vaccine development.
1.3.3 Nomenclature for designation of genotypes
There are various nomenclatures for designating genotypes (table 1).
Table 1Correspondence among the major published classification systems for hepatitis C virus
genotypes
From Pawlotsky et al (1995a). HCV types are designated by Arabic numerals in order of discovery (1, 2, 3 etc). Subtypes are
designated using these numerals and lower case letters.
Consensus proposed by
Simmonds et al (1994)
Okamoto et al (1993) Cha et al (1992) Nakao et al (1991)
1a I 1a PT
1b II 1b K1
1c NC
A NC NC
2a III 2a K2a
2b IV 2b K2b
2c NC NC NC
3a V 3 NC
3b NC NC NC
4a NC 4 NC
5a NC NC NC
6a NC NC NC
A NC=not classified.
The degree of correspondence of the full-length nucleotide sequences among types, subtypes and isolates within a
given subtype are 65.7 to 68.9 per cent, 76.9 to 80.1 per cent and 90.8 to 99 per cent, respectively. There are
other characteristic differences specific for a given  genotype, such as the length of the open reading frame
(ORF). The C gene is the most highly conserved gene of HCV, and nucleotide sequence within this region
accurately predicts genotype. The 5′  NC region is the most highly conserved region of the HCV genome, but
cannot accurately predict genotype. Characteristic genotype changes occur throughout the E1 gene, so that
analyses of fragments of 100 nucleotides have proved sufficient to accurately predict genotype. Cha et al (1992)
reported that several short nucleotide motifs throughout the HCV genome are predictive of genotype.
Current methods of genotype determination that do not include sequence analysis are not definitive. Although
methods that detect genotype-specific antibodies would be advantageous for epidemiological studies, antibody
markers are, at best, indirect markers of genotype and have limited specificity. There are problems because of
lack of4
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complete sequence data, and minor inconsistencies between typing systems. Genotyping should be based 
ultimately on sequence identity.
1.3.4 Distribution of hepatitis C virus genotypes
Distribution of HCV genotypes can vary by geographical area, positivity in first-generation or second-generation
tests, liver disease (presence, absence), or mode of transmission (IDU compared to other modes) (Davidson et al
1995; Simmonds 1996) (table 2).
Table 2Geographical distribution of genotypes
Type 1 isolates - widely distributed: Isolate
Predominant genotype in North and South America and Europe I/1a II/1b
Predominant genotype in Asia 11/1b
Within Japan, Taiwan and probably China 1a, 2a, 2b
Thailand, Singapore, Bangladesh, East India 3
The African continent - a very different distribution:
North and Central Africa, Egypt, Middle East 4
Southern Africa 5
Hong Kong - significant proportion of isolates 6
Vietnam, Thailand 7, 8, 9
1.3.5 Clinical implications of genotypic diversity
Most studies have found that genotype 1b is associated with more severe liver disease, although there is some
concern that the type of genotype may be confounded by length of infection. In many European countries,
genotype distributions vary with the age of patients, possibly reflecting the introduction of different genotypes
through practices such as IDU (Craxi et al 1991; SW Chan et al 1992; McOmish et al 1994; Anonymous 1995a).
Mahaney et al (1994) found that types 2b, 3, and 4 were found almost as frequently in IDU as type 1b (ratio
11:12) whereas in patients who had acquired HCV as a consequence of blood transfusion, type 1b predominated
over other types in a ratio of 20:3 (P=0.015). Cirrhosis has been observed in infections of all known genotypes,
and there is little evidence of completely non-pathogenic variants (Dusheiko et al 1994). Kobayashi et al (1996)
compared 100 patients with genotype 1 (1b) and 36 with genotype 2 for deterioration of liver histology with a
mean of over eight years of follow-up. Patients with genotype 1 were more likely to have higher HCV-RNA
titres, and those with genotype 1 had greater deterioration of liver histology and were more likely to develop
HCC. Pozzato et al (1994a) compared genotypes from Italian and Japanese patients and found that NS4-positive
patients were significantly older, had significantly lower ALT levels and had significantly more cirrhosis than
NS4-negative patients. Although the 1b genotype was more commonly associated with cirrhosis, most (74%)
patients were type 1b, making comparison with any other genotype difficult. There are also suggestions that HCV
genotype 3 is associated with a more aggressive form of CLD than the liver disease associated with types 1 and 2
(Preston et al 1995).
Preston et al (1995) examined HCV serotype and genotype in a cohort of 96 people with haemophilia infected
with HCV and the relationship between genotype and severity of CLD as determined by liver biopsy. HCV
serotype was determined by specific enzyme-linked immunosorbent assays (EIAs) and genotype by restriction
fragment length5
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polymorphism (RFLP) and HCV viral sequencing. The pattern of genotype distribution was  unlike that of
HCV-infected United Kingdom blood donors in that five of the six known HCV genotypes were represented
(50% were type 1; 13%, type 2; and 18%, type 3). An unexpected observation was the presence of HCV
genotype 4 in four patients and type 5 in two patients. An additional feature was the presence of mixed
infection, detected in 14 and 7 per cent by serotype and genotype analysis, respectively. Liver biopsies were
available from 51 patients. Cirrhosis was present in five of 27 (19%) individuals with type 1, in two of nine
(22%) with type 2, and five of eight (63%) of those with type 3. The heterogeneous pattern of HCV genotype
distribution in this cohort of patients and the observed relationship between the severity of the liver disease
and specific HCV genotype may relate to their reinfection with different HCV types, which could differ in
their replication rates and in their capacity to induce HCV antibody formation.
McGuiness et al (1996) found that HCV genotype 1b had a significantly higher mean intrahepatic HCV-RNA
load compared with the other genotypes (McGuiness et al 1996). They also reported the effect of IFN on
reducing intrahepatic HCV-RNA levels, but did not find an association of HCV viral load with more severe
liver disease assessed either histologically or by serum transaminase levels.
However, the influence of HCV genotype on the severity of subsequent disease is very difficult to establish in
cross-sectional clinic-based studies, and there is a need for more epidemiologically sound longitudinal studies
of community-based cohorts to define the effect with any degree of certainty (Sallie 1995).
1.3.6 Studies examining genotypes in liver and serum
Infection with multiple genotypes is not commonly reported when this is measured by HCV-RNA genotyping
of random serum samples, even in patients whose mode of HCV acquisition is attributed to IDU. Sallie (1995)
suggests that these findings might be an artefact of the selective and exponential amplification power of PCR,
which dictates that if one of a pair of competing molecular species is even slightly dominant during the early
rounds of the PCR, it will rapidly become increasingly more dominant during later cycles (Sallie 1995).
However, there are type-specific priming techniques used to try to minimise this effect. Sallie (1995) suggests
that the infrequent finding of multiple genotypes is important for two reasons: firstly, it supports the concept of
‘molecular Darwinism’; and secondly, it suggests that some genotypes of HCV have mechanism(s) by which
replication (and/or packaging and/or export into the serum) of other genotypes may be attenuated or even
abrogated completely (Sallie 1995).
Doubts have been raised about the interpretation of the relationship of genotypes to liver damage. Castillo et al
(1995) performed a paired serum/liver biopsy study of genotypes, and reported that a mixed HCV genotype
infection was detected in a significantly higher proportion of liver specimens than serum specimens. The
authors suggested two possible explanations: that the HCV-RNA load may be higher in liver cells than in
serum, permitting detection of the HCV subtype in the hepatocytes when the total body load of virus is lower;
or that HCV genotyping in serum may reflect only those HCV genotypes that are actively replicating in
hepatocytes and being released into the circulation, whereas in liver cells, those other HCV genotypes may be
synthesising viral proteins but are not actively replicating (or in a latent infection state). Thus, serum HCV
genotyping may not reflect the viral population infecting the liver of a given patient. Types might also be
detected in an inactive replication phase. Based upon these results the authors raise the possibility that serum
HCV genotyping may, therefore, not reflect the viral population infecting the liver of a given patient.
This is reinforced by Kao et al (1994) who examined 20 patients in Taiwan with chronic HCV infection
experiencing acute hepatitis exacerbations. They used PCR with genotype-specific primers, comparing the
group with exacerbations with 26 patients who did not appear to experience acute exacerbations. Eleven
(55%) of the group with exacerbations had mixed genotype infections, and those with heterologous infection
were significantly6
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younger than the nine without (55 v. 67 y, P<0.05). By contrast, only two of the non-exacerbation group had
mixed genotype HCV infections detected, and these two patients had higher mean ALT levels. The emergence
of the new genotype coincided with the abrupt elevation of serum ALT levels. There was no consistent virus
genotype emerging during these exacerbations, and often the newly introduced virus disappeared although the
original virus was also seen to disappear. The authors conclude that their work suggests the importance of
preventing superinfection in patients with chronic HCV infection to diminish the progression of chronic
hepatitis. An alternative explanation of these data is that co-existent infection with more than one genotype can
commonly occur, but that usually only one genotype is replicating, with occasional episodes of multiple
genotype replication coinciding with increased hepatitic activity. Either multiple genotype replication causes
increased hepatocyte damage, or less likely, increased hepatocyte damage causes multiple genotype replication
when multiple genotypes are present.
Castillo et al (1995) and Kao et al (1994) raise doubts about the design of many of the published studies on the
effect of HCV genotypes. Measurement of HCV-RNA genotype in serum at random times may not identify all
of the genotypes present that are capable of causing disease and further transmission. Much more attention
needs to be paid to the virology of acute exacerbations, and how these acute exacerbations relate to long-term
progress of liver and extrahepatic manifestations of HCV infection.7
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2 Diagnostic tests for hepatitis C virus
infection
2.1 Antibody tests
The initial clone of HCV was from the NS4 region and the derived protein was designated 5-1-1 (Cerino and
Mondelli 1991). This was expanded to form the c100-3 antigen that served as the basis of the first-generation anti-
HCV assay. The antibody tests contain antigens derived from the conserved parts of the HCV genome, but the
serological response to the prototype strain is not uniform in carriers infected with different genotypes. Second-
generation assays added the c22 core antigen and the c33c antigen from the NS3 region. The third-generation assay
adds an NS5 protein and reconfigures some of the earlier antigens. The third-generation assay provides only
incremental benefits in terms of disease prevention because of a very small increase in sensitivity but does not
provide improved specificity. Nonspecificity remains generally unexplained but has been associated with aged sera,
hyperglobulinaemia, rheumatoid-factor positive sera, sera from persons recently vaccinated for influenza and
persons with past or current syphilis (Sonmez et al 1997).
The sensitivity of detection of anti-HCV is influenced by the degree of conservation in different regions of the
genome among different HCV strains. Most patients with chronic HCV infection are anti-C22 positive, indicating a
strong anti-capsid response. Improvements in test sensitivity have been achieved by identifying antigenic sites and
immunodominant epitopes (Dusheiko et al 1994).
Table 3Relationship between serological markers of hepatitis C virus and phases of hepatitis C
virus infection
From Brunetto et al (1994).
Prodromic Acute Chronic Recovery
Viraemia
HCV-RNA ++ ++ ++ +/-
Antibodies against structural proteins
Anti-C22 - -/+ ++ +
Anti-E1 - - +/- -
Anti-E2 - -/+ +/- -
Antibodies against nonstructural proteins
Anti-C33 - -/+ + -
Anti-C100 - -/+ +/- -
Using a recombinant immunoblot (RIBA), HCV-reactive sera fall into two groups: strongly positive, with at least 3+
anti-capsid and anti-NS3 profiles; and weakly positive, with absent or weakly reactive (1+ or 2+) profiles. Over 908
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per cent of the former group are viraemic, compared with less than 10 per cent of the latter. Such weak profiles
are also seen early in seroconversion and late in the course of extinction of viral replication (Dubois et al 1998).
2.2 Other tests
The only direct marker of HCV infection is the detection of HCV RNA, typically by reverse transcriptase (RT)
PCR. Other methods are in situ hybridisation and branched DNA amplification assays.
The 5' NC region of the HCV genome contains sequence domains that are conserved among all known
genotypes. Because of the relative conservation of this region, primers and probes from these domains can be
utilised in assays for universal detection of HCV RNA in HCV-infected individuals and are superior to those
from NS3 and core in sensitivity and specificity.
The branched-chain DNA amplification assay is easy to perform and reproducible, but it is significantly less
sensitive than RT-PCR assays (Gretch et al 1995). Difficulties with consistency of PCR results are known to
occur. Branched-chain DNA amplification is widely used for measuring the level of HCV viraemia, although the
sensitivity may vary with the genotype being analysed.
The presence of HCV RNA in the absence of anti-HCV antibodies may reflect lack of immune reactivity,
particularly in immunosuppressed and haemodialysed patients. There are presently no antibody patterns that
distinguish between persistent viraemia and episodes of resolved viraemia, as the antibody patterns are frequently
similar. A proportion of people who clear HCV RNA may lose antibody reactivity, so that all identifiable traces
of HCV infection may disappear.
Dow et al (1993) reported on the results of 3,832 samples referred for confirmatory testing after being positive in
a screening test at blood donation. All were tested by recombinant immunoblot assay (RIBA3) with 2,710
negative, 945 indeterminate and 177 positive results. HCV RNA was detected by PCR in an average of 69.5 per
cent of RIBA3 positives but only 0.53 per cent of the RIBA3 indeterminates. HCV viraemia was greatest among
samples reactive with all four RIBA3 bands (84.1%) and lowest in those reactive with only two bands (34.1%).
Of RIBA3- positive samples containing three bands, all samples containing NS5 band were PCR positive. Type 1
genotype was the commonest genotype (53%) among RIBA-positive samples with all four bands, type 3 was the
commonest genotype among RIBA-positive samples with three (45%) and two (54%) bands. NS5 indeterminates
were the most common (40.2%) single-band pattern but yielded no PCR-positive samples, followed by c33
(23.3%) with one PCR positive and c100 (20.2%) with one PCR positive, whereas c22 indeterminates were least
common but included three PCR-positive donors. All five RIBA3 indeterminate PCR-positive donors were type 3
genotype.
The absence of antibody response to the 5-1-1 protein is frequent in genotype III/2a HCV carriers and may help
predict the response to IFN therapy (Yuki et al 1992).
Quantitative determination of viral load using PCR-based techniques is useful in predicting and measuring
response to therapy, but its place in assessment of overall prognosis is yet to be ascertained (Berger et al 1998).9
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3 Methodological issues in hepatitis C
virus epidemiology
Even before HCV infection was identified as a leading cause of non-A, non-B hepatitis (NANBH), particularly in
industrialised countries, there had been work on determining the epidemiological features of the condition.
Particular questions were related to routes of transmission, long-term outcome and patterns of occurrence within
populations. Investigations led to a recognition of the considerable methodological challenges that face
epidemiological research in HCV, even before the virus itself had been identified. Although the ongoing
development of immunological and molecular methods for detecting HCV infection has removed some major
obstacles, many of the challenges remain.
Primary among the challenges is probably the difficulty in detecting newly acquired HCV infection. Recognition
of such cases is an essential requirement in several areas of HCV epidemiology. These cases provide the best
means of investigating routes of transmission, but the greater the time passed since infection was acquired, the
more difficult it becomes to elicit accurate information on the circumstances of exposure. Cases for which the
time of acquisition is known represent the best opportunity to study HCV natural history because it is possible to
relate disease progression to time elapsed since the infection was acquired.
Detection of newly acquired infection is difficult primarily because only a very small proportion of cases appear
to manifest a clinical illness - hence, people who have recently become infected are not likely to seek medical
care for acute hepatitis. If they do happen to undergo testing, the only way that the timing of infection can be
established is through a known history of exposure, or a documented negative test in the recent past. Unlike some
other viral infections, it is not yet possible to identify acute HCV infection by detection of an IgM antibody
response.
The second major issue in HCV epidemiology has been the difficulty in gaining access to populations at high risk
of infection. The major route of transmission, IDU, is an activity that is illegal, socially marginalised and often
undertaken by people who are not in close contact with the health system. In addition, people who have injected
drugs but no longer do so may not be keen to acknowledge this aspect of their past. For these reasons, people
with, or at risk of, HCV infection may be difficult to recruit into studies and follow-up for any length of time. It is
also an ongoing challenge to enumerate these subpopulations.
Investigation of the natural history of HCV infection needs to take into account the long and variable course of
disease progression. It appears that four or five decades of follow-up will be required to fully characterise the
long-term outcome of chronic HCV infection. Study of outcomes is further complicated by their multifactorial
aetiology. For example, cirrhosis and cancer of the liver occurring in a person with HCV infection may also be
linked to HBV infection and alcohol consumption.
Finally, HCV epidemiology needs to take account the complex and evolving diagnostic methodology for HCV
infection. Since the virus was identified, there has been a rapid development of both immunological and
molecular techniques for detecting HCV antibodies and genetic material. Researchers of the epidemiology of
HCV have difficulty in gaining access to adequate diagnostic testing, much of which is expensive and requires
specialised laboratory skills to carry out.10
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4 Populations at risk and
transmission pathways
4.1 Injecting drug users
People who inject themselves or are injected by someone else with illicit drugs (IDUs) are at risk of many
infectious diseases because of unsterile injecting techniques, usually related to the illicit nature of the activity.
HCV is the most common of these infections among IDUs, with very high proportions of most IDU populations
studied having been exposed and being chronically infected. Conversely, among populations at risk of blood-
borne or sexually transmissible diseases (STDs) (eg STD clinic patients), or indeed often among general
populations (eg blood donors), a history of IDU is found to be the commonest risk factor. Such histories are often
hidden, however, and difficult to ascertain. For instance, in a study of attenders at a drug treatment centre in
Baltimore, USA, in 1990-91, 21 per cent of patients gave no history of IDU and yet had similar prevalences of
HCV to those who gave such a history, raising the possibility that they did not fully disclose HCV-risk behaviour
in this setting (Fingerhood et al 1993). As well, where this has been studied, HCV continues to spread among
IDUs often despite the introduction of seemingly effective HIV prevention strategies in the same populations.
4.1.1 Prevalence and associations of prevalence of hepatitis C virus among
injecting drug users
Prevalence of HCV among IDUs is almost uniformly very high, across a wide range of studies in varied
populations and many countries. Table 4 (see Tables section) shows the prevalence from 77 studies in 28
countries. Some variation in prevalence is caused by the sensitivity and specificity of the assay used, but most
variation is related to the length of time the HCV-infected person had been injecting (see next paragraph). In
general, prevalence of antibodies to HCV is higher than of antibodies to HBV and HIV, but there are exceptions
to this (eg Switzerland - Chamot et al 1990, Rohrig and Grob 1990; Poland - Halota et al 1991).
Multiple studies have found that the strongest association of HCV seropositivity among IDUs is duration of
injecting (Bell et al 1990; Girardi et al 1990; Rohrig and Grob 1990; Donahue et al 1991; Smiatacz et al 1991;
Zeldis et al 1992; Crofts et al 1993; Scheitlin et al 1992; Patti et al 1993; Crofts et al 1994; Lucidarme et al 1994;
van Beek et al 1994; Chetwynd et al 1995; Crofts et al 1995; Galeazzi et al 1995; Robinson et al 1995; Smyth et
al 1995; Thomas et al 1995a; Bolumar et al 1996; Garfein et al 1996; Kemp et al 1998; Lamden et al 1998;
Smyth et al 1998). In almost all cases, age is also associated but only because of relationship to duration of
injecting. Some studies have found extremely high prevalences within very short periods after beginning to inject,
and prevalences up to 100 per cent after eight years of injecting; these rates vary to some degree with the
specificity of the assay and the population studied (table 5). However, there is increasing evidence that at least at
some times and in some places new initiates into injecting are at the highest risk of exposure to HCV. For
example, in a study of IDUs in Baltimore, USA, recruited between 1988 and 1991, prevalences approaching 50
and 75 per cent were found in IDUs who had only been injecting for less than four months and five to eight
months, respectively (Garfein et al 1996).
Among the group of IDUs in this study who had been injecting for less than one year, the associations of HCV
seropositivity were: injecting daily, not always using new equipment, and injecting cocaine. HIV seropositivity in
the same group, however, was associated with sexual, but not injecting, risk variables. The authors’ conclusion
was that12
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in Baltimore, USA, in these years most HCV infections among IDUs occurred ‘very soon after initiation of injection
drug use’. One difficulty with this as with many United States studies was that the investigators were limited to
enrolling IDUs aged 18 years and over, posing a potential sampling bias. However, several studies have replicated
these results, finding high rates of exposure among IDUs within very short periods after beginning to inject (table 5).
Table 5Prevalence of antibody to hepatitis C virus among injecting drug users by duration of
injecting
Reference Lower duration
(years
A)
Prevalence (%) Upper
duration
(years)
Prevalence
(%)
Assay
(generation)
Bell et al (1990) <2 67 8+ 100 1
Galeazzi et al (1995) <4 40 >8 91 2
Smyth et al (1995) <2 70 >2 95 2
Thomas et al (1995) 2+ 78 1
Garfein et al (1996) 0-4 m 47 1-2 80 1
Garfein et al (1996) 5-8 m 72 5-6 82 1-2
Garfein et al (1996) <1 64.7 1-2
Robinson et al (1995) <4 53 1
van Beek et al (1994) <3 26 >10 94 2
Lucidarme et al (1994) <6 m 33 2+ 90 2
Bolumar et al (1996) <1 69 4-8 87.0 2
Bolumar et al (1996) <4 78.9 8+ 90.0 2
Chetwynd et al (1995) <5 73.5 >10 92.5 2
Kemp et al (1998) <5 35.6 >10 86.7 2
ADuration is in years unless stated otherwise; m, months.
A study in Hong Kong found that type 6a was associated with a history of IDU among blood donors to a far greater
extent than was type 1b, suggesting a more recent introduction of type 6a into the IDU population (Prescott et al
1996).
A second major association of HCV seropositivity among IDUs is exposure to HBV (ie those IDUs with antibody to
HCV are more likely to have antibody to HBV and vice versa) (Bell et al 1990; Gloria et al 1991; Trubner et al
1991; Rodriguez et al 1992a 1992b; Zeldis et al 1992; Cheng 1993; Fingerhood et al 1993; Patti et al 1993; van
Beek et al 1994; Coppola et al 1994; Crofts et al 1994; de Miguel et al 1994; Quaranta et al 1994; Galeazzi et al
1995; Bolumar et al 1996) although two studies have reported not finding such association (Payeras Cifre et al 1992;
Westh et al 1993). There are indications that IDUs who are exposed to both HCV and HBV are commonly exposed
to HCV some months or years in advance of their exposure to HBV (Rodriguez et al 1992a, 1992b; Abdel Rahman
et al 1993; Crofts et al 1995) and that where an IDU has been exposed to only one of these two viruses, it is much
more likely to have been HCV (Gloria et al 1991; Pont et al 1991; Trubner et al 1991; Li et al 1993; Coppola et al
1994; Crofts et al 1995; Hedberg and Gaub 1995; Ichimura et al 1995; Tennant and Moll 1995). This most probably
is a result of the much higher proportions of IDUs in any injecting network who are infectious for HCV than for
HBV.13
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Several studies have found associations between HCV seropositivity and particular drugs, with HCV exposure
more common among those most commonly injecting heroin or other opiates than amphetamines or other
stimulants (Zeldis et al 1992; Crofts et al 1993, 1994; van Beek et al 1994; Selvey et al 1996).
 However, where
cocaine is more commonly injected, it has also been found to be more associated with HCV (Fingerhood et al
1993; Thomas et al 1995a; Garfein et al 1996). One possible explanation of these findings is the relationship of
HCV risk to frequency of injecting, with opiates on average injected more frequently than stimulants in many
settings (although the variance of frequency is greater with stimulants); increased risk where cocaine is
commonly injected - mostly in parts of the USA - could then be a result of the very high frequency of injecting
among injectors of cocaine. A second, not exclusive, explanation may be that different injecting networks have
different degrees of risk behaviour for HCV. In either case, it would be the behaviour rather than the particular
drug which raises the risk of HCV transmission; the drug simply standing as a marker for the other factor(s).
There is no evidence currently in the literature to explain this association or test either of these hypotheses.
However, HCV seropositivity is clearly associated with injecting, and in several studies with the frequency of
injecting (Girardi et al 1990; Rohrig and Grob 1990; Van den Hoek et al 1990; Thomas et al 1995a; Garfein et al
1996). The inverse of this is the negative association in one study of HCV seropositivity with smoking, as
opposed to injecting, heroin (Van den Hoek et al 1990). The Baltimore cohort study found injecting daily or
more often to be strongly associated with HCV exposure, especially among young and new IDUs (Garfein et al
1996). A study of homosexual men in San Francisco in 1983-84 found a relatively low rate of HCV seropositivity
among those who gave a history of IDU, and suggested this was because frequency of injecting was low in this
group - only 9 per cent injected daily or more often (Osmond et al 1993a). The sharing of needles and syringes
has also been shown in several studies to be associated with HCV seropositivity (Girardi et al 1990; Rohrig and
Grob 1990; Scheitlin et al 1992; Chetwynd et al 1995; Galeazzi et al 1995; Garfein et al 1996), although one
study has found no such association (Cacopardo et al 1992) and one found the association to be weak (P=0.062)
(Bolumar et al 1996).
. One study found an increase in the numbers of other IDUs with whom equipment had been
shared among HCV- seropositive people compared with people who were seronegative (Robinson et al 1995).
One study found that daily drug expenditure of over 65 Irish pounds was associated with HCV seropositivity
(Smyth et al 1998).
Although there is a definite association between a history of sharing of needles and syringes and exposure to
HCV, there are some indications of HCV exposure among some IDUs who present no history of sharing. For
instance, in a study of 110 IDUs presenting between 1992 and 1994 at a treatment centre in New Zealand, 27
claimed never to have shared injecting equipment; 14 (76%) of 19 tested were anti-HCV positive, a rate similar
to those who gave a history of sharing (Robinson et al 1995). In a cohort study of IDUs in Victoria, the incidence
of HCV seroconversion among those who frequently reported sharing needles and syringes was 16.9 cases per
100 person-years, compared with an incidence of 4.3 per 100 person-years among those who denied sharing
needles and syringes (Crofts and Aitken 1997). A study of a cohort of IDUs in Sydney found an incidence of 11.9
per cent per year among IDUs who reported never sharing needles and syringes, compared with about 30.2 per
cent per year among those who reported sharing (van Beek et al 1998). These and other, anecdotal, data raise the
possibility of blood transfer between IDUs in ways other than reuse of contaminated needles and syringes. This
possibility is strengthened by the observation on video of possible routes of blood-borne transmission among
IDUs other than overt sharing of needles and syringes (Crofts 1994), and by analogy from studies of transmission
in dialysis units (vide infra).
4.1.2 Alcohol and injecting drug use
An increased prevalence of HCV over the general population has been observed in people with histories of
excessive alcohol consumption [eg 1.33% (cf 0.46% in blood donors) (Santos et al 1994); 14.5% (Verbaan et al
1993); 18.4% (Mendenhall et al 1993b)]. This has been shown to be because of a history of IDU in many people
with alcoholism, although it has been commented that eliciting this history may be a difficult process (Jiang et al
1995), and that the history may reside in the distant past (Mendenhall et al 1993b). In one study 58 per cent of 
HCV-positive patients14
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with alcoholism gave a history of IDU compared with 2 per cent of HCV-negative patients (Befrits et al 1995);
conversely, in another, 77 per cent of people with alcoholism with a history of IDU were HCV positive compared
with 16.7 per cent of those with no history of IDU (Jiang et al 1995). It has been said that IDU is ‘the
predominant route of HCV transmission among alcoholics’ (Jiang et al 1995).
This association is found also from investigation of current HCV patients, in whom excessive alcohol
consumption, especially among those with a previous history of IDU, may be more common than among the
general population (Verbaan et al 1993; MacLennan et al 1994). One study reported that 60 per cent of the IDUs
studied had a history of excessive alcohol consumption (Strasser et al 1995).
The combination of excessive alcohol consumption and increased prevalences of HCV infection as a result of
IDU lead to higher prevalences of, and more severe, CLD. For example, one study found among patients with
alcoholism that 21 per cent of HCV-positive patients were classified as having severe liver disease compared
with 7 per cent of HCV-negative patients (P<0.05) (Befrits et al 1995). A second similar study concluded that
‘HCV is responsible, at least in part, for the portal and/or lobular hepatitis associated with alcoholic liver disease’
(Rosman et al 1993). In this latter study, anti-HCV was strongly associated in these patients with alcoholism with
a history of IDU: 67 per cent of people were HCV seropositive compared with 4 per cent of people who were
HCV seronegative (P<0.001).
4.1.3 Genotypes and injecting drug use
There are at least six major genotypes of HCV with many subtypes, and there is a variable geographical
distribution of the different genotypes (see section 1.3). The activity and prognosis of HCV-related liver disease
may depend upon the particular genotype(s) involved, with HCV type 1b the most aggressive in terms of
pathogenesis. The response to IFN therapy also may be genotype dependent, with HCV type 1b having a poorer
response than other genotypes.
Studies of HCV genotypes among IDUs have found a varying predominance of different genotypes depending on
location; most of these studies are European. Among IDUs in France, for instance, one study found a marked
predominance of HCV type 1a (13/15, 87%) with occasional type 1b and 2a, and also found that the only
coinfections with different HCV genotypes occurred in IDUs (Gournay et al 1995). Another French study found a
high rate of HCV type 1a (33% of cases), but that the predominant type was 3a (63% of cases) (Pawlotsky et al
1995b); in one-third, 78 per cent of HCV-positive IDUs had genotypes 1a or 3 (Dubois et al 1997). In Austria, a
national study found the most prevalent genotype to be type 1b, but this type was less common among IDUs than
among other populations (Hofmann 1995). In Italy the commonest genotypes were found to be types 1, but type 3
was much more common among IDUs than among other groups [52% of those with genotype 3 infection had a
history of IDU compared with 9% of those with types 1, and 2% of those with types 2 (Pontisso et al 1995)].
Another Italian study also found that types 1a and 3a were commoner among IDUs than among other groups
(48.8 and 21.1%, respectively, of IDU infections compared with 17.6 and 11.2% of others) (Silini et al 1995). In
East Anglia in England genotype 1 predominated among IDUs with small proportions made up of genotypes 2
and 3 (Majid et al 1995). In a study in Iceland, of 40-PCR positive IDUs, 57.5% had genotype 1, 37.5% had type
3a and 2.5% had type 1b (Love et al 1996). Similarly, in an Amsterdam IDU cohort, serotype 1 was predominant
(57.2%), followed by 3 (26.8%) (Beld et al 1998b). It was noted in a Swedish study of genotypes among blood
donors, that while genotype 1a was commonest (40%) (with 29% having type 3a; 20%, type 2b; 10%, type 1b), a
history of IDU was commoner in donors with genotype 3a than in those with type 1a (Shev et al 1995b). In a
study carried out in Chiang Mai, Thailand, in 1994, type 3a was commonest among IDUs (30% of infections),
followed by 1a (21%), 1b (13%), 3b (13%) and 6a (2%) (Apichartpiyakul et al 1994). An Australian study found
that 60% of serotypes from15
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IDUs stored in 1971 were type 1, and less than 10% were type 3; almost 30% were type 2. In 1994, the use of
genotyping found a similar proportion with type 1, but less than 5% were type 2, and almost 30% were type 3,
suggesting a more recent date of introduction of type 3 (Moaven et al 1996).
These differing distributions of genotype according to risk classification and some other evidence have led
several groups to suggest that different genotypes have been introduced into different populations at different
times. The study of French blood donors referred to above (Gournay et al 1995) found that the risk factors for
HCV infection may differ for different genotypes, and that the mean time elapsed since HCV infection was much
higher for genotype 1b than for 1a (15.2 y cf 9.1 y). On the basis of this finding, the authors postulate that there
have been two distinct epidemics of HCV in France: the first with genotype 1b which began more than 10 years
ago and infected patients who received blood transfusions, and the second which occurred more recently with
genotype 1a and infected mainly IDUs (table 6).
Table 6Genotypes of hepatitis C virus by route of acquisition (France 1995)
From Gournay et al (1995).
Genotype Sporadic (%) IDU (%) Blood transfusion (%) Total (%)
1a 4  (36) 13  (87)2   (20)1 9   (53)
1b 6  (55) 1  (7) 7  (70)1 4   (39)
2a 1  (9) 1  (7)1   (10) 3  (8)
2b 0 0 0 0
Total 11 15 10 36
Coinfection 030 3
Pawlotsky et al (1995b), in the second French study referred to above, found that IDUs with HCV infection were
younger and had a different genotype distribution from blood transfusion recipients and sporadic cases, with
much higher proportions infected with genotype 3a. The authors concluded that transmission of HCV genotype
3a has only been observed over the last 20 years in France, whereas other genotypes were being transmitted up to
40 years ago. These results suggested to Pawlotsky et al (1995b) that for the past 20 years there have been two
ongoing independent epidemics of HCV in France. An Italian study with similar findings that patients with
genotype 3 were significantly younger and more likely to have a history of IDU came to the same conclusion
(table 7) (Pontisso et al 1995).
Table 7Genotypes of hepatitis C virus by route of acquisition (Italy, 1995a)
From Pontisso et al (1995).
Exposure Genotype (%) PCR -ve (%)
HCV-1 HCV-2 HCV-3
Blood transfusion 23 32 5 27
Surgery 24 28 21 25
Injecting drug use 9 9 52 30
Unknown 44 38 22 1816
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Another Italian study (Silini et al 1995) with similar findings concluded that genotypes 1a and 3a were recently
introduced in Italy, presumably via needle-sharing among IDUs, and from this reservoir to other groups,
‘particularly among younger subjects’ (table 8).
Table 8Genotypes of hepatitis C virus by route of acquisition (Italy, 1995b)
From Silini et al (1995).
Patient category HCV genotype (%) Total
1a 1b 2a 3a Other
IDU 44 (49) 13 (14) 1 (1) 19 (21) 13 (14) 90 (100)
Non-IDU 22 (18) 46 (37) 38 (30) 14 (11) 5  (4) 125 (100)
χ
2 analysis P<0.001.
A study in Hong Kong found that type 6a was associated with a history of IDU among blood donors to a far
greater extent than was type 1b, suggesting a more recent introduction of type 6a into the IDU population
(Prescott et al 1996).
In summary, there is variation in the distribution of HCV genotypes both geographically and between different
risk categories. In particular, it would seem from these mainly European data that genotype 3a is a more recent
arrival, at least in Europe, and that the route by which it arrived was through IDU contacts with Asia. Some data
indicate that the situation is similar in Australia. The importance of these very tentative conclusions is still
unclear, but given firstly that there is evidence that some genotypes may be more pathogenic, these data may
provide an alternative explanation: that the ‘less pathogenic’ genotypes may simply have been present in the
populations a shorter time, and have, therefore, had less time to cause disease. Secondly, given evidence that
there is a differential response to IFN with different genotypes, there is a need to understand which genotypes are
present in which populations when determining policy about the availability of IFN.
4.1.4 Contribution of injecting drug use to hepatitis C virus prevalence in other
populations studied
Many populations have been studied for prevalence and associations of HCV exposure. Two factors stand out as
the major associations: a history of blood transfusion prior to the introduction of screening, and a history of IDU.
In the following sections the evidence relating to the contribution of IDU to exposure in other populations is
reviewed.
4.1.5 Blood donors
A history of IDU is very common among blood donors found to be HCV antibody positive (table 9). For
instance, in an important study at the Sydney Blood Bank, the authors conclude that: ‘A history of injecting drug
use was elicited as the most important risk factor in ... blood donors with antibodies to hepatitis C’ [relative risk
(RR) 63, 95% confidence interval (CI) 19, 260] (Kaldor et al 1992).17
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Table 9Percentage of blood donors seropositive for hepatitis C virus, and percentages of HCV-
seropositive blood donors with histories of injecting drug use
Percentages (pct); with a history of injecting drug use (c h/o IDU).
Site Reference Pct HCV
+ve (n)
Pct HCV+ves
c h/o IDU (n)
Odds
ratio
95%
CI
Comments
Cairo Bassily et al (1995) 26.6 (188) 2.5
Copenhage
n
Winston et al (1995) 76 (21) Includes tattooing
Denmark Gronboek et al
(1996)
76 (21) Includes tattooing
France Jullien (1995) 0.38%
(19,632)
Risk factors: IDU
(P=0.0000006) and history of
transfusion (P=0.0071)
France Maisonneuve et al
(1991)
6.8 (117)
France Saura et al (1997) 25
France Tullen et al (1993) 0.25% French BB screening: risk
factors in donors: IDU and
previous transfusion
Goteborg Shev et al (1995a) 51
A Independently associated
with anti-HCV and HCV-RNA
positivity: IDU (P<0.001),
blood transfusion (P<0.01),
tattoos (P<0.001)
Iceland Love et al (1995) 0.07%
(12,000)
100 (8)
Norway Nordoy et al (1994) 0.10%
(16,756)
56 (16)
Sicily Soresi et al (1998) 5.74 Case control
Switzerland Zufferey et al (1992) 0.27%
(20,373)
9 (55)
Sydney Kaldor et al (1992) 0.31%
(217,020)
63 19-
260
Sydney McCaughan et al
(1992)
56 (50)
Thailand Sawanpanyalert et al
(1996)
2.2%
(1,756)
h/o IDU in some +ve donors
Trent
Region
Neal et al (1994) 53% Lower
limit
20
USA Conry-Cantilena et al
(1996)
42
AProportion of those +ve for HCV with IDU history.
4.1.6 Men who have sex with men
Although some studies have found higher than expected prevalences of HCV seropositivity among men with a
history of homosexual contact, here as elsewhere the strongest association with HCV infection is a history of
IDU. For example, in a study of 735 homosexual or bisexual men 34 (4.6%) were confirmed HCV positive
(Osmond et al 1993a). The study concludes that a ‘history of intravenous drug use and blood transfusion were
significantly18
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associated with HCV positivity (OR)=14.3 and 4.4, respectively)’, and that ‘IVDU was by far the strongest risk
factor for HCV positivity but was not a significant risk factor for HBV infection’ (OR, odds ratio; IVDU,
intravenous drug use; Osmond et al 1993a). Further, in this cohort, once IDU history was taken into account, the
number of sex partners had no relationship with HCV seropositivity. In a cohort of homosexually active men, 7.6
per cent were seropositive for HCV; only HIV-1 infection (OR=3.18, P<0.0001) and IDU in the previous six
months (OR=7.24, P<0.0001) remained significantly associated with the presence of HCV antibody in
multivariate analysis (Bodsworth et al 1996). Among 435 homosexual men recruited from a municipal STD
clinic from 1983 to 1984, 25 per cent reporting IDU and 5 per cent of men with no IDU were anti-HCV positive;
on multivariate analysis, only IDU was significantly associated with anti-HCV positivity (OR 6.4, 95% CI 3.2,
12.5) (Buchbinder et al 1994). Among 926 homosexual or bisexual men 15 (1.6%) were HCV seropositive, and
only IDU and a history of HAV were marginally associated with HCV (Donahue et al 1991).
4.1.7 Prisoners and prison entrants
See also section 4.7
High proportions of prisoners and prison entrants are HCV seropositive, in general because such high proportions
have histories of IDU. In Hamburg, Germany, of 539 prisoners in one study about 80 per cent of those with a
history of IDU were HCV positive and 50 per cent of the total HCV infections were due to IDU (Gaube et al
1993). In Valencia, Spain, 45 per cent of prisoners in 1991 were HCV seropositive, but of IDUs, 90 per cent
were seropositive whereas only 14 per cent of non-IDUs were (Anon et al 1995). Similarly in Victoria, Australia,
in 1991-92 of 3,627 prison entrants (>99% of all prison entrants) 46 per cent gave a history of IDU; 39 per cent
were anti-HCV positive including 914 (64%) of the male IDUs (Crofts et al 1995). Thirty seven per cent of 408
people voluntarily tested for HCV antibody at entry into the main reception centre in New South Wales between
June and December 1994 were found to have antibody to HCV (Butler et al 1997). A history of IDU, previous
imprisonment, sharing of injecting equipment and having had a tattoo were all significantly associated with the
diagnosis of HCV antibody. Of 70 new prisoners admitted to a Norwegian national prison, 46 per cent were anti-
HCV positive, and IDU was the predominant risk factor for HCV infection (Holsen et al 1993).
4.1.8 Pregnant women
Of 5,672 pregnant women living in North Italy, anti-HCV prevalence was 0.7 per cent (40/5,672), higher than
that observed among blood donors in the same geographical area (0.2%). IDU was by far the main risk factor for
HCV infection, resulting in a significantly higher risk than in the control group [50 v. 5.9% (OR 15.8, CI 5.4-
45.5)] (Marranconi et al 1994). Of 4,551 pregnant women in Catalonia, 1 per cent were HCV seropositive; again,
IDU was the only risk factor associated with HCV infection (Salleras et al 1994). One United States study found
75 of 1,700 consecutive pregnant women seropositive for HCV, and they were found significantly more likely to
have a history of IDU (Leikin et al 1994). A second study, which found 4.3 per cent of 599 inner-city prenatal
patients anti-HCV positive, also found IDU to be the most commonly identified risk factor for anti-HCV-positive
status: ‘although risk factor-targeted screening would have failed to detect half of the anti-HCV-positive women
in this study’ (Silverman et al 1993).
4.1.9 Hepatitis C virus clinic patients
Of all people referred to clinics because of their HCV diagnosis, varying but high proportions give a history of
IDU as the most likely cause of their exposure to HCV. The proportions of consecutive patients with diagnoses of
HCV infection who gave histories of IDU were 34 per cent of 50 admitted to a Norwegian medical department
(Bell et al 1992), 64 per cent of 160 in Finland (Pohjanpelto 1992), 51 per cent of 342 referred to the liver clinic
of a major Melbourne general hospital (Strasser et al 1995), 24 per cent of 59 at a United States community
teaching hospital (Woodall et al 1994), and 43 per cent of 63 patients at a gastroenterology/hepatology practice
in Ottawa (Scully et al19
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1993). In most of these studies, the male to female ratio was high (2.4:1 to 5:1), but the proportions of males and
females with HCV who gave a history of IDU was comparable. Generally, too, in these studies those HCV-
infected patients who gave a history of IDU were younger than those who gave a history of receipt of
transfusions.
4.1.10Sexually transmissible disease clinic patients
Studies of people at STD clinics have generally been carried out with the aim of assessing the contribution of
sexual transmission to spread of HCV. A familiar picture emerges from review of these data, especially with
regard to important transmission factors - IDU is the most important association with HCV in this group. For
instance, of 1,292 patients attending an STD clinic during a one-month period and having syphilis serology
performed, 99 (7.7%) were positive for anti-HCV, of whom 45 per cent reported IDU, the most important
association on multivariate analysis (Weinstock et al 1993). There was a similar finding at three STD clinics in
North Carolina, USA, in 1988, where 75 per cent of HCV seropositive patients admitted a history of IDU (Fiscus
et al 1994). Furthermore, of 526 persons who attended an STD clinic in Oslo, Norway, during four months in
early 1990, the overall prevalence of anti-HCV was 7 per cent; three-quarters of those positive gave histories of
IDU (Rollag et al 1993).
4.1.11Other clinic patients
Of 425 consecutive patients in one orthopaedic surgeon's operative practice for one year, 19 (4.5%) were positive
for HCV infection using a second-generation screening assay. The highest correlation with a positive test was the
presence of tattoos and the second highest was IDU, but only after a second interview, since most patients did not
report this risk on the initial questionnaire (Simonian et al 1995). Of 50 anti-HCV-positive patients attending an
Accident and Emergency Department in a suburban Detroit community hospital (USA), a history of blood
transfusions (58%) or of IDU (22%) were the most common factors elicited on first interview, but a remote
history of IDU or tattoo application was elicited in 55 per cent of individuals less than 40 years old (Meyer and
Gordon 1991).
4.1.12 Incidence of hepatitis C virus and associations of incidence among
injecting drug users
Incidence of HCV infection is difficult to measure except in situations in which there are serial measurements of
serological status because of the low clinical attack rate (ie the small proportion of people acutely infected with
HCV who present with a recognisable hepatitic syndrome). There are, therefore, few useful data on the incidence
of HCV to be found in most notifiable diseases surveillance systems (ie passive reporting); few active
surveillance systems for acute viral hepatitis exist. As well, opportunities for serial serological measurements
among IDUs are also few. As a result, compared with the plethora of studies examining prevalence of HCV and
its associations among IDUs, there are very few studies of incidence of HCV and its associations in the same
populations (table 10). These are, however, extremely important because of the light they shed on the detailed
circumstances of transmission - knowledge necessary to devise effective prevention strategies - and on identifying
areas of need and assessing the effectiveness of preventive interventions.20
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Table 10 Incidence of hepatitis C virus infection among injecting drug users
Site and
population
Reference No. of sero-
converters
Year(s) of
study
Rate per 100
person-years
95% CI Associations
Veneto -
clinic cohort
Galeazzi et al
(1995)
2 92 6.2 1.6, 24.8 Needle sharing
Amsterdam -
clinic cohort
Van den Hoek
et al (1990)
17 86
87
88
89
14.2
5.3
11.4
10.2
0, 30.3
0, 11.2
3.5, 19.3
0, 21.8
Baltimore Garfein et al
(1998)
13 16.0 Young IDUs,
injecting < 2y,
continuing to inject
during follow-up
Baltimore Villano et al
(1997)
43 88-96 6.4 Frequent injecting,
sharing of injecting
equipment
Naples -
treatment
centres
Rezza et al
(1996)
21 28.6 17.8,
43.4
Age >28 y, injecting
cocaine; MMT
A
protective
Seattle Hagan et al
(1999)
18 94-96 26.9 17.0-
39.0
Fewer years
injecting, indirect
exchange use or
pharmacy
purchases
Sydney van Beek et al
(1998)
31 92-95 20.9 13.5-
28.3
Age <20y,
imprisonment
Vancouver Strathdee et al
(1997)
24 18.6 11.1-
26.0
Victoria
prison
entrants - all
Crofts et al
(1995)
18.3
41
Young age, shorter
stay in prison
Victoria -
cohort study
Crofts et al
(1993)
5 19.6 2.4, 36.8 Older, male
injecting longer,
more opiate use,
based in the country
Victoria -
cohort study
Crofts & Aitken
(1997)
19 90-91
92-93
94-95
16.610.9
8.1
6.9, 40.0
5.5, 21.8
3.6, 18.0
Queensland -
MMT clinic
Selvey et al
(1997)
5 94-95 11 2, 20
Victoria -
MMT clinic
Crofts et al
(1997b)
19 91-95 22.2 14.2,
34.8
AMMT, Methadone maintenance treatment.
A key question involves the relative efficiencies of transmission of HCV and HIV among IDUs, and the effect of
HIV prevention measures on the transmission of HCV. It might be expected that the introduction of measures
designed to decrease the spread of HIV among IDUs (eg provision of sterile needles and syringes, increased
access to methadone maintenance programs, peer and other education) through the 1980s might be expected to
have an21
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effect  on the transmission of HCV in the same populations. Data on this point are scarce, because  investigations
of the epidemiology of HCV generally did not begin until after these programs  started and began to have an
effect. One indication of the effect of these measures to prevent  spread of HIV transmission of HCV among
IDUs comes from surveillance data for acute viral hepatitis, where the incidence of NANBH has been
documented over the relevant period. A second comes from longitudinal studies (clinic-based or field-based)
where transmission of both viruses is studied directly in the same populations.
4.1.13Surveillance data
Few countries have published analyses of surveillance data for acute NANBH over the relevant period. A review
of Italian surveillance data on acute hepatitis found that the national rate of acute NANBH decreased
significantly during the last decades (Zanetti et al 1995b). However, while the incidence of transmission-
associated (TA)-NANBH decreased markedly, the percentage of patients with acute NANBH who give a history
of IDU has risen from 18 to 33 per cent, suggesting that if there has been a decline in incidence among IDUs, it
has been smaller than that among transfusion recipients.
Arising from United States surveillance data is a case-control study that compared people acutely infected with
HBV or with HCV with controls who remained seronegative for the respective virus (Hagan et al 1995). This
study, carried out in a United States county, was  unusual in two ways: it has one of the few and one of the oldest
needle and syringe exchange programs in the USA, and it is one of four sentinel counties for acute viral hepatitis.
The study found that, after adjusting for demographic characteristics and duration of injecting drugs, non-use of
the exchange during 1991-93 was associated with a six-fold greater risk of HBV (OR 5.5; 95% CI 1.5, 20.4) and
a seven-fold greater risk of HCV (OR 7.3; 95% CI 1.6, 32.8). The authors estimate that use of the syringe
exchange would have led to a 65 per cent reduction in incidence of HCV among IDUs in this county.
4.1.14Cohort and clinical studies
Studies of IDUs followed over time with regular (or more often irregular, but at least repeated) measurements of
both serological status and behavioural characteristics provide the most direct and useful measures of incidence
rates and associations of behaviours and incidence. These studies potentially suffer from many biases, however,
and generalising from such studies requires care: this caveat relates more to measured incidence rates than to the
associations between behaviours and viral transmission.
A prospective follow-up study of 268 IDUs in Amsterdam, the Netherlands, recruited from methadone
maintenance clinics and an STD clinic for IDU sex workers in Amsterdam, found that despite a diminution in
incidence of HIV from 1986 through 1989, incidence of HCV was ‘high and stable’ through the same period
(table 11) (Van den Hoek et al 1990). Prevalence of HCV among the IDUs on entry was 73 per cent and of HIV
was 35 per cent. Seroconversion to HCV in this study was associated only with ‘recent injecting’.22
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Table 11 Incidence of human immunodeficiency virus and hepatitis C virus among
injecting drug users in Amsterdam
From Van den Hoek et al (1990).
Year: 1986 1987 1988 1989 Total
HCV Total no. 3 2 8 3 16
Person-years 17.8 50.3 64.1 26.9 159.0
Incidence rate
A 16.9 4.0 12.5 11.2 10.1
HIV Total no. 5 4 6 1 16
Person-years 42.6 97.2 131.9 54.2 326.0
Incidence rate
A 11.7 4.1 4.6 1.8 4.9
APer 100 person-years.
A similar study among 106 initially HCV-seronegative IDUs attending drug treatment centres in Naples in 1991
through 1993 found that 21 had seroconverted, an incidence rate for HCV of 28.6 per 100 person-years (95% CI
17.8, 43.4) (Rezza et al 1996). The HIV incidence in the same period was zero (out of 281 initially HIV-
seronegative IDUs who were followed) (95% CI 0.0, 1.7). Seroconversion to HCV was associated with older age
(>28 y), to some degree with duration of injecting, and with the injecting of cocaine. The authors point out that
risks for HIV infection (then at low prevalence in this region) were different from this. As well, they associate
cocaine as a risk factor for HCV infection with the frequency of injecting and, therefore, of sharing, not as a
result of any pharmacological or behavioural factor associated with the drug itself. ‘Participants who had not
been having methadone treatment in the previous six months were approximately 3 times more likely than the
others to be HCV-infected’ (lower 95% CI 0.9), suggesting some protective effect of participation in methadone
maintenance. However, small numbers may have obscured real associations, as duration and frequency of
injecting were found to be associated with HCV seroconversion but not significantly.
A study of 227 IDUs attending treatment centres in Veneto, Italy, found two seroconverters to HCV of 34
initially HCV-seronegative followed for at least six months, an incidence rate of 6.2 per 100 person-years (95%
CI 1.6, 24.8) (Galeazzi et al 1995).
. Only one of the seroconverters reported sharing needles and syringes before
seroconversion. A study in Sweden found that of 106 IDUs initially seronegative for HCV, 21 per cent
seroconverted over unstated periods of time (so that incidence rates are not available from this study) (Widell et
al 1991). However, 3 per cent are also reported to have lost antibody in the same period. These figures may be
misleading, however, because of the use of the first-generation assay in this study.
In a field-based prospective study of IDUs in Victoria, Australia, five seroconverters were found among 32
initially HCV-seronegative IDUs in 1991-92, an incidence rate of 19.6 per 100 person-years (95% CI 14.1, 27.2)
(Crofts et al 1993). Those who seroconverted were older, more likely to be male, had been injecting longer, more
often reported opiate use, and were more likely to be based in rural areas. A further report from this same study
after five years found 19 seroconverters and an overall incidence of 10.7 per 100 person-years (Crofts and Aitken
1997). A study of prison entrants in Victoria, Australia, in 1991-92 found, among those who entered prison more
than once in the 12 months, incidences of 12.6 and 18.3 per 100 person-years for HBV and HCV, respectively
(Crofts et al 1995). In men who injected drugs and were aged less than 30 years (29% of all prison entrants),
these were 21 and 41 per 100 person years. Seroconversion to HBV or HCV  was associated with young age and
a shorter stay in prison.23
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4.1.15Discussion
The generally very high prevalences of HCV among IDUs would seem to indicate that the virus has been present
among most of these populations for some decades, long enough to reach endemicity. This is perhaps also
indicated by the much greater variability of HIV prevalence in these populations. (Perhaps where there has been
wider spread of HIV among an IDU population there is an apparent decrease in prevalence of HCV exposure
because of decreased antibody response). The data on genotypes in these populations suggest, however, that this
has been a dynamic situation, with the introduction of genotypes new to a particular population over time.
The extremely rapid rises in prevalence in the first few years of injecting seen in some studies may be explicable,
to some extent, by sampling bias, with those more at risk of exposure also more readily accessible for study, but
they also indicate the rapidity with which a blood-borne virus can spread in these populations in the absence of
preventive measures. The increased infectiousness of HCV over HBV in most of these populations, as indicated
by the earlier infection with HCV, probably relates more to higher prevalences of infectious people than any
inherent property of the virus or the viral carrier.
The contribution of IDU is underestimated because of difficulties of ascertainment (which may vary from country
to country, time to time, researcher to researcher or group to group), an ignorance of, or a reluctance to,
acknowledge the widespread nature of IDU in these societies, and the length of time since the event(s) which may
have been very few in number.
The evidence of continuing high rates of transmission of HCV among IDUs in situations in which HIV and HBV
spread seem to be controlled demands explanation. Firstly, the prevalence of HCV carriage is generally much
higher than that of HIV or HBV in most populations of IDUs (in Australia, on average, of the order of 50% of
current IDUs will be infectious for HCV compared with less than 2% for HIV and HBV), then much smaller
frequencies of behaviours allowing transmission of these viruses are sufficient to maintain a high rate of
transmission of HCV than would be the case with low prevalence viruses such as HIV or HBV. Secondly,
because of relatively higher concentrations of infectious particles in the blood of an HCV carrier than in that of
an HIV carrier, for most of the course of the infection, much smaller amounts of blood would be necessary to
carry an infectious dose. Both these factors can explain continued high rates of HCV transmission simply because
of continued sharing of needles and syringes, albeit at a much reduced rate and one sufficient to substantially
decrease the transmission of HIV and HBV in the same populations.
The findings of relatively high incidences of HCV transmission among IDUs who report never sharing needles
and syringes with the video observation of unsafe practices other than needle and syringe sharing, and the
findings from dialysis units of environmental contamination resulting in HCV transmission, raise doubts about
the ability of eradication of needle and syringe sharing (if this is possible) to completely control the spread of
HCV among IDUs. However, it has been argued that the relative contribution of sharing of needles and syringes
to the transmission of HCV among IDUs is much greater than that of sharing of other injecting equipment or
environmental contamination. On this basis, further diminution in the sharing of needles and syringes is both a
necessary and perhaps a sufficient condition for control of the epidemic among IDUs (Crofts et al 1999).
Further, the observations that, at least in some populations of IDUs, substantial proportions are exposed to HCV
within the first year or two of beginning to inject provide further challenges. In general, these young IDUs are not
in touch with treatment programs, and are less in touch with needle exchange than their older counterparts. They
constitute a group especially difficult to contact and among whom to promote behavioural change.
And lastly, high prevalences among IDUs entering methadone maintenance programs, and continued high
incidences among those attending such programs, cast doubt on the usefulness of these programs in slowing HCV
transmission among IDUs.24
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The epidemiology of HCV infection among IDUs, therefore, currently poses great challenges for control of the
epidemic. Facing these challenges is urgently and vitally necessary. As can be seen from this report, IDUs are the
only substantial core group for continued transmission of HCV, and if the overall epidemic is to be contained, it
is among IDUs that control of the HCV epidemic must be the first priority.
4.2 Nosocomial transmission: transmission of hepatitis C virus by
medical procedures and in the health care setting
4.2.1 Introduction
HCWs and their clients are exposed to HCV through contact with blood and other body fluids. In addition to
being detected in blood, HCV RNA has been detected in ascitic fluid, seminal fluid and in urine from HCV-
positive patients with CLD (Liou et al 1992). HCV transmission in the health care setting can occur from client to
staff, from staff to client or between patients. The transmission may be direct or via contaminated instruments and
other surfaces.
4.2.2 Background
Hepatitis viruses were among the first viruses found to be transmitted by blood or blood products. The
recognition of hepatitis B surface antigen (HBsAg) in 1965 provided a mechanism for screening blood donors to
reduce the transmission of hepatitis by blood transfusion (Boscan et al 1995). However, testing for HBsAg did
not prevent all cases of TA-hepatitis even though it substantially reduced the transmission of HBV. After the
development of a serological test to detect HAV, it became apparent that 95 per cent of all posttransfusion
hepatitis were associated with neither HAV nor HBV (Feinstone et al 1975; Aledort 1993). This type of hepatitis
became known as NANBH and early studies reported the incidence of NANBH to be as high as 21 per cent after
transfusion (Gocke 1972; Alter et al 1975). The introduction of measures such as the use of nonpaid donors
instead of paid donors and the exclusion of institutionalised donors in the late 1970s reduced the incidence of
posttransfusion NANBH to around 10 per cent (Barbara and Contreras 1991).
Retrospective studies showed that donors with elevated levels of ALT appeared more likely to transmit hepatitis
to recipients than those with normal ALT levels. A similar relationship was seen between the presence of
hepatitis B core antibody (HBcAb) and donor infectivity. These findings led to the use of ALT levels and HBcAb
as surrogate tests for NANBH in many countries between 1986 and 1988. However, surrogate screening for
NANBH using anti-HBcAg screening was not effective in areas where HBV infection was endemic and most of
the adult population tested positive to serum antibody to HBcAg. To overcome this problem, donor populations
in these regions were often tested for HBsAg instead of HBcAb (Wang et al 1994).
In late 1989, HCV was isolated and serological tests that detected antibody to HCV became available (Choo et al
1989). First-generation EIAs were based on the detection of antibodies to a part of the HCV genome called the
C100 antigen. False positives were common with these first-generation EIAs and the sensitivity of these assays
was reported to range from 59 to 85 per cent (McFarlane et al 1990). The sensitivity and specificity of HCV
EIAs improved with the introduction of second-generation EIAs which incorporated structural antigens of HCV
in addition to the C100 antigen. Around the time the second-generation assays were developed, RIBA2 also
became available. The RIBA2 system utilised four different recombinant HCV antigens to increase test
sensitivity. When used together with the second-generation EIA, false positives are uncommon (Laurian et al
1992; Watson et al 1992).
Techniques to detect HCV nucleic acid sequences using PCR technology have also been developed. However,
limited access, prohibitive cost and interlaboratory variability has resulted in variable findings from studies using25
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PCR techniques. The recent availability of commercial PCR kits has improved the standardisation of
seroprevalence studies and improved reliability (Tilston et al 1994).
4.2.3 Blood transfusion recipients
Investigations carried out after cloning HCV and development of a serological assay for the detection of antibody
to HCV have shown that 80 to 95 per cent of hepatitis infections that have occurred in recipients of blood
transfusions in the last two decades were associated with HCV infection (Aach et al 1991; Tremolada et al 1991).
Studies performed in the 1970s and early 1980s estimated that the posttransfusion risk of NANBH infection was
between 5 and 18 per cent (Alter et al 1981; Stevens et al 1984). The risk was reduced by 30 to 56 per cent after
the introduction of screening for the surrogate markers of NANBH; elevated levels of serum ALT and HBcAb
(Koziol et al 1986; Donahue et al 1992). After the introduction of first-generation screening assays for antibodies
to HCV this risk was further reduced by 60 to 84 per cent and the subsequent introduction of second-generation
testing has been estimated to reduce the risk by 88 to 93 per cent (table 12).
Table 12 Posttransfusion risk of hepatitis C virus infection by country
Country Rate of HCV infection in recipients Reference
After the introduction of screening for surrogate markers (%)
Australia 1.0 Ismay et al (1995)
Japan 4.9-16.3 Japanese Red Cross Non-A hepatitis Research Group
(1991)
Spain 10.7 Gonzalez Quintela et al (1995)
Taiwan 11-12.4 Lee et al (1991b), Wang et al (1994)
USA 1.54 Donahue et al (1992)
After the introduction of first-generation screening
A (%)
Canada 1.1 Preiksaitis and Rivet (1995)
Finland 0.3 Ebeling et al (1991)
Japan 1.9-3.3 Japanese Red Cross Non-A Hepatitis Research Group
(1991)
Spain 1.5 Gonzalez Quintela et al (1995)
Sweden <0.06 Norda et al (1995)
USA 0.57 Donahue et al (1992)
After the introduction of second-generation or third-generation screening
A (%)
Spain 0.86 Gonzalez Quintela et al (1995)
Taiwan 0 Wang et al (1994)
USA 0-0.06 per unit Alter (1995b), Nelson et al (1992)
AStudies that used both HCV antibody screening and supplemental testing.
The risk of acquiring HCV through blood transfusion has steadily declined with the introduction of screening
tests for HCV-specific antibody. In addition to these screening tests, other mechanisms have been introduced to
improve the safety of blood and blood products. These include donor interviewing and deferral to preclude
donors with risk factors associated with chronic or acute hepatitis or HIV infection.26
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Further prospective studies are required to estimate the incidence of posttransfusion hepatitis in different
geographical areas with high or low prevalence of HCV in donor populations. The prevalence of HCV antibodies
in different populations varies from about 1 per cent in most developed countries to <10 per cent in developing
countries (Purcell 1994). However, in Egypt, the prevalence of HCV antibody is estimated to be between 10 and
20 per cent (Hibbs et al 1993).
4.2.4 People with haemophilia
Studies have shown that the prevalence of HCV in people with haemophilia who received nonheat-treated
concentrates after 1970 ranges from 60 to 96 per cent (Brettler et al 1990; Eyster et al 1993; Lee et al 1995).
These differences are probably because of different patient selection criteria and the use of different detection
systems.
Studies using second-generation assays have demonstrated that before effective procedures to inactivate virus in
clotting factor concentrates were introduced, the rate of HCV transmission in people with haemophilia who were
previously untreated was as high as 100 per cent (Laurian et al 1992; Watson et al 1992; Lee et al 1995).
The introduction of viral inactivation processes, such as pasteurisation, steam treatment and solvent-detergent
treatment used in the preparation of clotting factor concentrates, has substantially decreased the risk of HCV
transmission in people with haemophilia (Mannucci et al 1990a, 1992; Suomela 1993; Bertorp 1994). However,
isolated reports of new transmissions continue.
4.2.5 Dialysis
Prevalences and associations of hepatitis C virus exposure among dialysis patients
Raised prevalences of antibody to HCV among patients receiving dialysis have been noted in multiple studies
from many parts of the world (table 13, see Tables section). However, there is much more variation in prevalence
according to location and other factors than there is, for instance, among IDUs. This remains the case even when
discrepancies in prevalence rates as a result of the use of first-generation or second-generation HCV antibody
assays are accounted for (Rosen et al 1996a, 1996b). This, and the various associations of HCV seropositivity
among dialysis patients, suggests that factors other than simply dialysis are responsible for exposure to HCV
among these patients.
In general, the prevalence of anti-HCV among patients who have received dialysis is about 30 per cent, but it
ranges from 0 per cent in some South American centres (Ibarra et al 1995; Fernandez et al 1996), to 75 per cent
or more in Romania (Boscan et al 1995), at an Italian centre (Fabrizi et al 1994), and in Indonesia
(Hadiwondowo et al 1994).
  A study in the USA of 2,304 dialysis centres found an overall prevalence of less than
10 per cent (Tokars et al 1996). There are no published data on the prevalence of anti-HCV among dialysis
patients in Australia.
Several studies have compared prevalences among patients who have received haemodialysis (HD) and patients
who have received constant ambulatory peritoneal dialysis (CAPD) at the same dialysis centre (Castelnovo et al
1995; Cendoroglo Neto et al 1995b; Dussol et al 1995; Golan et al 1996; McIntyre et al 1994; Vanderborght et al
1995). Three have found the prevalence to be 3.7, 3.8 and 4.6 times higher among HD patients than among
CAPD patients (Castelnovo et al 1995; Vanderborght et al 1995; Golan et al 1996); the fourth, from Brazil
covering 1987-90, found equal prevalences (Cendoroglo Neto et al 1995b).
Among HD patients, many studies have found two major associations: number of transfusions received and
duration of dialysis; most find these to be inextricably associated. Several investigators have found that HCV
seropositivity in HD patients is most strongly associated with a history of blood transfusion; for instance, in two
Japanese studies, prevalence among HD patients with a history of transfusions was 3.9 and 1.4 times higher than
among HD patients with no such history (Fujiyama et al 1995; Nakayama et al 1996).27
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The evidence supports the hypothesis that a major part of the transmission of HCV to dialysis patients has in the
past come from the receipt of contaminated blood transfusions. However, even among dialysis patients who have
never received a transfusion, the rate of HCV seropositivity is increased over the general population, raising the
possibility of nosocomial transmission in these settings. Several investigators have also reported on prevalence of
anti-HCV among dialysis staff, finding rates between 0 and 7.9 per cent (Jankovic et al 1994; Tokars et al 1994,
1996; Ambrozaitis et al 1995; Anonymous 1995c; Cassidy et al 1995; Fujiyama et al 1995). There may be some
association between the degree of nosocomial transmission in a dialysis centre (reflected in higher prevalences
among CAPD or nontransfused HD patients) and staff exposure, but this is not clear from current studies. For
instance, in two studies where prevalence among HD patients overall was high, and prevalence among
nontransfused HD patients or CAPD patients was also substantially elevated (25.7 and 17%, respectively),
prevalence among dialysis staff was 2.3 and 2.9 per cent (Fujiyama et al 1995; Vanderborght et al 1995)
compared with 0 to 1.6 per cent in other centres with lower prevalences among patients.
Other associations of HCV seropositivity among dialysis patients reported by some studies include ethnicity
(Huraib et al 1995; Golan et al 1996); exposure to HBV (Boscan et al 1995; Cendoroglo Neto et al 1995b;
Dussol et al 1995; Incandela et al 1994; Slizien et al 1995); and gender (male - Huraib et al 1995; female -
Kumar et al 1994;  Dussol et al 1995).
Many of these studies have investigated the proportions of patients who have detectable serum HCV RNA by
serostatus. Most find very high proportions of anti-HCV positives viraemic, from 41 (Fabrizi et al 1994) and 56
per cent (Tsuyuguchi 1994) to 96 (Bukh et al 1993b) and 98 per cent (Courouce et al 1995), depending partly on
the date of the study and therefore the sensitivity of the RT-PCR assay used.
Among anti-HCV negatives there are several reports of small, but substantial, proportions positive for HCV RNA
in serum, generally in the range of 2 to 4 per cent (Bukh et al 1993b; Chan et al 1993; Kuhns et al 1994; Seelig et
al 1994; Aucella et al 1995; Castelnovo et al 1995) although there are also studies that have found no evidence of
HCV RNA among seronegative dialysis patients (DuBois et al 1994; Boero et al 1995; Courouce et al 1995). The
finding of these proportions of HCV-antibody-negative patients with detectable serum HCV RNA may be as a
result of lack of sensitivity on the part of the antibody assays used, or it may reflect silent carriage, which may
itself be more common in these patients because of immunosuppression.
This finding plus the knowledge that chronic HCV infection without elevated biochemical markers of liver
dysfunction is common in haemodialysis patients implies that only direct determination of the presence or
absence of HCV RNA in the serum is adequate for classification of dialysis patients as HCV infected or HCV
uninfected.
Incidence of hepatitis C virus infection among patients on dialysis
Studies of the incidence of HCV infection among haemodialysis patients (table 14) report findings that accord
with prevalence studies reviewed above (table 13, see Tables section). Incidence varies greatly depending on
location and year, from 15 cases per 100 person-years in a Brazilian study covering 1987-90 (Vanderborght et al
1995) and 19.4 per 100 person-years in a Venezuelan centre (Pru et al 1994) to 0 and 0.44 per 100 person-years
in two Italian studies (Fabrizi et al 1994; Incandela et al 1994). Where it has been investigated, the same gradient
in incidence has been found between HD and CAPD patients as in prevalence studies. There are no published
Australian studies of incidence of HCV infection among dialysis patients.28
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Table 14 Incidence of hepatitis C virus infection among haemodialysis patients
Site Reference Year No. at risk Seroconverters Incidence per 100
person-years
Belgium Stuyver et al (1996) 1991-92 68 25 (37%)
Brazil Cendoroglo Neto et al (1995a) 1987-90 HD: 83
CAPD: 46
18 (22%)
2 (4.3%)
15
3
Brazil Vanderborght et al (1995) 11.5
Croatia Jankovic et al (1994) 63 4
Hong Kong Chan et al (1993) 40 3 (7.5%) 4.9
Italy Capra et al (1995) 5.5
Italy Fabrizi et al (1994) 183 2 (1.1%) 0.44
Italy Incandela et al (1994) 76 0 (0%) 0
Italy Aucella et al (1995) 2.4
Spain Oliva et al (1995) 42 5 (12%) 4
Venezuela Pru et al (1994) 37 17 (45.9%) 19.4
Outbreaks of hepatitis C virus in haemodialysis units
Several outbreaks of HCV infection among patients in haemodialysis units have been described. In 1991-92, 25
out of 68 patients undergoing haemodialysis in a Belgian centre were observed to seroconvert for HCV (Stuyver
et al 1996). Of the 25, 20 had a unique sequence motif, demonstrating patient-to-patient spread within the unit;
despite intensive investigation, no traceable source or transmission mechanism was proven. In Sweden in 1994,
14 haemodialysis patients with chronic HCV infection were investigated (Allander et al 1994). Sequence analysis
showed that five were infected with a common strain, and another two with a different common strain.
Investigation showed that transmission was not related to blood transfusions or use of the same dialysis machines,
but was related to being dialysed on the same shift, suggesting blood transfer between patients by environmental
or staff contact. Investigation of several transmission events in a Japanese haemodialysis unit found that patients
at different but proximate consoles were being exposed to HCV (Okuda et al 1995). After exclusion of other
possible routes of transmission it was concluded that the likeliest transmission pathway was on contaminated
gloves of nursing staff withdrawing needles from patients. There are several other studies similarly describing
outbreaks of HCV among haemodialysed patients on the basis of common sequence strains but which could not
exactly determine the route of transmission other than to exclude the reuse of contaminated dialysis equipment
(Chiaramonte et al 1992; Corcoran et al 1994; Sampietro et al 1995).
One study from Germany, however, found only two isolates with common sequences among 14 HCV-RNA-
positive haemodialysis patients, suggesting that nosocomial transmission in this unit was uncommon (Zeuzem et
al 1996).
Methods of transmission of hepatitis C virus among haemodialysis patients
Several routes have been hypothesised as responsible for transmission of HCV among dialysis patients: through
unrelated risk factors such as IDU, through transfusion of contaminated blood and blood products, nosocomial
transmission from patient to patient by several mechanisms (including shared and contaminated equipment,
contamination by staff not strictly observing universal precautions, and by patients helping each other on the
ward), and through the actual dialysis equipment or process itself.29
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The role of transfusion in transmission of HCV among dialysed patients is clearly indicated by  the following
associations with HCV exposure among haemodialysed patients:
·  a history of blood transfusion;
·  a dose-response relationship with the number of blood transfusions;
·  higher rates of HCV exposure among HD compared with CAPD patients; and
·  higher rates of HCV exposure among transfused HD patients compared with nontransfused HD patients.
However, the higher prevalences of HCV exposure among nontransfused HD patients and among CAPD patients,
and the very strong association of HCV exposure with length of time on dialysis (independent of history of blood
transfusion) demonstrate that other mechanisms are also important (Tsuyuguchi 1994).
Several authors have concluded that environmental factors are important in nosocomial transmission of HCV in
dialysis units (Irie et al 1994; Cendoroglo Neto et al 1995b; Nakayama et al 1996), with an Italian study
concluding that ‘with two new needle holes made along the anastomosed blood vessels two to three times per
week, the chances of patient exposure to HCV may increase with time’ (Irie et al 1994). However, one Japanese
study found very low rates of HCV exposure among female dialysis patients who had not received a transfusion,
concluding that such exposure is not inevitable (Nakayama et al 1996).
A Venezuelan study found 17 seroconversions among 37 initially negative, indicating that,  according to the
authors, ‘the existence of a route of transmission from patient to patient through the dialysis machine’ (Pru et al
1994). The role of dialysis itself has been investigated in two studies, the first in Austria indicating that no HCV
RNA (cells or cell particles) passed through dialysis membranes (Hubmann et al 1995). In a second study, from
Spain, PCRs performed on haemodialysis ultrafiltrate or peritoneal effluent from HCV-RNA-positive patients
were always negative for HCV RNA (Caramelo et al 1994). This same study found no transmission of HCV from
HCV serum RNA-positive patients to negative patients sharing dialysis monitors, a finding which was replicated
in an Italian study (Gilli et al 1995). Despite a high starting prevalence in the patients on the dialysis ward, no
new HCV infections were observed either in patients on separate machines or in patients sharing machines. The
authors conclude that, ‘(t)he possibility of an intradialytic diffusion of HCV appeared to be very low and the
treatment of infected patients on separate machines not strictly necessary’, and further that universal precautions
should be rigorously applied. However, the authors of a Swedish investigation of HCV transmission in a
haemodialysis unit have suggested that there may be high frequencies of HCV transmission even where
precautions are rigorously applied (Allander et al 1994). They particularly point out that such spread can occur
unnoticed if it is not searched for.
Prevention of hepatitis C virus transmission in dialysis units
A decrease in the risk of transmission of HCV through transfusion of blood is the most important method of
decreasing risk for dialysis patients. Universal screening of blood donors, decreasing the number of transfusions
and increasing the use of erythropoietin all diminish the risk of TA-HCV in these patients (Incandela et al 1994;
McIntyre et al 1994; Fujiyama et al 1995). Screening of blood donors for anti-HCV has been shown to have
decreased prevalence of HCV antibody in one French HD unit from 43.6 to 21.2 per cent (Simon et al 1994).
With these measures in place, nosocomial transmission becomes the largest threat to dialysis patients (Paydas et
al 1994), raising the importance of strict adherence to universal precautions (Incandela et al 1994; Dussol et al
1995; Fujiyama et al 1995; Huraib et al 1995). A Saudi Arabian multi-centre study found that ‘the major
difference between HD centres with low and with high prevalence was the adherence of the staff to universal
infection precautions’ (Huraib et al 1995).30
Epidemiology of the hepatitis C virus - Chapter 4
The need to subject HCV-infected patients to quarantine or isolation in special wards or units has been raised by
several authors in the light of continuing HCV transmission among dialysis patients (Aucella et al 1995;
Blumberg et al 1995; Dussol et al 1995), and some have found that limited isolation does indeed decrease
transmission 0(
Blumberg et al 1995). For instance, an outbreak of HCV infection among HD patients in an Italian unit with
.machines without completely disposable dialysate circuits was seen to have been stopped by transferring patients
with acute hepatitis to machines with completely disposable circuits (Chiaramonte et al 1992). However, the
existence of dialysis patients who had been diagnosed as positive by PCR for HCV RNA in their serum while
remaining anti-HCV negative (as indicated above) has been used to question the long-term efficacy of such
policies (Fernandez et al 1996). As well, there are logistical implications inherent in such policies which involve
the multiplying of separate wards or the application of costly routine testing programs (Jadoul et al 1993).
In conclusion, an Italian group has shown that ‘traditional dialysis, employing low-permeability machines and
disposable dialysate circuits on machines without an ultrafiltration control device’ together with rigorous
application of universal precautions can prevent HCV transmission among dialysis patients. Jadoul et al (1993)
and Jadoul (1995) have concluded that ‘the most cost-effective alternative may be strict adherence to basic
barrier precautions: cleaning and disinfecting instruments, machines and surfaces as well as frequent
handwashing and the systematic use of gloves’. In the words of a Lancet editorial on the subject, ‘Now wash your
hands’ (Heptonstall and Mortimer 1995).
4.2.6 Intravenous anti-D immunoglobulin
Anti-D immunoglobulin is prepared from the plasma of donors with high concentrations of anti-rhesus D
antibody. Intravenous anti-D immunoglobulin was first reported to be involved in the transmission of HCV in an
outbreak of NANBH that occurred in East Germany between 1978 and 1979 (Dittmann et al 1991). A similar
outbreak was also reported in Ireland where 12 women received anti-D immunoglobulin manufactured in 1977
that contained HCV-RNA sequences (Stevens et al 1984; Power et al 1994; Power et al 1995a). Both of these
outbreaks were traced to index cases who donated HCV-antibody-positive blood.
Another intravenous preparation implicated in the transmission of HCV was an immunoglobulin product,
Gammagard, used to treat primary immunodeficiency disorders such as hypogammaglobulinaemia. In the USA,
43 people with acute HCV infection were reported to the Centers for Disease Control and Prevention (CDC)
between 1993 and mid 1994 where the only risk factor for HCV infection was receipt of the intravenous
immunoglobulin, Gammagard (Anonymous 1994). Gammagard was subsequently removed worldwide in early
1994. Preliminary epidemiological investigations in the USA have indicated that no other intravenous
immunoglobulin products or intramuscular immune globulin have been associated with HCV transmission
(Anonymous 1994).
The recent introduction of anti-viral treatments used in the manufacture of immunoglobulin products has
substantially reduced the risk of transmission of HCV to recipients of these products.
4.2.7 Hepatitis C virus and dentistry
It is a commonly believed that there are ‘large numbers of hepatitis C carriers in whom no route of infection can
be identified’ (Tibbs 1995). Given the findings of HCV RNA in saliva and higher than expected prevalences of
HBV in dentists, some of these cases (if this is indeed the case) may be explained by transmission in the dental
setting. There is also the question of the degree to which dental staff are at occupational risk of HCV infection.
Presence of hepatitis C virus in saliva
HCV RNA has been detected in saliva in the dental setting, both with and without blood contamination. In one
study of 26 anti-HCV-positive patients, of whom 11 were coinfected with HIV, HCV RNA was detected in the
sera of 23 (88%) and in the saliva of 4 (17%) of these viraemic patients. The authors suggest that HCV is present
in saliva in31
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less than 25 per cent of HCV viraemic people, and the virus in saliva is restricted to the cell fraction, so that
saliva may serve as a nonparenteral transmission route of HCV but at a low probability, which would be
increased by blood contamination of saliva during and after oral surgery (Chen et al 1995). A second study of 21
HCV-seropositive patients with haemophilia attending an Oral Surgery Unit, all of whom were HCV-RNA
positive and six of whom were also HIV-antibody positive, found HCV in saliva from 10 of the subjects (8 HIV
seronegative, 2 HIV seropositive) (Roy et al 1996).
Prevalence of hepatitis C virus in and risks of transmission to dental staff
For exposure of dental staff to HCV to occur, HCV must be present in the population of dental patients and the
dentist must experience an exposure-prone injury. That dentists are at risk of occupational injury conducive to
exposure to blood-borne viruses is undoubted. A survey of 310 dental practitioners in Scotland found that 56 per
cent of respondents reported at least one such injury within the preceding year, half of which were judged to have
constituted a moderate or high risk of transmission to the dental practitioner (Felix et al 1994). That HCV is
present in dental populations is equally undoubted: it has been estimated that in an average dental practice in the
USA that treats 20 patients each day, one HCV-infected patient will be encountered every 2 weeks (Wisnom and
Kelly 1993). A study of 500 dental school patients in the USA found more than 5 per cent were HCV
seropositive; it also found that responses to questionnaires of risk factors were not of practical value in predicting
who was seropositive (Shopper et al 1995).
Given the presence of HCV in saliva, the prevalence of occupational exposure-prone incidents among dentists
and the prevalence of HCV in some dental populations, it would be expected that there would be a high
prevalence of HCV exposure among dental staff. There have been four major surveys of dentists and oral
surgeons examining prevalence and associations of HCV, and their conclusions are not totally in accord.
In a survey of dental professionals attending the annual meeting of the College of Dental Surgeons of British
Columbia, Canada, in June 1990, 401 of 1,995 convention attendees (20%) participated. Fourteen (3.5%) had
markers of HBV infection, of whom one (0.25%) was also HCV-seropositive: none was positive for antibody to
HIV (Roscoe et al 1991). In Taiwan in 1990-91, 3 of 461 dentists (0.65%) were HCV-seropositive, comparable
with the prevalence in healthy blood donors (0.95%) and pregnant women (0.63%), leading to the conclusion that
in this area the practice of dentistry carries no increased risk of HCV infection (Kuo et al 1993). Among 456
dentists in the New York City area anti-HCV was found in 8 (1.75%), compared with 1 (0.14%) of 723 controls
(OR 12.9, 95% CI 1.7, 573). Seropositive dentists claimed to have treated more IDUs in the week (P=0.04) or
month (P=0.03) before the study than did seronegative dentists. In this study, anti-HCV was found in 4 (9.3%) of
43 oral surgeons compared with 4 (0.97%) of 413 other dentists (OR 10.5, 95% CI 1.9, 58) (Klein et al 1991).
And lastly, among 343 oral surgeons and 305 general dentists, recruited at national meetings of the American
Dental Association, anti-HCV was found in 2.0 and 0.7 per cent, respectively (OR 3.2, P=0.13), associated with
older age, longer time in practice, and evidence of past HBV exposure (Thomas et al 1996).
Two other studies that have included dentists along with other HCWs have similarly found low rates of exposure
to HCV, even where prevalence is high in the patient population. One study in the USA found anti-HCV
prevalence to be 1.6 per cent (95% CI 0.0, 3.2%), similar to volunteer blood donors, despite high degrees of
blood exposure in the HCWs (Cooper et al 1992). A survey of hospital-diagnosed acute viral hepatitis in the
United States Air Force staff from 1980 to 1989 found an increased risk of HCV for ‘procedurally oriented
medical personnel’ (including dentists) when compared to all other occupations, but this increase was not large
(RR 1.5, 95% CI 1.1, 1.9).
Taken together, these data tend to confirm high rates of HBV exposure among dental staff, but suggest that the
risk of HCV infection is considerably lower: it seems to be increased with risk of blood contamination and degree
and frequency of exposure-prone procedure.32
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Knowledge of transmission of viral pathogens among dental staff
Some researchers have investigated dentists’ awareness of the risks of transmission of viral pathogens, and their
response to these risks. A survey in British Columbia, Canada, showed that many of the mechanisms, routes and
risks for the transmission of viral pathogens in the dental setting were not clearly understood by the dentists
surveyed, and recommended continuing education to ensure that compliance with current infection control
recommendations be based on a clear understanding of the mechanisms of infection (Epstein et al 1995). The
Roscoe et al (1991) survey of dental professionals in British Columbia also assessed compliance with infection
control guidelines, and found acceptance to be high, with 92 per cent of participants reporting use of gloves for
all patients and 82 per cent reporting use of masks and eye protection.
Risks of patient-to-patient transmission in the dental setting
Returning to the question of whether dental procedures constitute a risk for HCV infection for the patient, there
are few studies which have identified a history of dental work as a risk factor among HCV-infected people. In
Hangzhou, China, 22 per cent of 1,248 people with acute viral hepatitis were NANBH, and among these cases
‘seeing dentist was the main risky factor’[sic] (Sun 1990). A second study in China found that for three (7.5%) of
40 HCV-seropositive patients frequent visits to the dentist were the only discoverable risk factor (Garassini et al
1995). An analysis of data on acute viral hepatitis collected by an Italian surveillance system found that 9 per
cent of all cases of acute HCV infection had only a history of dental work as a risk factor in the preceding six
months (Piazza et al 1995).
On the basis of Piazza et al (1995), environmental contamination of dental surgeries by HCV was investigated by
following 35 anti-HCV and HCV-RNA-positive patients with chronic hepatitis through dental treatment; 328
samples were collected from instruments and surfaces after their dental treatment. Twenty (6.1%) were positive
for HCV RNA, including samples from work benches, air turbine handpieces, holders, suction units, forceps,
dental mirrors and burs. The authors conclude that ‘these data indicate that there is extensive contamination by
HCV of dental surgeries after treatment of anti-HCV patients and that if sterilisation and disinfection are
inadequate there is the possible risk of transmission to susceptible individuals’ (Piazza et al 1995).
4.2.8  Hepatitis C virus and surgery
The existence of HCV infection among surgical patients or surgeons raises the possibility of its transmission in
the surgical setting, from patient to surgeon, from surgeon to patient, or from patient to patient. Partly because of
the low clinical attack rate with acute HCV infection, there have been few reported outbreaks or transmissions in
this setting, but some evidence in some settings suggest surgery can be a risk for HCV transmission.
Environmental studies on this subject are lacking.
It has been estimated in the USA that the risk of a surgeon acquiring a disease from one percutaneous exposure is
0.3 to 0.4 per cent for HIV, 6-30 per cent for HBV and 2.7 to 10 per cent for HCV, and that rates of blood
contacts vary (particularly with the type of surgery) but may reach up to 11.9 per 100 hours in the operating room
(Patz and Jodrey 1995).
Environmental studies
One Japanese study (Higashi et al 1994) found HCV RNA in the irrigating solution aspirated by the ultrasonic
dissector system used in liver surgery, correlating with HCV RNA in the serum of the patient operated on. The
authors conclude ‘that it is necessary to be cautious regarding the transmission of HCV during liver surgery when
using the ultrasonic dissector in HCV RNA seropositive patients, because the irrigating solution aspirated by this
device appears to be highly infectious’ (Higashi et al 1994). Studies in the dental setting have found evidence of33
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HCV RNA both in patients’ saliva (Roy et al 1996) and in the dental environment following dental work on
HCV-RNA-positive patients (Piazza et al 1995).
An Australian study of exposure of endoscopic surgeons engaged in transurethral resection using fluoroscein
staining of irrigating fluid found that in 17 out of 20 consecutive operations splashes on the face of the surgeon,
although few, were visible to the naked eye (Taylor 1990). A Japanese study of 226 ophthalmological patients
found HCV antibody in the aqueous humour of 11 (4.9%), but in six eyes of five of these patients, HCV RNA
was not found by PCR (Kobayakawa et al 1993). Other than these, there are no reported studies of investigation
of HCV RNA in the surgical environment.
Prevalence of hepatitis C virus in surgical populations
In several studies of surgical patients, increased rates of HCV seropositivity have been reported in several studies
of presurgical patients in several locales. Associations of HCV seropositivity have been reported as having liver
disease or risk factors for HCV infection, especially tattoos, a history of transfusion or a history of IDU. One
investigation of risks for HCV infection in a consecutive series of surgical patients in the USA found that a
history of  IDU was difficult to elicit in this setting, raising doubt about the usefulness of this history as a screen
for HCV risk (Simonian et al 1995), but a second in Japan found a history of risk factors for HCV to be very
discriminating (HCV prevalence among those with risk factors was 54 per cent, while among those with no
discoverable risk it was 1.9%) (Yanaga et al 1995).
Risks to surgeons
Several studies in different locales have reported higher than expected rates of HCV seropositivity among
surgeons, although these rates generally are lower than those for HBV. Twenty-seven per cent of 2,887 surgeons
at 21 hospitals in moderate to high AIDS incidence areas participated in a voluntary, anonymous serosurvey of
blood-borne viruses, of whom 7 (0.9%) had anti-HCV (Murphy et al 1995). The authors concluded that HBV
posed the highest risk of infection with a blood-borne pathogen to a surgeon, followed by HCV and HIV
(Panlilio et al 1995). Of 343 oral surgeons and 305 general dentists recruited at national meetings of the
American Dental Association, 2.0 per cent of the former and 0.7 per cent of the latter were found to be HCV
seropositive, compared with 21.2 and 7.8 per cent, respectively, for HBV. HCV seropositivity was associated
with age, longer practice, and markers of HBV exposure (Thomas et al 1996). In a study of surgeons in
Argentina, the fields of surgery in which there were higher rates of HCV seropositivity were haemodialysis,
obstetrics, surgery and intensive care (Frider et al 1994). Similarly in the USA, surgeons at greatest risk are
residents and those working in obstetrics and gynaecology (Patz and Jodrey 1995). Contributing risk factors are
said to include trauma or emergency orthopaedic procedures, high patient blood loss, long procedures and
holding tissue by hand while suturing (Patz and Jodrey 1995).
Potential transmission of hepatitis C virus by surgery
There remains only one proven example of patient-to-patient transmission of HCV in a surgical setting, which
occurred in Sydney, Australia, in a surgical setting in a private hospital (Chant et al 1994). Investigation of a
cluster of five people with HCV infection, all of whom had surgical procedures in the same session at the same
operating theatre, came to the conclusion that four were infected from the other, although the actual path of
transmission was not determined.
However, there are two reports in which HCV was transmitted from a surgeon to the patients upon whom surgery
was performed. The first was reported from England (Anonymous 1995b). The second involved a cardiac
surgeon in Barcelona, Spain, who infected five patients between 1988 and 1994. The viral strain was the same in
each case as demonstrated by sequencing of the virus and phylogenetic analysis. The surgeon reported an overall
incidence of 20 percutaneous injuries per 100 procedures, but the commonest injury, and the one thought to have
been most likely34
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involved in HCV transmission, occurred during the procedure of tying the wires during closure of the sternum
(Esteban et al 1996).
Other than these cases, evidence of surgical transmission of HCV to patients (whether from surgeon to patient or
from patient to patient) is indirect, identifying a history of surgery as an independent risk factor in those
diagnosed as HCV seropositive. This has been found in several studies, mostly in developing countries. In the
Yemen, in a survey of 348 people without liver disease, HCV seropositivity was significantly associated with age
and prior surgery (OR 10.1), but was not associated with a history of prior blood transfusion or markers of HBV
infection (Scott et al 1992). In Indonesia, HCV seroprevalence among 7,572 healthy volunteer blood donors from
21 of the 27 Indonesian provinces was 2.1 per cent; risk factors for HCV seropositivity included a history of
surgery, blood transfusion, intravenous medication, and acupuncture (Sulaiman et al 1995). In Taiwan, among
126 family contacts of 42 HCV-infected patients without histories of parenteral exposure, 21 (17%) were HCV
seropositive, and histories of blood transfusion and surgery were the factors significantly associated with HCV
infection, suggesting an independent route of infection rather than household contact in these people (Chang et al
1994b). Several studies from Portugal and Spain also have found a history of surgery without transfusion to be an
independent risk factor for HCV seropositivity (Barcena Marugan et al 1992a, 1992b; Santos et al 1994; Suarez
et al 1994).
It is clear that HCV can be transmitted in the surgical setting; however, the rate at which this happens in any
particular population of surgical patients is unknown but clearly low.
4.2.9 Transmission of hepatitis C virus to health care workers
Early evidence of an association between HCV infection and health care employment was provided in a case
control study of patients with acute NANBH (Alter et al 1989a). Case control studies of blood donors with HCV
antibody have also reported increased risk with health care employment (Kaldor et al 1992; Neal et al 1994).
Community-based studies carried out in the USA between 1990 and 1993 report that health care employment
represents 2 per cent of people with acute HCV infection (Alter 1995b). In Australia, 1.4 per cent of the 138
incident cases of HCV (notified under an enhanced surveillance for incident cases of HCV trial in 1995) were
attributed to needlestick injury among nonIDUs (Andrews and Curran 1996).
Case reports of NANBH after percutaneous exposure were published in the early 1980s, and since the
development of the HCV-antibody assay, case reports of HCV seroconversion have been published (Seeff 1991;
Tsude et al 1992; Garces et al 1996). In Brisbane, Australia, 7 of 33 HCWs referred to a HCV clinic between
1990 and 1994 were documented as people with occupationally acquired HCV infection.
The risk of HCV transmission to HCWs has been investigated in cohort studies of HCWs negative for HCV
antibody on enrolment (table 15), cohort studies of HCWs following percutaneous exposure from source patients
who were antibody or RNA positive (tables 16 and 17, respectively), cohort studies of HCWs following
nonpercutaneous exposure from source patients who were antibody positive (table 18) and cross-sectional
surveys of HCV prevalence among HCWs, not employed and employed in haemodialysis units (tables 19 and 20,
respectively).35
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Table 15 Incidence of hepatitis C virus antibody seroconversion in cohorts of health care
workers negative for hepatitis C virus at baseline (enrolment)
Country Reference Year Assay Number
tested at
baseline
Number tested at
follow-up (%)
Incidence
(%)
95% CI
Italy Di Nardo et al (1995) 1986-92 EIA2 937 765 (82) 1 (0.13)
Italy Puro et al (1995) 1992-93 EIA2
RIBA
3006 2622 (87) 3 (0.1) 0.02, 0.34
USA 1987-89 EIA1 50 3 (6.0)
USA 1984-92 EIA1
EIA2
RIBA
556 1 (0.2)
Incidence of HCV antibody was 0.8 per 1,000 person years (95% CI 0.03, 3.6) in a cohort of hospital staff from
San Francisco with no self-reported behavioural risk factors followed from 1984 to 1992 (Gerberding 1994). In
this study, first-generation HCV-antibody tests were confirmed by testing all seropositives and a random sample
of seronegatives with second-generation tests. The single incident in this study occurred in a nurse from the
emergency department who could not describe a specific exposure event. Comparison was also made with HIV
and HBV; HIV incidence was 0.55 per 1,000 person-years and HBV incidence among never-vaccinated staff was
30.5 per 1,000 person-years.
Transmission of HCV from patient or laboratory material to HCW generally has been documented following
percutaneous injuries (tables 16 and 17). HCV incidence in HCWs following percutaneous injury to HCV
reported in studies using second-generation or third-generation EIA assays with RIBA confirmatory testing
ranged from 0 to 6 per cent. Many of these studies have small sample sizes. The upper limit of the 95 per cent
confidence intervals ranged from 3 to 18 per cent. Several studies included some patients with both HCV and
HIV infection. There does not appear to be an increased risk of transmission associated with HIV coinfection
although sample sizes are very small and the number of studies limited (Hernandez et al 1992; Perez Trallero et
al 1994; Puro et al 1995). The level of viraemia, however, does appear to influence transmission. Two studies
measured HCV RNA in the source and one study tested a random sample of source sera for HCV RNA; HCV
transmission was 2.5, 3.4 and 10.3 per cent of 80, 29 and 68 injuries from a source with HCV RNA, respectively,
with no reported transmission from sources negative for HCV RNA (Mitsui et al 1992; Sodeyama et al 1993;
Perez Trallero et al 1994).36
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Table 16 Hepatitis C virus transmission to health care workers following percutaneous
injury from a source with hepatitis C virus antibody
Country Referenc
e
Insti-
tution
Assay Type of
injury
No. of
sources
with HCV
antibody
No. sero-
conversions
(%)
95%
CI
Comments
Australia NCHECR
(1998)
NSI
A 28 0 (0) 0, 12
Italy Puro et al
(1995)
H
B(16)
H (16)
EIA2
RIBA
EIA2
RIBA
NSI
NSI
Sharp
97
331
105
1 (0.75)
4 (1.2)
0
0.02,
4.1
0.3,  3
Includes 123 sources with
HIV antibody (2/123 v.
2/208). Loss to follow-up 9%
Italy Petrosillo
et al
(1994)
Dialysi
s units
(9)
EIA2
RIBA2
NSI 61 0 0.0,  6
Japan Kiyosawa
et al
(1991)
UH
C EIA1
RIBA
NSI 110 3 (2.7) 0.6,
8.0
Loss to follow-up, 44%
Japan Sodeyama
et al
(1993)
UH EIA1 NSI &
sharp
90 2 (2.2) 0.3,
7.8
Japan Mitsui et al
(1992)
H EIA1 NSI 76 7 (9.2) 3.8, 18
Spain Hernande
z et al
(1992)
TH
D EIA2
RIBA
NSI 81 0 0.0,  4 Includes 38 sources with HIV
antibody (0/38 v. 0/43)
Spain Perez
Trallero et
al (1994)
HE I A 2
EIA3
NSI 53 1 (1.9) 0.1, 10 Includes 42 source with HIV
antibody (1/42 v. 0/11)
UK,
London
Zuckerma
n et al
(1994)
UH EIA2
RIBA2
NSI 24 0 0.0, 14
USA Lanphear
et al
(1994)
UH EIA2
RIBA2
NSI 50 3 (6.0) 1.3, 17 Loss to follow-up, 56%
ANSI, needlestick injury. 
BH, hospital. 
CUH, university hospital.
.DTH, teaching hospital.
Table 17 Hepatitis C virus transmission to health care workers following percutaneous
injury from a source with HCV RNA
Country Reference Source
with
HCV
RNA
No. sero-
conversions
(%)
95% CI Source
without HCV
RNA
No. sero-
conversions
95% CI
Japan Sodeyama et
al (1993)
80 2 (2.5) 0.3, 9 10 0 0, 31
Japan Mitsui et al
(1992)
68 7 (10.3) 4.3, 21  8 0 0, 37
Spain Perez Trallero
et al (1994)
29
A 1 (3.4) 0.1, 18 13
A 00 ,  2 5
AAll sources with HIV antibody.
In table 18 the studies reporting nonpercutaneous injuries from a source with HCV antibody are summarised.
There have been two case reports of HCV transmission through nonpercutaneous exposure; these occurred via
blood splash to the eye in a health care worker (Sartori et al 1993) and a prison worker (Rosen 1997).37
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Several studies have reported the seroprevalence of HCV among HCWs to be generally around less than 1 to 2
per cent except among oral surgeons and haemodialysis staff. Among oral surgeons, HCV antibody prevalence
was 9 per cent with first-generation testing and was significantly higher than dentists in the same study (Fabrizi et
al 1994). A lower prevalence (2%) was reported among oral surgeons in a later study using second-generation
antibody testing (Thomas et al 1996). Some of these studies have shown prevalence to be associated with
increasing age (De Brouwer and Lecomte 1994; Puro et al 1995; Thomas et al 1996), increasing length of
employment (Jadoul et al 1994; Thomas et al 1996), serological markers for HBV (Polish et al 1993; Puro et al
1995; Thomas et al 1996), and a history of blood transfusion (Polish et al 1993; Petrosillo et al 1995; Puro et al
1995).
Table 18 Hepatitis C virus transmission to health care workers following
nonpercutaneous injury from a source with hepatitis C virus antibody
Country or
region
Reference Institution Assay Type of injury Source with
HCV antibody
No. of sero-
conversions
Australia NCHECR (1998) Multi-site:
Hospitals
Nonpercutaneous 16 0
Italy Petrosillo et al
(1994)
Dialysis units (9) EIA2
RIBA2
Mucous
membrane
Nonintact skin
29
40
0
0
Italy Petrosillo et al
(1995)
Dialysis units (9) EIA2
RIBA2
Mucous
membrane
Skin
contamination
29
271
0
0
Italy Puro et al (1995) Hospitals (16) EIA2
RIBA
EIA2
RIBA
Other than
needlestick
Mucous
membrane
Skin
contamination
36
85
125
0
0
0
Scandinavia Sartori et al
(1993)
Haemodialysis
unit (1)
EIA2
RIBA
Conjunctival
splash
11
USA Rosen (1997) Prison EIA2 Conjunctival
splash
11
The risk of transmission of HCV infection depends not only on the likelihood of transmission per blood contact
and the frequency of occupational contacts but also on the prevalence of infection among the patient population.
The prevalence of HCV among hospitalised patients varies according to specialty and community prevalence. In
studies carried out in the dialysis setting, a high-risk environment for transmission of blood-borne viral infections
to both patients and health care staff, the prevalence of HCV among patients ranged from 5 to 75 per cent
(median). Among hospitalised patients other than those in dialysis units, prevalence was generally less than 2 per
cent except in patients in emergency departments and autopsy cases in the USA  where prevalence was almost 20
per cent and associated with IDU. HCV prevalence among patients in dialysis units was associated with increased
duration of dialysis and blood transfusion. In contrast, other studies have found no association with blood
transfusion. HCV prevalences of 11 and 18 per cent have been reported from 159 and 36 patients, respectively,
with no history of blood transfusion. Among haemodialysis patients in the USA and Belgium, incidence rates of 2
to 3 per cent have been reported: most new infections were unrelated to blood transfusion (Niu et al 1993; Jadoul
et al 1994; Peco Antic et al 1994).38
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Table 19 Hepatitis C virus antibody prevalence among health care workers (other than
staff employed in haemodialysis units)
Country Reference Assay Health care facility No. of
HCWs
With HCV
antibody(%)
Comment
Belgium De Brouwer
& Lecomte
(1994)
EIA3
RIBA3
University hospital 2031 1.48 Non-significant increase with age
France Germanaud
et al (1994)
EIA2
RIBA2
Medical and
nursing staff
430 4 (0.9) Hospital office workers, 1.7%
Germany Jochen
(1992)
EIA2
RIBA
Hospital employees 1033 0.58
India,
Bombay
Amarapurk
ar (1994)
Not
reported
Hospital staff 90 0
Italy De Luca et
al (1992)
Not
reported
Hospital staff 945 45 (4.8) Factory workers 10%
Italy Petrosillo et
al (1995)
EIA1
Matrix
assay
Public hospitals (5) 5813 116 (2) Associated with history of blood
transfusion; No association with
occupational or behavioural risk
factors
Italy Puro et al
(1995)
EIA2
RIBA
Hospitals (16) 3006 2.2 Associated with previous acute
hepatitis, blood transfusions, older
age, and housekeeping occupation
Italy Di Nardo et
al (1995)
Not
reported
Psychiatric hospital 937 0.85
Japan Nakashima
 et al (1992)
EIA1
RIBA
GOR EIA
Acupuncturists
Medical staff
Nursing staff
Other HCWs
183
115
670
310
5.5
4.3
2.2
0.0
No association with age
South
Africa
Soni et al
(1993)
EIA2
NA
A
Nurses 212 0 Antenatal patients, 0 of 100
Taiwan Kuo et al
(1993)
EIA2 Dentists 363 0.8
UK Herbert et
al (1992)
EIA2 Dental surgeons 94 0
UK Zuckerman
et al (1994)
EIA2
RIBA2
Hospital staff 1053 0.28 No association with age.
Anonymous survey.
USA Gerberding
(1994)
EIA2
RIBA
Hospital staff 851 1.1
USA Polish et al
(1993)
EIA1
NA
Hospital staff 677 1.1 Significant association with HBV
core antibody, needlestick, blood
transfusion
USA Thomas et
al (1993)
EIA1
EIA2
RIBA
Primary care facility &
tertiary referral centre
943 7(0.7) Voluntary anonymous survey.
Response rate 90%.
Table 19 continued next page39
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Country Reference Assay Health care facility No. of
HCWs
With HCV
antibody(%)
Comment
USA Thomas et
al (1996)
EIA2
RIBA
Oral surgeons      
General dentists
343
305
2.0
0.7
Associated with older age, more
years of practice and serological
markers for HBV invection
USA Goetz et al
(1995)
EIA2
RIBA
Liver transplant unit
Other HCWs
57
184
5
0
Voluntary anonymous survey. No
association with sex, age, race,
length of occupation.
USA Panlilio et
al (1995)
EIA1
RIBA
Surgeons at 21 hospitals 740 7 (0.9) 27% response rate
USA Gershon et
al (1995)
Not
reported
Funeral practitioners 130 0 50% response
USA Klein et al
(1991)
EIA1
RIBA
Oral surgeons
Dentists
43
413
9.3
1.0
ANA, neutralising assay.
Table 20 Hepatitis C virus antibody prevalence among staff employed in haemodialysis
units
Country Reference Assay No. of HCWs With HCV
antibody (%)
Comment
Belgium Vanderschueren et al
(1991)
EIA1 35 0
Egypt el Gohary et al (1995) 7.7 Urban blood donors 14.5%
2 rural communities 15%
Italy Besso et al (1992) EIA1
EIA2
55 3.6
Japan Oguchi et al (1992) EIA1
EIA2 at 2
units
150 2
Japan Oguchi et al (1992) EIA2 150 2.0
Japan Fujiyama et al (1995) EIA 2 216 2.3
New
Zealand
Blackmore et al (1992) EIA1
EIA2
20 0
Taiwan Lin et al (1991) EIA1 69 2.9
USA Niu et al (1993) EIA1 142 1.0 Cumulative incidence=0%
over 18 months
USA Forseter et al (1993) EIA
RIBA1
29 3.5
USA Jadoul et al (1994) EIA2
RIBA
120 4.1 Associated with longer
employment in unit40
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4.2.10Conclusion
Transmission of HCV infection in the health care setting depends on the likelihood of acquiring infection after
blood contact from a source with HCV infection, the frequency of blood contact and the prevalence of HCV
infection in the patient population. Current evidence suggests that the risk of transmission of HCV through
percutaneous injury from an infected patient is higher than that for HIV but lower than that for HBV. From a
limited number of studies it would appear that risk of HCV transmission is associated with level of viraemia.
The transmission studies are limited by nonreporting of incidents within the hospital setting, loss to follow-up of
HCWs and possible selection biases in the testing of sources. Further studies are required to estimate the risk of
transmission following blood contact with a source with HCV viraemia.
4.3 Sexual transmission of hepatitis C virus
HCV is known to be present in genital tract secretions. Other blood-borne viruses such as HBV and HIV can be
sexually transmitted, so the sexual route of transmission for HCV is plausible.
Research to date on sexual transmission of HCV can be divided into three areas. Firstly, studies have searched for
HCV in genital tract secretions among people known to be seropositive for HCV. Such research can only
demonstrate the theoretical possibility of sexual transmission of HCV. Secondly, populations at increased risk of
STDs, such as sex workers, male homosexuals and STD clinic attenders, have been studied for their rate of HCV
seropositivity. Thirdly, and most directly, stable sexual partners of known HCV-positive individuals have been
studied. These studies can be further classified as cross-sectional, in which the HCV prevalence of current sexual
partners of HCV positives is measured, and longitudinal, in which HCV-negative partners of HCV-positive
patients are followed and the rate of seroconversion calculated. The prevalence of HCV in the study populations
is then compared to that in the ‘general population’. Blood donors are often used as the ‘general population’
comparison, although it is acknowledged that this group may underestimate the true rate of anti-HCV
seropositivity in the general population because of donor deferral policies.
4.3.1 Hepatitis C virus in body fluids
If HCV is sexually transmitted, the virus needs to be present in secretions of the genital tract (table 21). This has
been studied in individuals known to be seropositive for HCV RNA. In such individuals, one study has confirmed
that 100% of specimens (10/10) of first-day menstrual blood of serum HCV-RNA-positive women with chronic
hepatitis were positive for HCV RNA (Silverman et al 1994). Whether HCV is present in semen is more
controversial. In men positive for serum HCV RNA, rates of semen positivity have varied from 0 (0/14) (Fried et
al 1992) to 24 per cent (4/17) (al Dhahry et al 1993). The rate of positivity of saliva is also uncertain, with two
reports suggesting rates of 0 (al Dhahry et al 1993) and 48 per cent (Donahue et al 1991).41
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Table 21 Hepatitis C virus in body fluids
Country Reference Assay No. of
subjects
Body fluid Per cent HCV-
RNA positive
Comments
Italy Fiore et al
(1995)
HCV RNA 11 Serum
Semen
919 All subjects coinfected with HIV
Taiwan Liou et al
(1992)
HCV RNA 34
7
31
17
29
Serum
Ascites
Saliva
Semen
Urine
100
100
48
24
7
8 patients with HCV but who
were serum HCV-RNA negative
were negative in all fluids tested
USA,
Maryland
Fried et al
(1992)
HCV RNA 14 Serum
Saliva
Semen
100
0
0
USA,
Michigan
Silverman et
al (1994)
HCV RNA 10 Menstrual
blood
100 in serum
and menstrual
blood
Day 1 of period. All women had
chronic hepatitis.
From these data, it appears that in persons who are serum HCV-RNA positive, HCV is present in menstrual
blood in a very high proportion of cases. Semen appears to carry the virus in a smaller proportion of cases, but is
nevertheless positive in some individuals. Thus, there is biological plausibility for sexual transmission of HCV.
Contrary to most other STDs, male-to-female transmission may be less effective than female-to-male
transmission, at least if sexual intercourse occurs during menstruation, because of the likely higher infectivity of
menstrual blood than of semen.
4.3.2 Studies in populations at high risk of sexually transmissible diseases
High rates of STDs may be found in certain populations (table 22). These may include commercial sex workers,
male homosexuals and STD clinic attenders. High rates of HCV would be expected in these populations if HCV
were sexually transmitted. Studies in populations at high risk of STDs are of limited use if they do not also
collect data on other known means of transmission of HCV, such as IDU and tattooing. This is especially
important as these behaviours may be common in populations at high risk of STDs. Even studies that attempt to
take into account the effect of IDU on the data may be biased if, as is likely, study participants are reluctant to
admit to past or present IDU. For this reason, results that are ‘adjusted’ for IDU still need to be viewed with
caution.42
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Table 22 Hepatitis C virus in populations at high risk of sexually transmissible diseases
Country Reference Assay Population Results (% positive for HCV)
Australia,
Victoria
Crofts et al 
(1994)
EIA2 HCV
RNA
Currently active IDU Homosexuality not related to HCV,
whereas it was to HBV and to HIV
Belgium Vanderschueren
et al (1991)
EIA1 81 IDU
114 prostitutes
132 healthy homosexuals
31 HIV+ homosexuals
47
3.5
0.8
0
Brazil, Goiania Martins et al 
(1995)
EIA2, IA
A 1378 children/adolescents. 0/280 at day care (age <9) positive.
1/607 public school students (0.2%),
7/491 (1.4%) of adolescents, 6.9% in
those aged 17-20. Prevalence
related to multiple sexual partners,
but not to STD history, in univariate
analyses (also to IDU, tattooing,
blood transfusion).
Brazil, Rio de
Janeiro
Edelenyi Pinto et
al (1993)
EIA1,
RIBA2
2494 voluntary blood donors
202 HIV infected homosexuals
2.1
8.0
Cameroon Ndumbe &
Skalsky (1993)
EIA 2
RIBA2
Pregnant women
Sickle cell patients
Prostitutes
Blood donors
5.5
31
15
6 , 5 if HIV+. 7 if serologically
positive for syphilis, 4 if negative for
syphilis.
Denmark Westh et al
(1993)
? 147 homosexual men
123 IDU
1.4
98
Finland Kolho et al
(1992)
EIA1,
RIBA2
Blood donors In positive donors there was no
association with sexual risk
behaviour.
Hong Kong Chan et al
(1992)
EIA1 Homosexuals
Female prostitutes
0
0
Italy, Bologna Ricchi et al
(1992)
EIA1 Homosexual men 6.9. Association with markers of
HBV, HIV, HCV-positive partner, >20
partners past year.
No adjustment for IDU.
Italy, Milan Salvaggio et al
(1993)
EIA2 151 female IDU 74 in HIV+, 74 in HIV-. Anti-HCV
associated with STDs and number of
sexual partners in HIV negative but
not positive women.
Italy, North Marranconi et al
(1994)
EIA2,
RIBA2
Pregnant women Sexual contacts with IDU, OR=19
Japan,
Fukoaka
Nakashima et al
(1992)
EIA1
RIBA1
Female prostitutes
Females with STD
Males with STD
Controls
6.2
6.1
2.9
1.5. Prevalence rose with age.
Patients with a history of syphilis had
higher incidence.
Japan Utsumi (1995) EIA2 201 prisoners Frequent, aggressive or
promiscuous sexual behaviour
associated on univariate analysis.
Netherlands van Doornum et
al (1991)
EIA1,
RIBA1
468 heterosexual STD clinic
attenders
1.5
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Country Reference Assay Population Results (% positive for HCV)
New Zealand Chetwynd et al
(1995)
EIA2, HCV
RNA
116 IDU attending a methadone
program.
84 HCV positive, and 66 PCR
positive. No relationship with sexual
practices (not specified how this was
measured).
Somalia Watts et al
(1994)
EIA1/2
RIBA 2
236 female prostitutes, 80 STD
patients, 79 male soldiers
No association with syphilis or HIV
serology
South Africa Schoub et al
(1992
EIA2
RIBA2
STD clinic (272)
Family planning (148)
Blue collar workers (246)
New blood donors (117)
1.8
0.7
3.3
0.9
Spain, Seville Lissen et al
(1993)
EIA 2
RIBA2
310 female prostitutes
88 clients of prostitutes
168 homosexual men
147 heterosexual partners of
HCV+400 blood donors
6.4
6.8
4.2
7.4
1.2
Sweden Shev et al (1995) EIA2 51 anti-HCV and HCV RNA
positive blood donors and
matched controls
History of STD significantly
associated with anti-HCV (P<0.001).
HSV2
B serology also associated
(P=0.015).
UK Tedder et al
(1991)
EIA1,
RIBA1
Genitourinary clinic
275 homosexuals
771 heterosexuals
Association with HIV, HBV, lifetime
no. of STDs in homosexual men,
age.
2.2
0.4
UK, England Neal et al (1994) EIA?1
RIBA2
Blood donors No association with multiple sex
partners.
USA, Atlanta Weinstock et al
(1993)
?EIA1,
NA
A
Inner city STD clinic 7.7. In univariate analysis, sex with
IDU and history of gonorrhoea were
associated with risk, but these were
not present after adjusting for
confounders.
USA,
Baltimore
Donahue et al
(1991)
EIA1
RIBA1
500 multi-transfused patients
225 IDU
Homosexual men
4
85
1.6
USA,
Baltimore
Thomas et al
(1994)
EIA1, NA 1257 Non-IDU STD patients Syphilis, HBV serology, and >1 male
sex partner in last month (in females)
all associated with HCV positivity
USA,
Baltimore
Thomas et al
(1995b)
EIA2 1039 non-IDU patients at a STD
clinic
Risk factors for HCV included male
homosexuality, greater numbers of
lifetime sex partners. Females whose
sexual partners were anti-HCV
positive were 3.7 times more likely to
be anti-HCV positive.
USA, Florida Daikos et al 
(1994)
EIA2,
RIBA2
Inner city heterosexuals, IDU
excluded
>10 heterosex.  partner OR=3.7
Sex > 1x/week OR=3.3
USA, North
Carolina
Fiscus et al 
(1994)
EIA1,
RIBA2
STD clinic attenders Homosexuality, syphilis serology,
history of syphilis not related to anti-
HCV
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Country Reference Assay Population Results (% positive for HCV)
USA, San
Francisco
Osmond et al
(1993a)
EIA1,
RIBA2
Homosexual men 4.6 (cf 81% for HBV). After
controlling for IDU, weak
associations with >50 sex partners
per year, >25 oral receptive partners
per year, >25 anal partners/y HBV
more strongly associated with these.
USA, San
Francisco
Osmond et al
(1993b)
RIBA2 Couples recruited for a study of
heterosexual HIV transmission.
64 in IDU.
Not correlated with history of STDs,
sexual behaviour, numbers of sexual
partners.
A NA, neutralisation assay.
BHSV2, herpes simplex virus type 2.
4.3.3 Commercial sex workers
Some studies have found a higher prevalence of HCV in female sex workers compared with the general
population. This has ranged from 15 per cent in Cameroon (Ndumbe and Skalsky 1993), 6.4 per cent in Spain
(Lissen et al 1993), to 6.2 per cent in Japan (Nakashima et al 1992). The results from Cameroon are difficult to
interpret as only blood that was negative for HBV surface antigen was tested. A high prevalence (6.8%) was also
found in male clients of female sex workers in Spain (Lissen et al 1993). In contrast, studies of commercial sex
workers in Somalia (Watts et al 1994) and Hong Kong (GC Chan et al 1992) have found rates of seropositivity
no higher than in the background population.
Risk factors for seropositivity to HCV have also been studied in these sex workers. Number of sexual partners
per year was not a risk factor in Spain (Lissen et al 1993). In Japan, sex workers who had worked for more than
one year had a higher prevalence than those who had been involved for less than one year (8.1 v. 1.4%), but as
age is strongly related to risk of HCV in many studies, this may be related to age rather than duration of
prostitution (Nakashima et al 1992). In Ghent, Belgium, those sex workers who reported a history of at least one
episode of syphilis had a significantly higher prevalence of HCV. However, no data were available on IDU or
history of blood transfusion in these sex workers (Vanderschueren et al 1991). In Somalia, no association
between HCV and syphilis or HIV positivity was found (Watts et al 1994).
In summary, the prevalence of HCV infection in commercial sex workers has often been found to be somewhat
higher than in the general population, but it is difficult to be certain whether this may be accounted for by IDU
among commercial sex workers. However, an association with other STDs, particularly syphilis, among sex
workers who deny IDU suggests that sexual transmission may occur, at a low rate.
4.3.4 Homosexual males
High rates of STDs have been reported in homosexual males. Rates of HCV infection, however, are
inconsistently raised in this population. Although homosexuality has been associated with HCV seropositivity in
some studies (Ricchi et al 1992; Edelenyi Pinto et al 1993; Thomas et al 1995b)
  it is not in most studies
(Donahue et al 1991; Tedder et al 1991; Vanderschueren et al 1991; GC Chan et al 1992; Westh et al 1993;
Fiscus et al 1994). Of those studies which have attempted to account for the effect of IDU on the data collected
on male homosexuals, any association with sexual behaviour is lessened after adjustment, although a weak
relationship may still exist (Osmond et al 1993b). Among IDU, homosexuality does not appear to be a risk factor
for HCV seropositivity (Crofts et al 1994), suggesting that IDU is the more important risk factor. A recent report
has suggested there is a high level of nonspecific anti-HCV reactivity among homosexual males (ie EIA2
positive, RIBA2 negative) so the true45
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seroprevalence in homosexual males may be lower than described in studies not using RIBA2 confirmatory tests
(Andreu et al 1994).
These data suggest that HCV is inefficiently, if at all, transmitted sexually among male homosexuals.
4.3.5 Attenders of sexually transmissible disease clinics
Many seroprevalence surveys have been performed among people attending STD clinics, and other studies have
examined risk factors for HCV seropositivity in these populations. Factors associated with seropositivity have
included a greater number of sexual partners (Thomas et al 1994), known HCV-positive sexual partners (Thomas
et al 1994), positive syphilis serology (Thomas et al 1995a), and positive HBV serology (Thomas et al 1995a).
Factors not associated with HCV have included positive syphilis serology (Fiscus et al 1994; Watts et al 1994). A
study that accounted for the effect of IDU on the data found that much of the association with STDs disappeared
when IDU was accounted for (Weinstock et al 1993).
4.3.6 Studies of sexual partners of HCV-positive individuals
The most reliable means of assessing sexual transmission of HCV is to follow-up known HCV- negative sexual
partners of HCV-positive individuals, and to calculate their rate of seroconversion to HCV. Alternatively, the rate
of anti-HCV seropositivity among partners of known HCV-positives may be calculated (table 23, see Tables
section). This method is a less reliable indicator of sexual behaviour because of past behaviours that may be
inaccurately recalled. Examples of such behaviours include sharing of needles for recreational or medical drug
use, or other activities which led to blood-to-blood contact.
Studies of sexual partners of people with haemophilia have shown generally low rates of seropositivity in
spouses, of 0 to 3 per cent (Eyster et al 1991; Brettler et al 1992; Kolho and Krusius 1992; Brackmann et al
1993; Hallam et al 1993). Risk factors for seropositivity in these spouses included HIV seropositivity in the
person with haemophilia, and known risk factors for HCV infection in the partner. A possible explanation for the
very low seroprevalence in these partners is that the couples use condoms frequently. However, the rate of HCV
seropositivity is much lower than that for HIV, so condoms are unlikely to be the primary explanation for the low
rates of infection in spouses.
Sexual partners of people who are HCV positive through IDU or other, often unknown, means have shown higher
rates of seropositivity. Several studies have shown seroprevalence rates of 20 per cent or more in sexual partners
(eg Kao et al 1992; Napoli et al 1993; Oshita et al 1993; Coltorti et al 1994; Gabrielli et al 1994; Shev et al
1995a). However, others have found seroprevalence rates of 5 per cent or less (GC Chan et al 1992; Gordon et al
1992; Bresters et al 1993; Scully et al 1993; Garcia Bengoechea et al 1994; Diaz et al 1995; Meisel et al 1995). It
is difficult to be certain in these cases whether the high rate in the partner is due to sexual transmission, or due to
other shared behaviours, such as IDU, or shared needles used for medical purposes. Factors associated with
seroconcordance in sexual relationships have included sharing of toiletry items (Gordon et al 1992; Diaz et al
1995), IDU (David et al 1995), and HIV seropositivity in the index case (Lissen et al 1993; Gabrielli et al 1994;
Soto et al 1994). Longer duration of a sexual relationship has also been found to be related to seroconcordance
(Kao et al 1992; Coltorti et al 1994; Garcia Bengoechea et al 1994), but duration of partnership is confounded
with age, which may be associated with other behaviours that lead to HCV infection.
Thus, the results of partner studies are somewhat conflicting. The most reliable studies, in female partners of
males with haemophilia, suggest very low rates of transmission. Other studies are prone to bias due to unknown
or unadmitted shared behavioural factors between sexual partners.46
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4.3.7 Discussion
Sexual transmission of HCV is less efficient than for HIV, HBV, and most other sexually transmissible agents. The
most reliable studies suggest that the rate of transmission is low, but it seems likely that a low rate of sexual
transmission of HCV does occur. The most reliable studies, in long-term sexual partners of HCV-infected people
with haemophilia, suggest that 3 per cent or less of long-term sexual partners become infected. The relatively low
rate of HCV in male homosexuals suggests that anal sex is not a high risk behaviour for HCV transmission.
Although one review concluded that sexual transmission of HCV is absent or rare (van der Poel et al 1994), another
has suggested that nonparenteral transmission (including sexual transmission) may still be significant (Alter 1995b).
There is no evidence that the use of condoms will prevent HCV transmission, although the use of condoms is often
recommended (Tibbs 1995).
4.4 Vertical transmission of hepatitis C virus
Other blood-borne viruses such as HBV and HIV are known to be transmitted vertically from mother to child.
However, compared to the amount of research on parenteral and sexual transmission, comparatively little research
has been undertaken into mother-to-infant transmission of HCV, and most studies have been small scale.
Vertical transmission studies follow babies born to HCV-positive mothers and determine the rate of infection in the
infant. Comparison of studies is hampered by differences in definitions of infection of infants. Early studies (1990
and before) tended to define infection as the persistence of anti-HCV antibody beyond three to six months of age,
whereas later studies have used serum HCV-RNA presence in the infant as being indicative of infection. The
evidence is summarised in table 24 (see Tables section), and possible risk factors for transmission are reviewed in
the text. In addition to direct studies of vertical transmission, studies reporting rates of HCV infection in children in
communities with high levels of HCV infection in adults were reviewed.
4.4.1 Rate of vertical transmission
In mothers who are otherwise well, the rate of vertical transmission of HCV is low, probably less than 5 per cent.
Studies which have found higher rates than this have generally been of HIV-coinfected women.
Further evidence that vertical transmission occurs at a low rate comes from a Japanese community survey of HCV
(Hayashi et al 1995). Although the prevalence of anti-HCV in children of positive mothers was 18 per cent, this rate
was similar to the rate in the same age group of the general population. Furthermore, all HCV-positive children of
HCV- positive mothers were aged more than 20. The prevalence of anti-HCV in 292 persons aged less than 20 was
0. The prevalence in women of child-bearing age was 4 per cent in those aged 20 to 39, and 10 per cent in those
aged 40 to 49.
4.4.2 Possible risk factors for vertical transmission
Breast feeding
HCV RNA has been detected in human breast milk by some investigators (Uehara et al 1993; Turnbull and Sugano
1994), although not by others (Kurauchi et al 1993). A later report suggests that HCV RNA is found in breast milk
only when maternal viraemia is high (Zimmermann et al 1995). No association of risk of transmission with breast
feeding was reported in one study (Paccagnini et al 1995) although another found a longer duration of breast feeding
in mothers whose infants became infected (Ohto et al 1994). Transmission of HCV by breast feeding remains a
theoretical possibility in women with high levels of viraemia, but appears to occur at very low frequency.
Method of delivery
HCV RNA has been found in vaginal secretions of pregnant women (Kurauchi et al 1993), and one study has
suggested lower rates of HCV transmission in mothers who undergo caesarean section (Paccagnini et al 1995). This
study also47
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reported that some infants who did become HCV infected and were vaginally delivered were HCV-RNA negative at
birth, suggesting that infection may have occurred late in pregnancy or during delivery.
Maternal level of hepatitis C virus RNA
A high level of maternal HCV RNA has emerged as the strongest risk factor for vertical transmission of HCV. Higher
levels of transmission (often of around 10%) are reported in those studies that have separately analysed transmission
rates in HCV-RNA-positive mothers. Transmission has not been demonstrated to occur when the mother is negative
for HCV RNA. Transmission is also more likely when the mother is seropositive for HIV, which may result in
increased viral levels of HCV through immune suppression. Whether HIV infection is an independent risk factor for
HCV transmission is unclear.
Hepatitis C virus genotype
One study has suggested that only HCV subtypes 1b or 3a, which are more pathogenic in adults, are transmitted to
babies (Zuccotti et al 1995).
Discussion
Mother-to-infant transmission occurs from 0 to 10 per cent of infected mothers, most likely in less than 5 per cent of
infected mothers. It is much more likely to occur when levels of HCV RNA are high, and in HIV-infected mothers.
Transmission appears not to occur when HCV RNA is undetectable in the mother, and may be less likely to occur
when the baby is delivered by caesarean section. The marked variation in results of studies may possibly be explained
by differences in HCV RNA levels in mothers between studies, or possibly by differences in HCV genotypes. Vertical
transmission of HCV has been inadequately researched and these estimates should be seen as preliminary.
4.5 Household transmission of hepatitis C virus
The existence of nonparenteral routes of transmission of HCV has been suggested because of the relatively high
proportion of people infected with HCV who have no identifiable parenteral risk factors. For example, of 342
consecutive anti-HCV-positive patients presenting to a liver clinic at a major Australian metropolitan general hospital,
27 per cent had no definite percutaneous risk factor (Strasser et al 1995).
Most studies identified in this report were cross-sectional surveys of the HCV status of family members of known anti-
HCV positive people. In many studies, the HCV prevalence was then compared to the prevalence in a control group,
or to available figures from blood donors. These studies usually found higher prevalence levels than in blood donors,
but this is a biased comparison because of the donor deferral policies practised by most blood banks.
Other studies reviewed included genetic studies of whether individuals within the same family are infected with the
same strain of the virus, and studies of specific risk factors that may have led to household transmission.
4.5.1 Rate of household transmission
There has been considerable debate about the rate of household transmission of HCV, and of whether this route of
transmission exists at all. Studies reporting the rate of seropositivity in the household contacts of people who are HCV
positive have been summarised in table 25 (see Tables section). A problem with studies of household transmission is
that members of a household often share behavioural characteristics that put them at risk of HCV, particularly IDU,
and that they may be reluctant to admit to these behaviours. Although many of these studies have found a higher than
background prevalence of HCV, there is considerable debate about whether a higher rate of HCV in family members
of HCV-positive index cases truly represents nonpercutaneous transmission. Most studies have found much higher
prevalence in older household contacts, and rates in children which are similar to background rates. This may be
because the shared48
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behavioural factors which led to transmission are no longer relevant. For example, two Japanese studies in regions
with high levels of HCV endemicity have found higher rates in older people, and very low rates in children without
other risk factors (Hayashi et al 1995; Nakashima et al 1995). The use of nonsterile injecting equipment in medical
care has been implicated as a possible cause of the high seroprevalence of HCV in these areas. Studies in people
infected with HCV through medical procedures (people with haemophilia, dialysis patients) have found no evidence of
household transmission (Brackmann et al 1993; Hou et al 1995).
Honda et al (1993) found a greater degree of HCV nucleotide homology among family members with HCV than with
infected nonfamily members in Japan, suggesting that intrafamilial transmission had occurred. This has not been
confirmed by others, who have found no clustering of genotypes between spouses (Nakashima et al 1995).
4.5.2 Possible routes of household transmission
Ritual blood exchange
Atrah et al (1994) found that of 52 blood donors in England who were HCV positive, 14 per cent gave a history of
ritual blood exchange during childhood or early adult life (the practice of having ‘blood brothers’ or ‘blood sisters’)
and denied other risk factors.
Sharing of nonsterile medical equipment
Sharing of nonsterile injecting equipment within families as a part of medical care has been implicated as a cause of
horizontal transmission in Italy where it was a common practice until the 1970s (Buscarini et al 1993; Frosi et al
1995). In Japan, sterile injection equipment is still not used in some parts of the country, and this, combined with the
Japanese usually being given drug treatment by injection, may explain the very high rates of HCV in parts of Japan
(Hayashi et al 1995; Nakashima et al 1995). Many other studies of household transmission have not investigated this
route of transmission, and this route may explain the apparently high rate of horizontal transmission in Japan and Italy.
This route may explain the strong relationship of anti-HCV positivity with age in these countries, because the medical
use of nonsterile injecting equipment has probably decreased recently.
Razors
The presence of very high levels of HCV infection (38%) in 37 Sicilian barbers who shave themselves with the same
instruments they use to shave their customers suggests that sharing of shaving equipment may be a risk factor for
acquisition (Tumminelli et al 1995).
Saliva
HCV RNA has been detected in the saliva, although at lower titre than in serum (Wang et al 1991; Liou et al 1992).
The epidemiology of HCV infection does not support a role for transmission by saliva.
Discussion
Families of known anti-HCV positive patients often have rates of HCV positivity which are higher than in the local
general population. In most cases, this appears to be explained by shared behavioural characteristics (especially IDU),
or by sharing of nonsterile medical injecting equipment. There is no strong evidence that there are nonpercutaneous
means of household transmission. Potential means of transmission by blood-to-blood contact, such as sharing of razors
or toothbrushes, have not been shown to be important epidemiologically, but remain potential means of transmission.49
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4.6  Tattooing and skin penetration
Tattooing is the practice of making indelible patterns on the skin by inserting pigments through punctures made with
sharp instruments. In modern professional tattooing, electrical tattooing machines with combinations of solid needles
and numerous coloured pigments are used. During tattooing, dye from the layer on the needles is spattered loosely on
the skin surface, before being tapped into the skin by the rapid pricking action of the needles. Spattered dye tends to
obliterate the design ahead of the needle, so it is frequently necessary for the tattooist to wipe away excess dye and any
blood that has exuded to the surface of the skin. Periodically, the tattooist sprays the area with a cleaning solution and
the excess solution, dye and blood are wiped away, generally with a disposable tissue. As the tattooist moves the
needles over the design on the skin, the layer of dye on the needle is replenished by frequently dipping the tip into the
dye container. Depending on the size and the complexity of the tattoo design, the process can take between minutes
and hours, and is completed sometimes over several sittings (Long and Rickman 1994). Since tattooing necessarily
involves breaching of the epithelium, bleeding and reuse of equipment, there is the potential for risk of transmission of
pathogens - patient-to-patient, operator-to-patient and patient-to-operator. Bleeding is less profuse than in other forms
of skin penetration, but nevertheless the possibility for transmission of pathogens pertains.
Since 1947, blood-borne hepatitis viruses have emerged as the most serious and well-documented infections attributed
to tattooing (Smith 1950; Long and Rickman 1994; Mercer and Davies 1991). Between 1947 and 1980, reports were
published relating to 20  outbreaks and over 300 cases of viral hepatitis, most presumed to be due to HBV (Hopkins et
al 1973; Limentani et al 1979; Harrison and Noah 1980; Silvers and Gelb 1991; Loimer and Werner 1992). In most of
the reported cases, tattooists had used the same needle for several customers without adequate sterilisation (Long and
Rickman 1994). Other noted defects in hygiene in tattooing procedures have included (Davis 1995):
·  tattoo needles being immersed in chlorhexidine between clients but not sterilised;
·  pigments being reused;
·  bowls used for surgical spirit being emptied but not changed between clients;
·  tattooists not washing their hands between clients; and
·  gauze swabs being reused on other clients.
Interest in blood-borne viruses has increased due to the discovery and reported effects of HIV, continuing
transmission of HBV despite availability of an effective vaccine, and the availability of a test for HCV which has
revealed the extent of infection with this virus. Case reports (Abilgaard and Peterslund 1991; Thompson et al
1996), 
 research studies (Holsen et al 1993; Ko et al 1992) and the results of routine blood-donor screening (Kaldor
et al 1992; Neal et al 1994) have all implicated tattooing as a risk for transmission of HCV. An Italian surveillance
scheme that evaluated the role of ear-piercing, tattooing, attendance at a chiropodist or manicurist and barber shop
from 1985 to 1993 found that tattooing, ear piercing and barber shop shaving were all associated with NANBH
(56% of 1991-93 cases were HCV positive), while attendance at a chiropodist or manicurist was only associated
with HBV. The authors argue that although the incidence of infections declined by half during 1991-93, because
many in the population are exposed, the role of beauty treatments should not be underestimated (Mele et al 1995).
Another study found that Sicilian barbers had a higher prevalence of HCV antibodies (14/37=38%, 11 RIBA
positive, 3 indeterminate), compared to 0/50, age and gender matched, new blood donors from the same region.
This supports the authors’ hypothesis that barbers who use a traditional shaving technique with nondisposable and
unsterilised blades and haemostatic sticks might transmit infection - including to themselves if they use those same
instruments on themselves (Tumminelli et al 1995).
Identification of the exposure risk for an infection acquired at some unknown time in the past is very difficult.
Although HCV is generally acquired by parenteral routes, there are people for whom no risk factor can be elicited
(Estaban et al50
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1991). Of 342 consecutive patients referred to the liver clinic at St Vincent’s Hospital in Melbourne, 20 (6%)
reported tattooing as their only percutaneous risk factor (Strasser et al 1995). Davies reported that 5 of 13 tattooed
donors at the Sydney Red Cross Blood Bank who were positive as identified by third-generation EIA and
immunoblot assay reported tattooing as their only risk factor (Davis 1995). Several other studies have implicated
tattooing as the only discoverable risk factor in proportions of those with HCV investigated: 12.1 per cent of HCV-
positive blood donors in a series in Argentina (Sookoian et al 1997), a similar series in Hong Kong (Prescott et al
1996), and in a patient series in Taiwan (Li et al 1996).
Yet for many of those for whom tattooing was (initially) considered to be a risk for having acquired HCV, other
potential sources of exposure exist. Moreover, there have been dramatic reductions in the prevalence of HCV
infection in tattooed donors since testing was introduced - a function not only of removing prevalent infections from
the donor pool but also probably reflecting increased community consciousness about the strong association
between HCV and IDU acting to decrease donor deferral where past IDU exists. The figures from Victoria
(Australia) are shown in Figure 1.
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Figure 1. Rate of hepatitis C-positive tests per 1000 donations.
A particular deficiency in current data systems is the dearth of information on the tattooing experience of those with
HCV attributed to tattooing: where they were tattooed, how long ago and how many tattoos or occasions of
tattooing they have experienced. An unpublished study of blood donors at the Melbourne Red Cross Blood Bank
attempted to obtain such information, and all donors with a reactive HCV test who were interviewed over 13
months  were asked about their tattooing experience (S. Thompson, personal communication). Of 29 donors
interviewed, most had been tattooed at registered premises, spanning a range of years, many before 1984. Many
who reported tattooing outside a registered premises had tattooed themselves, in circumstances unlikely to result in
transmission of HCV. Half of those interviewed had only one or two tattoos and had few occasions of tattooing, and
after comprehensive testing, many of51
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these donors were determined to be ‘biological false positives’. There was no clear dose-response relationship with
tattooing, although all the confirmed positives had more than one tattoo, and interestingly all three people with
indeterminate results all had more than five tattoos. Some donors lacked any recollection of the circumstances
surrounding tattooing episodes suggesting that at least some people have obtunded consciousness at the time
tattooing is done. There are studies that suggest that problematic groups, groups with poorer health, and groups
with a greater risk of contracting infectious diseases have a higher prevalence of tattoos. Groups with which
tattooing is associated include IDU, prostitutes, incarcerated persons and individuals with personality disorders
(Rukstinat 1941; Goldstein 1979; Grumet 1983; Silvers and Gelb 1991; Loimer and Werner 1992; Watson et al
1973; Crofts et al 1996). In the absence of any disclosed risk factor, it can not be assumed that a tattooed blood
donor’s exposure is necessarily due to their tattooing experience.
Surveillance undertaken through the Communicable Diseases Network for incident cases of HCV in Australia
during 1995, identified 138 incident HCV infections. (An incident case was defined as documented seroconversion
to HCV where the previous negative was within 12 months of a positive test result, or a positive test result was
associated with clinical hepatitis where other causes of the hepatitis have been excluded). Numerous problems were
identified with the surveillance - variable methods of case ascertainment, response bias and perhaps duplicate
notifications. Only one person (0.7%) reported skin penetration in a nonmedical setting (type not specified) as their
sole risk factor, with 22 people (16%) having no risk factors indicated, and IDU accounting for the overwhelming
majority (105/116, 91%) of reports, with 18 cases having both skin penetration in a nonmedical setting plus IDU
(Anon et al 1995). These results highlight the importance of IDU as a risk factor and the confounding which occurs
if skin penetration procedures are elicited in isolation from those infected with HCV.
Although tattooing is recognised as a risk factor for transmission of HCV, the efficiency with which transmission
occurs is unknown. Some information might be gained by determining the occupational risk to tattooists, although
requirements for informed consent make a representative serosurvey of tattooists difficult to achieve today.
However, sera stored at Fairfield Infectious Diseases Hospital from a serosurvey of tattooists undertaken in
Melbourne in 1984 to test for HIV provided the opportunity to determine the prevalence of serological markers of
HBV and HCV in tattooists at that time. The serum specimens had been obtained from five unregistered and 36/37
(97%) of the registered tattooists operating in 1984, and thus provide an unbiased picture of the prevalence of HBV
and HCV infection in this group in 1984, although no information was available about other risk factors in those
tested. Serological status for HBV (HBsAg, anti-HBs, anti-HBc in standard assays) or HCV (anti-HCV reactivity in
second-generation and third-generation tests, confirmed by RIBA) was determined. No serum was HIV positive or
HBsAg positive. Of 35 specimens tested for HCV-specific antibody, only two (5.6%) were positive despite markers
of HBV in 48.6 per cent of the same sera. Despite frequent needlestick injuries reported by tattooists at the time, the
low seroprevalence of HCV in this group suggests that HCV may not be efficiently transmitted by intradermal
inoculation using solid bore tattooing needles (Thompson et al 1997).
Since skin penetration procedures provide potential for the spread of blood-borne viruses, performing these
procedures necessitates adequate control of infection. Knowledge of the characteristics of blood-borne viruses has
enabled health agencies to develop guidelines on safe practices and infection control aimed at limiting spread of
these viruses, although such guidelines are not necessarily well understood or well adhered to.
There are concerns about the practice of infection control in registered tattooing and skin penetration premises
throughout Australia, but relatively few formal studies have been undertaken. The most detailed assessment of
infection control in tattooing premises has been undertaken in Victoria. Registration of tattooing is based on the
premises and often only involves inspection of the physical condition and facilities of the building. Operators are
not licensed, and no training in infection control is necessary to become a tattooist. Through examination of
historical records it is apparent that hygiene has improved in registered premises since the days when HBV cases
attributed to tattooing were not uncommon (Goudey and Thompson 1994a). Tattooists chosen as part of a random
sample of registered tattooing52
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premises were surveyed for self-reported compliance with infection control practices specified in the Victorian
Standards of Practice for Tattooing (Health Department Victoria 1993) and some were observed while tattooing.
Of 35 respondents, 94 per cent reported that they believed their practice fully met the Standards, yet 19 per cent of
tattooists did not have a copy of the Standards at their premises. There was considerable discrepancy between self-
reported practice and the practices observed. Few tattooists understood or implemented universal precautions and
although most wore gloves, there was low use of eye and clothing protection. Tattooists touched many surfaces that
were not cleaned or disinfected between clients. Glutaraldehyde was not often used for disinfecting equipment,
ultrasound cleaners were generally operated without lids and at no premises was equipment used that had been
cleaned according to the Standards and sterilised in an autoclave that had passed a sterilisation test (Goudey and
Thompson 1994b). There is nothing to suggest that circumstances in Victoria are dissimilar to those in other parts
of Australia. Tattooists found it difficult to understand why each State and Territory has different standards and
they seek and follow advice from a multiplicity of sources: health departments, Environmental Health Officers
(EHOs), government and medical publications, magazines, other tattooists, tattooing associations both in Australia
and other countries, equipment and material suppliers. Inconsistent, contradictory, misleading or misunderstood
advice provides a cogent reason to work towards uniform national skin penetration guidelines. While demonstrable
problems with infection control occur, the potential for transmission of blood- borne pathogens exists and tattooing
will continue to be a potential means of HCV transmission.
The deficiencies in knowledge of some tattooists regarding infectious diseases and infection control can largely be
explained by the lack of suitable training opportunities available to the industry. The situation in Victoria is similar to
those identified in other States and Territories and there is an urgent need for training of both tattooists and the EHOs
who supervise them. Studies in Central and Southern Sydney in 1991, in Brisbane, Darwin and Canberra in 1993 and
in Victoria in 1994 support appropriate training and education for skin penetration operators and tattooists (Drake
1993; Edwards et al 1993; Kallir Preece 1993; Trott 1993; Bouwman et al 1994). An infection control course
designed for staff working for general practitioners, hairdressers, tattooists and other relevant services has been
approved to be delivered at the Sydney Institute of Technology (Long and Rickman 1994; NSW TAFE Commission).
Similar courses are required elsewhere, and cogent arguments exist for establishment of national standards for skin
penetration.
4.7  Hepatitis C virus infection in prisoners
Among the small number of published studies of HCV infection in prisoners, HCV antibody prevalence was generally
high (15-46%) compared with the prevalence among blood donors (<0.5%). The high HCV prevalence was attributed
predominantly to a history of IDU reported by a substantial proportion of prisoners.
In Australia, HCV-antibody testing of 3,627 people received into prisons in Victoria from October 1991 through
September 1992 indicated an HCV prevalence of 39 per cent (Crofts et al 1995). Prevalence of HCV antibody was
significantly higher in women (66.7%) than in men (36.9%) and in people who reported a history of IDU (63.6 cf
16.0% among those with no reported history of IDU). Among 119 prisoners received into prison on more than one
occasion over the 12 months who were initially HCV-antibody negative, 10 males were subsequently found to have
HCV antibody, giving an incidence rate of 18.3 per 100 person-years. Risk factors for incident HCV infection were
young age (22.2 v. 26.2 y) and a history of IDU (80 v. 36%). A high HCV antibody prevalence (30.8%) had
previously been documented among Victorian prisoners (Fairley et al 1990) and HCV prevalence among IDU in
Victoria in 1990-92 was 68 per cent (Crofts et al 1994). Among 408 people tested for HCV antibody at entry into New
South Wales prisons in 1994, 37 per cent had HCV antibody; HCV antibody prevalence among those with a history of
IDU, previous imprisonment and those who reported IDU during a previous imprisonment was 66 per cent, 48 per
cent and 77 per cent, respectively (Butler et al 1997).53
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Among 265 male prisoners received into prisons in Maryland, USA, for whom serum specimens were available both at
reception and at follow-up, prevalence of HCV antibody at reception in 1985-86 was 38.1 per cent (Vlahov et al 1993).
HCV prevalence may, however, have been underestimated because it was measured among volunteers who were in
prison for at least one year. HCV prevalence was significantly higher among prisoners aged 25 years or older (55%)
than among prisoners younger than 25 years (20%), and was significantly higher among black prisoners (43%)
compared with nonblack prisoners (29%). Among 164 prisoners who were initially HCV-antibody negative, two
seroconverted, giving an incidence of 1.1 per 100 person-years in prison.
Of 70 prisoners (mean age, 28.4 y), received into a national prison in Norway in October-December 1991 and tested
for HCV antibody using a second-generation EIA, 46 per cent had HCV antibody (Holsen et al 1993). Both a history
of IDU and presence of tattoos were associated with HCV infection.
Voluntary testing for HCV antibody among male prisoners in a medium security prison in Ontario, Canada, carried out
in June 1995, indicated a prevalence of HCV antibody of 27.9 per cent (Pearson et al 1995). In an earlier study of male
prisoners in British Columbia, Canada, HCV antibody prevalence was 25.5 per cent (Prefontaine and Chaudhary
1990). HCV prevalence among prisoners held in a long-stay penitentiary for women who were voluntarily tested in
June 1994 was 39.8 per cent (Ford et al 1995a, 1995b).
HCV infection in 756 prisoners in Naples, Italy, was assessed in serum samples collected between July 1992 and
December 1994 using a second-generation RIBA (Chiron) (De Mercato et al 1995). In this population (mean age, 34.7
y), no history of IDU was reported and men who reported a history of male homosexual contact were excluded.
Prevalence of HCV antibody was 15.5 per cent and was similar for males and females. Prevalence of HCV antibody
increased from 7.6 per cent among those imprisoned for less than three years to 21.6 per cent among those imprisoned
for more than six years.
In a random sample of prisoners held in the only reception centre in Connecticut, USA, for women, prevalence of HCV
antibody was 32 per cent (Fennie et al 1996). HCV antibody prevalence was 76 per cent among women who reported a
history of IDU, whereas among women whose only reported risk for HCV antibody was sexual contact with an IDU,
prevalence was 46 per cent. Incidence of HCV, estimated among initially HCV-antibody negative IDU women, who
were received into prison at least twice over one year, was 52 per 100 person-years (3/13).
Among 250 young (mean age, 23 y) British prisoners with a history of sharing drug injecting equipment, HCV
antibody prevalence was 17.2 per cent (Mohanty and Biswas 1996). Among 157 IDUs in Mid-Glamorgan, UK, HCV
antibody prevalence was significantly higher among those with a history of imprisonment (46%) compared with those
with no history of imprisonment (29%) (McBride et al 1994). In Greece, prevalence of HCV antibody among 450
IDUs in prison remained higher than 80 per cent in 1991-95.
4.8 Hepatitis C virus-RNA load
There are several techniques that can be used to quantify HCV by RT-PCR, including competitive PCR, end-point
titration, branched DNA assay and internal standard RNA. Many of the techniques have potential disadvantages,
including lack of resolving power of titre-based assays, poor sensitivity of branched-chain DNA assays, and time-
consuming preparation of competitive RNA templates.
Many studies addressing the question of whether viral load correlates with the degree of liver injury have measured the
amount of HCV in serum. It has been argued that HCV RNA should be measured directly from liver tissue, because
serum levels may be contributed to and be influenced by extrahepatic sources, and immune complexes in the serum
may provide interference (McGuinness et al 1996). Mannucci et al (1990b) have reported also that sample-to-sample
variation occurs in detectable HCV genome molecules in serum compared to plasma from the same patient. This
suggests that serum54
Epidemiology of the hepatitis C virus - Chapter 4
specimens, although widely used for qualitative molecular investigation of HCV-infected patients, may not provide
reliable quantitative data on HCV viraemia from these patients.
Several studies that have looked at viral load and its relationship to liver disease have been cross-sectional single-point
analyses. However, tissue injury may be related to virus release from infected cells, so ideally studies need to examine
fluctuations of liver damage and HCV-RNA levels over time.
HCV-RNA-positive hepatocytes were more frequently detected in specimens with advanced periportal, bridging and
intralobular necrosis but showed no correlation with the extent of inflammatory cell infiltration (Haruna et al 1993).
These findings suggest a close correlation between the detection of HCV RNA in hepatocytes and advanced necrosis of
the specimens. The average number of HCV-RNA molecules per millilitre of serum was found to be greater than 10
7 in
patients with HCV-associated hepatitis, cirrhosis or HCC (Hagiwara et al 1993; Gretch et al 1994).
4.8.1 Level of infectivity among people with hepatitis C virus infection: the role of
polymerase chain reaction
The counselling of people with HCV infection would be assisted by an effective measure of their risk of transmitting
HCV in various settings. The development of PCR methods for detecting HCV RNA has provided a potential means of
assessing anti-HCV positive people in terms of their level of infectivity. Factors such as level of viraemia and HIV
coinfection may also be predictive of transmission risk.
Published studies that examined HCV transmission from anti-HCV-positive individuals were reviewed. Anti-HCV-
positive individuals were tested for evidence of HCV viraemia by PCR for HCV RNA. Studies were included if HCV-
PCR status of sources corresponding to cases of HCV exposure was recorded. Estimates of number of those exposed to
HCV-PCR- positive and HCV-PCR-negative sources were required in those studies with differential source or exposed
numbers, such as two retrospective vertical transmission studies (Meisel et al 1995; Power et al 1995a). Transmission
rates were calculated separately for exposure to HCV-PCR-positive and HCV-PCR-negative sources. Pooled estimates
of HCV transmission rates were made for different modes of transmission. Additional information such as level of
viraemia and coinfection with HIV was also sought, and the effect of these factors on transmission efficiency
examined.
Identification of anti-HCV was generally with EIA and confirmatory RIBA, although first-generation, second-
generation and third-generation assays were used in various studies. Detection of HCV RNA was by PCR with nested
primers derived from the 5' noncoding region of the HCV genome.
A total of 29 articles published between 1992 and 1996 met the above criteria. Most of these studies examined vertical
HCV transmission (n=21), with the remainder examining HCV transmission following transfusion of blood products
(n=3), bone marrow or solid organ transplantation (n=3), and needlestick exposure (n=2) (Dore et al 1997).
4.8.2 Vertical transmission studies
In the vertical transmission studies, the percentage of anti-HCV-positive mothers who were also HCV-PCR-positive
varied from 46 to 100 per cent, with a pooled estimate of 54 per cent (table 26). Among 903 children born to mothers
with a positive HCV PCR, the HCV transmission rate varied from 0 to 42 per cent, with a combined rate of 6.2 per
cent (95% CI 4.6, 7.8%). In contrast, no case of HCV transmission was reported among 735 children born to mothers
who were HCV-PCR negative (95% CI 0.0, 0.4%) (table 26). Among HCV-PCR-positive mothers, other factors that
were reported to influence HCV transmission were level of viraemia (Lin et al 1994; Ohto et al 1994; Matsubara et al
1995; Moriya et al 1995; Zanetti et al 1995a), and coinfection with HIV (Paccagnini et al 1995; Zanetti et al 1995a;
Zuccotti et al 1995). The pooled HCV transmission rate from HIV/HCV-antibody-positive mothers was 16 per cent
(95% CI 12, 20%) (Latt et al 1994). In contrast, a HCV transmission rate of 1.9 per cent (95% CI 1.2, 2.6%) was seen
among children born to mothers with HIV seronegative or unknown status (Dore et al 1997) (data not included in table
26).55
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Table 26 Studies of mother-to-child transmission of hepatitis C virus
Study Country No. of subjects
(Mother/infant)
Source positive
by PCR (%)
Transmission of HCV [proportion (%)]
Positive by PCR Negative by PCR HIV-Ab positive
or HCV-Ab
positive
Fischler et
al (1996)
Sweden 55/58 75 0/40 0/18 0/2
Pipan et al
(1996)
Italy 25/25 72 0/18 0/7 No HIV
Sabatino
et al (1996)
Italy 30/30 33 3/10 (30) 0/20 No HIV
Giacchino
et al (1995)
Italy 31/31 61 2/19 (11) 0/12 No HIV
Manzini et
al (1995)
Italy 45/45 63 0/27 0/16 1/18 (6)
A
Matsubara
et al (1995)
Germany 29/31 66 3/21 (14) 0/10 No HIV
Meisel et al
(1995)
B
Germany 55/55
C 57 1/23 (4) 0/32 No HIV
Moriya et al
(1995)
Japan 84/87 100
D 2/87 (2) - No HIV
Paccagnini
et al (1995)
Italy 37/37
E 62 9/23 (39) 0/14 12/53 (23)
Power et al
(1995a)
B
Ireland 545/840 46 7/386
F (2) 0/454
F NA
G
Resti et al
(1995)
Italy 22/22 55 5/12 (42) 0/10 No HIV
Zanetti et al
(1995a)
Italy 116/116 55 8/64 (13) 0/52 8/22 (36)
Zuccotti et
al (1995)
Italy 37/37 57 6/21 (29) 0/16 4/20 (20)
Lin et al
(1994)
Taiwan 15/15 100
D 1/15 (7) -
H No HIV
Ohto et al
(1994)
Japan 53/54 58 3/32 (9) 0/22 NA
Kurauchi et
al (1993)
Japan 16/16 94 0/15 0/1 No HIV
Lam et al
(1993)
Scotland 56/66 59 4/38 (11) 0/28 3/58 (5)
Roudot-
Thoraval et
al (1993)
France 17/18 47 0/8 0/10 No HIV
Uehara et
al  (1993)
Japan 12/12 58 1/7 (14) 0/5 NA
Reinus et
al (1992)
USA 23/24 70 0/16 0/8 0/4 (0)
Wejstal et
al (1992)
Sweden 14/21 100
D 1/21 (5) -
H No HIV
Total 1317/1640 54
I (648/1204) 56/903 (6.2; 95%
CI, 0.0-0.4%)
28/177 (15.8; 95%
CI, 11.8-19.8%)
16/122 (13)
A Transmission case from HIV-positive mother of unknown status of HCV by PCR.
B Retrospective analyses of children born after infection of mothers with HCV from anti-D immunoglobulin.
C Numbers of mothers corresponding to these 55 perinatally exposed children (subgroup of tested children) not known and may be <
55.
D Only mothers with evidence of chronic HCV infection selected.
E HCV RNA determination performed on only 37/70 mothers in study.
F Estimated number from proportion positive by PCR (46%) in total cohort infected from anti-D immunoglobulin.
G NA, not applicable.
H Not measured.
I Excludes studies where only mothers with chronic HCV infection selected.56
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In five of seven vertical transmission studies in which quantitation of HCV viraemia was reported, transmission was
associated with higher level viraemia (Lin et al 1994; Ohto et al 1994; Matsubara et al 1995; Moriya et al 1995; Zanetti
et al 1995a). One study demonstrated a significantly higher transmission rate among vaginally delivered infants
compared with infants delivered by caesarean section (32% v 6%) (Paccagnini et al 1995) but showed no association
between risk of transmission and breast-feeding. The only case of HCV transmission reported by Lin et al (1994) was
associated with a maternal HCV-RNA level of 10
10 copies/mL, as opposed to levels of 10
5-10
6 copies/mL among seven
nontransmitting mothers with detectable HCV RNA. The HCV-RNA levels reported by Ohto et al (1994) were
significantly higher among HCV transmitting mothers (mean +/- s.d., 10
6.4+/-0.5 copies/mL) than nontransmitting
mothers (10
4.4+/-1.5 copies/mL) (P<0.001). Zanetti et al (1995a) reported a mean HCV-RNA level among eight
transmitting mothers (all coinfected with HIV) of 10
7.1 copies/mL, as opposed to 10
6.7 copies/mL among 10
nontransmitting HIV-coinfected or HCV-coinfected mothers, and 10
5.9 copies/mL among 10 nontransmitting mothers
with HCV alone.
4.8.3 Other hepatitis C virus transmission studies
Three studies examining HCV transmission from anti-HCV positive transplant donors to anti-HCV-negative recipients
(table 27) gave a transmission rate of 21/27 (78%) (95% CI 72, 94%) from HCV-PCR-positive donors, as opposed to 0
(95% CI 0, 15%) from HCV-PCR-negative donors (Pereira et al 1992; Roth et al 1992; Shuhart et al 1994). Three
studies of HCV transmission following transfusion of blood products from anti-HCV-positive donors demonstrated a
rate of 83 per cent (95% CI 74, 92%) from EIA-positive, HCV-PCR-positive donors, as opposed to 0 among 97
recipients of blood components from EIA-positive, HCV-PCR-negative donors (Norda et al 1995; Vrielink et al 1995;
Foberg et al 1996).
Table 27 Studies of transmission of hepatitis C virus related to transplantation and blood
transfusion
Study Country No. of subjects Source
positive by
PCR (%)
Transmission of HCV [proportion (%)]
}}}} Positive by PCR Negative by PCR
Foberg et al
(1996)
A
Sweden 12/36 (blood
donor/recipients)
75 21/27 (78) 0/9
Norda et al
(1995)
A
Sweden 21/39 (blood
donor/recipients)
33 11/11 (100) 0/26
B
Vrielink et al
(1995)
A
Netherlands 71/94 (blood
donor/recipients)
31 26/32 (81) 0/62 
C
Shuhart et al
(1994)
USA 12/12 (bone marrow
donor/recipients)
58 7/7 (100) 0/5
Pereira et al
(1992)
USA 11/16 organ (heart,
liver, kidney)
donor/recipients
82 13/13 (100) 0/3
Roth et al
(1992)
USA 21 kidney transplant
recipients
33 1/7 (14) 0/14
Total 148/218 68 79/97 (81.4%; 95% CI
72.3-88.6%)
0/119 (0.0; 95% CI
0.0-2.5%)
A Retrospective studies of donors positive for antibody to HCV and their multiple recipients of blood component.
B Two recipient cases excluded: one recipient found to be positive for antibody to HCV and positive by PCR but had received over 100
blood components from donors of unknown HCV status (2 other recipients from same donor negative by PCR had no evidence of
infection).  Further recipient was ELISA positive but negative by PCR and had also received previous blood components from donors of
unknown HCV status.
C Excludes those who received EIA-positive (first generation), RIBA-negative blood (n=78) as probable false positive EIA results.57
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Although several studies have examined prevalence and incidence of HCV among HCWs, only two studies (table 28)
have reported on HCV-antibody and HCV-PCR status in source cases of needlestick exposures to HCWs (Mitsui et al
1992; Sodeyama et al 1993). Combining these two studies, the HCV transmission rates following needlestick exposure
to anti-HCV-positive patients were 6.1 per cent (95% CI 2.3, 9.9%) for HCV-PCR-positive patients, and 0 (95% CI
0.0, 18.5%) following exposure to HCV-PCR-negative patients.
Table 28 Studies of transmission of hepatitis C virus related to occupational exposure
Country Reference No. of
subjects
HCV-PCR positive
(source) (%)
HCV transmission to HCWs from
patients who were:
HCV-PCR
positive
HCV-PCR
negative
Japan Mitsui et al (1992) 74 92 7/68 (10%) 0/8 (0%)
Japan Sodeyama et al
(1993)
90 89 2/80 (2.5%) 0/10 (0%)
Total 164 90 9/148 (6.1%) 0/18 (0%)
4.8.4 Discussion
The absence of PCR-detectable HCV viraemia appears to indicate an extremely low risk of HCV transmission. In the
29 studies examined, a total of 874 people were exposed to sources positive for HCV antibody, but negative by HCV
PCR, through vertical, transplant, blood transfusion and needlestick exposures. Among these people, no HCV
transmission was reported. In contrast, 148 cases of HCV transmission occurred among the 1,148 people exposed to a
HCV-PCR-positive source. Pooled rates of transmission from HCV-PCR-positive sources were 4.5 per cent following
perinatal exposure, 6.1 per cent following needlestick exposure, 78 per cent following transplant exposure and 83 per
cent following transfusion of blood products.
Based on vertical transmission studies, level of viraemia and coinfection with HIV were also risk factors for HCV
transmission. For mothers coinfected with HIV, transmission occurred in 16 per cent of cases, whereas the rate of
transmission from those HIV seronegative or of unknown status was less than 2 per cent. Most vertical HCV
transmissions occurred when the maternal HCV-RNA level was greater than 10
6 copies/mL.
The importance of individual characteristics associated with an increased likelihood of transmitting HCV in various
settings was highlighted by Alter (1994). However, this editorial also asserted that advice to anti-HCV-positive people
on their level of infectivity could not be based on PCR testing for detection of HCV viraemia. The possibility of both
false positive and false negative PCR results (Busch et al 1992), the difficulty of interpretation of results and the lack
of widespread availability of PCR testing were put forward as supportive arguments. A particular concern was that a
person with very low-level viraemia could still transmit HCV if the inoculum was large enough.
However, rapid developments in PCR technology have overcome many of these concerns. The sensitivity of HCV PCR
has been optimised through the use of PCR primers based on the very highly conserved 5' noncoding region of the
HCV genome (Garson 1994). Thus, improved standardisation of PCR technology together with ongoing monitoring by
national reference laboratories should limit the possibility of false negative results. The findings from our report  also
support the high sensitivity of HCV PCR, at least in the setting of research laboratories where specimens generally
were tested in duplicate.
The main drawback of extreme sensitivity of PCR technology is an enhanced possibility of contamination and, thus,
suboptimal specificity. This has been emphasised by an international HCV-PCR-quality assurance survey which
detected58
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false positive results from many  laboratories (Zaaijer et al 1993). Although increased vigilance to limit contamination
and continued monitoring of specificity of HCV PCR are required, an occasional false positive HCV PCR result does
not alter the finding of absent HCV transmission from people with negative HCV PCR and the implications arising
from such a finding.
The labour intensiveness of inhouse PCR technology, in particular inhouse nested PCR, has limited the availability of
HCV PCR. However, new methods such as nucleic acid amplification system (NASBA) and the Amplicor kit (Roche
Diagnostic Systems, Basel, Switzerland) enable testing of many specimens in a single day, and have equal sensitivity
and specificity to the inhouse PCR methods (Lunel et al 1995).
This review of published studies of HCV transmission strongly supports the use of PCR testing for determination of
level of infectivity. Even in situations where the HCV inoculum was large, such as following blood transfusion, HCV
transmission from an anti-HCV-positive, PCR-negative person was not documented.
Despite the improvements in PCR technology outlined, it is recommended that a person with HCV infection is
counselled on the basis of a persistently positive or negative HCV PCR (at least two tests over a three month period),
rather than a single assessment of PCR status. Even greater consistency would be required in a person receiving or
having received IFN therapy due to the fluctuation in HCV-PCR status among this group. The greatest benefit would
be in identifying those persons anti-HCV positive, who have no biochemical or clinical evidence of chronic infection,
and who are persistently HCV-PCR negative. This group of people could be counselled as to their lack of infectivity,
and most probable lack of chronic HCV infection, with HCV PCR playing a similar role to that of HBV surface
antigen in defining infectivity and chronic HBV carriage status.
Pregnant women, or women considering becoming pregnant who are anti-HCV positive, could be offered HCV-PCR
testing to assist in determining their risk of transmitting HCV to their children. Women with a persistently negative
HCV PCR could be reassured that their risk of transmitting HCV perinatally was extremely low, if not zero.
Determination of HCV-PCR status would also be useful following a needlestick exposure to blood or body fluid from
an anti-HCV positive patient. If the source patient had no biochemical or clinical evidence of chronic HCV infection
and was negative on HCV PCR testing, an exposed HCW could be informed that the risk of acquiring HCV was
negligible. This information could allay significant anxiety over the next three to six months required before
postexposure anti-HCV testing is concluded.
The recent reports of HCV transmission from two cardiothoracic surgeons to their patients has placed increased
scrutiny on HCWs who are anti-HCV positive (Anonymous 1994; Esteban et al 1996). In some situations, surgeons are
already prevented from performing exposure-prone procedures if found to be anti-HCV positive. HCV-PCR testing
could be useful in assessing the potential for transmission from HCWs. Surgeons who are persistently HCV-PCR
negative would not be required to undertake measures in addition to the normal universal precautions for infection
control.
Although HCV transmission efficiency through sexual contact appears to be low, many people who are anti-HCV
positive are counselled to use condoms. A person found to be HCV-PCR negative could be advised that the risk of
transmitting HCV sexually was negligible.
In summary, it appears that there is virtually no risk of HCV transmission in the absence of HCV viraemia as detected
by PCR. This finding has important implications in regard to counselling both those people at risk of transmitting
HCV, and people exposed to anti-HCV-positive sources. Additional investigation of HCV transmission based on
clinical stage of HCV infection, level of HCV viraemia and HCV genotype is required to further define level of
infectivity in various settings.59
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5 Pathogenesis and natural history
A schematic outline of events involved in the natural history of HCV infection is shown in Figure 2.
Figure 2. Aspects of the natural history of hepatitis C virus infection.
5.1 Acute hepatitis C virus infection
Acute HCV infection usually produces initially only a mild illness and is often totally asymptomatic, although
fulminant hepatitis can occur rarely. In the transfusion setting where acute onset is best documented, 70 to 80 per
cent of cases are anicteric and asymptomatic. Alter (1995a) describes a National Institutes of Health (Bethesda,
MD, USA) series of 86 consecutive cases of posttransfusion hepatitis, of which only 30 per cent had a bilirubin
concentration greater than 2.5 mg/dL and where the mean peak ALT was 708 U/L. Most patients had very mild
illness and none had a protracted, severe, acute illness. In community-acquired infection, where people with HCV
are generally identified and defined because of presentation with overt clinical illness, 70 per cent of people were
icteric; 4 per cent had an ALT between 2.5 and 5 times the upper limit of normal (ULN); 22 per cent had an ALT
6-15 times ULN patients. Because the community-acquired cases had to be ill to seek treatment, they are not
useful in defining the clinical spectrum of acute HCV infection. However, they show that HCV can present as an
acute overt hepatitis that can not be clinically distinguished from acute cases of HAV and HBV. By extrapolation
from transfusion studies, clinically apparent illness occurs in no more than 25 per cent of HCV infections (Alter
1995a).
Seroconversion to HCV can take as long as 26 weeks following infection (Alter et al 1989b), although with
second-generation assays the mean time between infection and the development of a detectable antibody response
is more often about two to three weeks (Aach et al 1991; Mattsson et al 1992). HCV RNA can be detected in the
serum even earlier, as soon as one week after infection (Farci et al 1991).
Brunetto et al (1994) quotes Alberti (1991) and Alter (1991) as showing that anti-HCV detected during the
convalescent phase of an acute self-limited HCV hepatitis becomes negative after one to four years, and its
persistence indicates a chronic HCV infection. He also implies that posttransfusion hepatitis proceeds to a higher
number of cases than community- acquired, sporadic hepatitis.
5.2 Fulminant hepatic failure
Documented fulminant HCV infection is extremely rare, although HCV appears to be the causative agent of a
substantial number of cases of fulminant hepatic failure (FHF) previously classified as indeterminant (Viladomiu
et al 1992). The mechanism by which it occurs is obscure. In-depth study of the few cases has unequivocally
established:
·  the acute appearance of HCV RNA coincides with the onset of fulminant disease;
·  high levels of viraemia (10
7 HCV-RNA equivalents/mL); and
·  HCV genotype and sequence was not unique, suggesting that disease is related to viral burden or host
response rather than virus genotype.
Viral hepatitis is the most common cause of FHF, followed by drug overdoses or drug-induced hepatotoxicities.
Some patients with FHF of presumed viral cause (40-60%) have negative serological markers for HAV and HBV,Quasispecies Mutation
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being classified as of NANBH or indeterminate cause. The role of HCV in FHF is controversial. Reported series
of FHF of indeterminate cause have shown a prevalence of HCV RNA by PCR of from 0 to 12 per cent in the
USA and Europe, but is substantially higher in Asian series (Villamil et al 1995). However, Villamil et al (1995)
found that HCV appears to be the causative agent of a substantial number of cases of FHF classified as
indeterminate in the Los Angeles area, and suggested that differences in patient populations or risk factors may
explain the discordant incidences of HCV infection in FHF observed among different programs. In many patients
with FHF, anti-HCV remains negative although HCV RNA is detected; some of these patients go on to develop
histological hepatitis after liver transplantation, sometimes severe and sufficient to require retransplantation.
 HCV RNA, rather than serological tests, should be used to establish the presence of infection, because anti-HCV
seroconversion may take weeks after acute infection. Also, if an overwhelming immunological response occurs in
fulminant HCV, analogous to the one that occurs in HBV (table 29), then the amount of virus present may be
small and be detected only in liver. Hence, the amount of virus should be measured in both serum and liver using
PCR as the most sensitive test available. Biopsy should show massive hepatocellular necrosis with an absence of
significant fibrosis to distinguish acute hepatic failure due to HCV from HCV CLD with superimposed acute
liver failure due to some unrelated cause (Terrault and Wright 1995b).
Table 29 Serum hepatitis C virus and anti-hepatitis C virus in fulminant hepatic failure of
indeterminate cause and fulminant hepatic failure due to hepatitis B virus
infection
From Villamil et al (1995).
Reference Indeterminate cause HBV infection
HCV-RNA+ Anti-HCV (+) HCV-RNA+ Anti-HCV (+)
Chu et al (1994) 5/11 (45%) 1/11 (9%) 9/51 (18%) 6/51 (12%)
Feray et al (1993) 0/23 0/23 8/17 (47%) 0/17
Ferraz et al (1993) 0/15 0/15 0/4 0/4
Liang et al (1993b) 1/17 (6%) 0/17 NR
A NR
Munoz et al (1992) 1/18 (6%) NR 0/16 NR
Sallie et al (1991) 0/30 0/30 NR NR
Theilmann et al (1992) 1/8 (12%) 0/8 0/4 0/4
Villamil et al (1995) 9/15 (60%) 6/16 (37%) 2/7 (29%) 1/7 (14%)
Wright et al (1992) 0/6 0/17 1/4 (25%) 1/4 (25%)
Yanagi et al (1991) 3/7 (43%) 2/7 (29%) 3/8 (37%) 3/8 (37%)
Yoshiba et al (1991) 10/17 (59%) 9/17 (53%) 0/5 0/5
ANR, not recorded.
5.3 Progression to chronicity
A wide range of chronicities has been reported for HCV infection in different studies, and may be explained in
part by differences in length of follow-up, irregular fluctuations of ALT, and the difficulty of diagnosing the
extent and progression of disease without serial liver biopsies. Much of our current knowledge about the natural
history of chronic HCV infection is based upon cross-sectional data, and it is difficult to predict the course in a
patient seen at62
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one point in time. Longitudinal data often derive from those infected as a result of blood transfusion. It is clear
that progressive HCV disease can occur without symptoms and although serological test results do not predict
histology, patients who are not viraemic, or whose RIBA results are indeterminate, are less likely to have
significant liver disease on biopsy.
There is continuing debate about whether there is such a person as a healthy carrier of HCV, some people having
persistently detectable HCV RNA but no symptoms or signs of liver disease. It is likely that persistent viraemia
corresponds to mild hepatitis with an inflammatory portal response and a variable lobular inflammation with
parenchymal apoptoses. For example, Chemello et al (1993) took liver biopsy samples of 23 patients and found
that all patients with viraemia (HCV-RNA positive on PCR analysis) had CLD detectable on biopsy, whereas
seven HCV-RNA negative cases had normal liver histology (Chemello et al 1993). Lymphoid infiltrates can
occur in the portal inflammatory infiltrate and periportal necrosis is usually mild (Dhillon and Dusheiko 1995).
The infiltrate generally consists of T cells, and is similar in chronic active and chronic persistent patterns of HCV
infection, although it varies in intensity. Prieto et al (1995) studied 98 blood donors found positive for anti-HCV
(second-generation EIA confirmed using RIBA2) by liver biopsy, PCR for HCV RNA and a panel of liver injury
tests. Almost all (97%) of the anti-HCV-positive blood donors had some type of histological abnormality: 22
(22%) had minimal changes; 1 (1%) had chronic lobular hepatitis; 40 (41%) had CPH; and 32 (33%) had chronic
active hepatitis (CAH). Only three subjects had a normal liver histology. HCV RNA was detectable in the serum
in 65 per cent. HCV RNA in serum was detectable in none of the donors with a normal liver histology, in 36 per
cent ((CI 17, 59%) of those with minimal changes, in 70 per cent (CI 53, 83%) of those with CPH, and in 87 per
cent (CI 71, 96%) of those with CAH (P=0.00001). HCV RNA was detectable in 75 per cent of the donors with
elevated (>45 U/L) ALT values and in 59 per cent of those with normal ALT levels (P=not significant). The
incidence of chronic hepatitis was higher in HCV-RNA-positive than in HCV-RNA-negative donors (88 v. 50%;
P=0.00005). Age older than 50 years (OR=17.5), an elevated ALT (OR=74.4) and serum HCV RNA (OR=18.9)
were independently associated with the presence of chronic hepatitis. The authors suggested that the detection of
HCV RNA in 36 per cent of the donors with minimal changes on biopsy, all of them with normal ALT levels,
suggests that a healthy carrier state may exist. However, Gunji et al (1992) followed four patients who were
persistently HCV-RNA positive for three years with monthly serology and reported that despite persistent
viraemia, the subjects consistently had normal ALT levels and a liver biopsy was normal. Yuki et al (1996) used
branched-chain DNA to quantitate HCV RNA and found a significant inverse relationship between levels of
viraemia and the duration of aminotransferase normalisation (r=-0.46, P<0.01). They interpret their findings to
indicate that biochemical remission of HCV infection may be frequent in haemodialysis patients and may be
related to viral attenuation, but unfortunately no liver histology was available.
Shindo et al (1995) investigated HCV titres, HCV-RNA levels in liver and serum, genetic variability in the
hypervariable region (HVR) of the genome, the form of the virus in the circulation, and liver histology in 21 anti-
HCV-positive patients with sustained normal liver biochemical values. Titre of anti-HCV was determined by
second-generation anti-HCV-passive haemagglutination assay, and HCV-RNA levels were semiquantified by
RT-PCR. In 19 (90%) of the 21 subjects who had a higher titre of anti-HCV [>2], HCV RNA was detected in
both serum and liver samples, and histological examination showed minimal or mild chronic hepatitis in all
(Allander et al 1994). In the remaining two patients who had a lower titre of anti-HCV, HCV RNA was not
detected in serum and liver samples, and liver histology was normal. Anti-HCV titres and HCV-RNA levels in
serum and liver in the 19 HCV-RNA-positive patients were compared with those levels in the 41 patients with
biopsy-proven chronic HCV infection and elevated serum ALT levels as a control group. There were no
significant differences in viral levels in serum and liver between the two groups. Anti-HCV-positive patients with
normal liver biochemical values had quasispecies of the HCV genome similar to the patients with chronic HCV
disease. The authors argue that since both63
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groups have similar virological characteristics, but different patterns of serum ALT levels and histological
findings, the two groups may have different immune responses to the virus.
ALTs that are normal for many months or years can then unpredictably increase many fold. It is not known
whether changes in HCV during infection or mutation to a particular variant affect different episodes of the
disease, but sequence changes in the envelope protein may correlate with exacerbations in hepatitis (Gunji et al
1992).
Kurosaki et al (1995a) using SSCP analysis found 13 amino acids in the 5' end of the HVR were completely
identical in three sequences of free HCV, whereas there were three and seven amino-acid differences in two
sequences of antibody-bound HCV. This suggests that isolated specific epitopes for envelope antibodies exist
within the HVR, and that a portion of the circulating virus population is captured by HVR antibodies to form
immune complexes and cryoprecipitants, while the others with different HVR sequences escape from the
antibodies. The escape mutant in the HVR may be related to the persistence of HCV infection.
Following transfusion, chronic HCV infection is believed to be the result in about 70-80 per cent of patients with
acute HCV infection (Iwarson 1994). Since around only 5 per cent of acute HBV infections that occur in adults
lead to chronic carriage, the number of chronic carriers following acute HCV infection is more than ten times the
number following acute HBV infection. There is no evidence to suggest that the progression to chronicity is
different with different ways of contracting the disease.
Chronic HCV is said to have a variable course that in some people is rather indolent. The time elapsing between
diagnosis of chronic hepatitis, cirrhosis and HCC appears to be 10, 20 and 30 years, respectively (Kiyosawa et al
1990) and 14, 20 and 30 years, respectively (Tong et al 1995). Such follow-up studies that have been reported so
far have found a wide variation in proportions developing liver disease (table 30). Factors that promote chronicity
and progression of HCV-related disease remain unclear. Postulated factors include age at infection, route of
transmission, duration of infection, serum ALT levels, viral load, genotype, alcohol consumption and coinfection
with other blood borne viruses (Gordon et al 1993; Strasser et al 1995; Kobayashi and Thomas 1996; Mangia et
al 1997; Schiff 1997; Seeff 1997). Seeff (1997) grouped factors into virus related (viral dose, viral load and
quasispecies), host related (age, race, sex) and other (alcohol, viral coinfection, environmental, smoking).
Viral load at the time of infection may influence progression of disease. There is, however, little conclusive
evidence to date. Those acquiring infection through IDU would appear to acquire a lesser dose at the time of
infection than those infected through contaminated blood products acquired, and this may be a factor involved in
the possibly more benign nature of HCV in the former group. This requires further evaluation.
The role of genotype is also unclear with several studies reporting increased pathogenicity in those infected with
subtype 1, in particular subtype 1b. Silini et al (1996) studied three groups of patients: 593 patients with chronic
hepatitis, 166 patients with HCC and cirrhosis, and 219 patients with cirrhosis but without HCC. A cross-
sectional study of frequency distribution and a case-control analysis were performed. They concluded that HCV
type 1b is overrepresented in patients with cirrhosis and HCC and significantly influences the risk of HCC in
cirrhosis, independent of sex, age, and Child's class. Kobayashi et al (1996) examined 140 patients with chronic
HCV. Deterioration of the grade of liver histology during the follow-up period was seen in 68 per cent of the
patients with genotype 1 as compared with 41 per cent of those with genotype 2 (P<0.01). In addition the mean
serum HCV-RNA titre was significantly higher in the patients with genotype 1 than in those with genotype 2
(P<0.001). The authors conclude that more severe progression of chronic HCV is seen in genotype 1b. Several
other studies have, however, refuted any connection between genotype and severity and progression of disease, in
particular any connection between genotype and progression to HCC (Romeo et al 1996; Benvegnu et al 1997).
Age is another factor that appears to influence outcome. The National Heart, Lung and Blood Institute study
(Seeff 1994) reports that HCV infection in those older than 55 years was associated with an increased mortality
with the64
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opposite outcome noted in those infected at < 55 years. Age may also play a role in those already chronically
infected and may be associated with clinical decline beyond the two decade mark (Seeff 1997).
Coinfection with HIV (see section 5.9.2) causes an increase in progression to liver disease and is associated with
increased levels of HCV viraemia (Cribier et al 1995). Coinfection does not appear to cause an increased rate of
progression of HIV (Quan et al 1993).
The presence of chronic HBV in addition to chronic HCV appears to increase the severity of disease and risk of
HCC (see section 5.9.1). Benvegnu et al (1994) followed 290 consecutive cirrhotic patients for 46.3±21.4
months.  HCC developed in 32 patients (11.0%). By multivariate analysis, age (P<0.01), positivity for HBsAg
and HCV antibodies (P<0.05), male sex (P<0.05), and previous alcohol abuse (P<0.08) were independently
related to tumour appearance. The authors conclude that although male sex and previous alcohol abuse are risk
factors for HCC in cirrhosis, concurrent HBV and HCV infection determines the highest risk of developing HCC.
This increased risk of disease, in particular HCC, has been noted in other studies (Chiba et al 1996; Tsai et al
1997). However, the viruses also have an inverse relationship, in that the presence of HCV appears to suppress
HBV replication (Fong et al 1991).
Several studies (Tanaka et al 1996; Petrik et al 1998) indicate that HGV coinfection has no important effects on
histological features in chronic HCV carriers and that it is unlikely that HGV infection causes chronic liver
disease.
Alcohol is increasingly recognised as being important in progression to cirrhosis and HCC (see section 5.6). 
Alcohol in excess of 10 g/day is associated with increased HCV RNA and aminotransferase levels, the
mechanism of which is not well understood (Schiff 1997). It is unknown whether HCV and alcohol are
independent risk factors for chronic liver disease or whether they act synergistically. However, patients with
HCV should be encouraged to restrict alcohol intake.
Table 30 Results of long-term histological follow-up of posttransfusion hepatitis C virus
infection
From Alberti et al (1995).
Country Reference No. of patients Years of
follow-up
(mean)
Findings at end of follow-up
CPH (%) CAH/CPH
(%)
HCC (%)
Italy Tremolada et al (1992) 104 1-15 (7.5) 30 69 1
Japan Takahashi et al (1993) 100 5-32 (11) 34 42 19
Japan Yousuf et al (1992) 62 5-15 (8.8) 25 23 52
Long-term histological follow-up reveals bile duct damage, lymphoid aggregates or follicles and lobular
inflammation in a substantial proportion of patients. The lymphoid involvement suggests that an immunological
mechanism for liver injury may be involved.65
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5.4 Long-term consequences
There remain unanswered questions regarding the natural history of chronic HCV infection. Some patients, even
those with cirrhosis, appear to do very well over long intervals, whereas others progress rapidly to a fatal
outcome within a decade. Whether this is related to the virulence of the viral strain, levels of virus in the liver,
host immune response or genetic susceptibility or to other cofactors that increase the severity of HCV infection
is still unclear.
Determining the natural history of HCV is difficult, principally due to the problems of identifying those with
incident infection, the long latent period before development of liver-related disease and the difficulties of
following up the largest affected group, IDUs, over long periods of time. Therefore, much of the reported data
are on transfusion-acquired diseases and are based on cross-sectional, retrospective studies with their inevitable
biases in estimation of rates and proportions of disease progression. Despite this a great deal of information has
been gathered over the past 15 years that provides considerable insight into the natural history of HCV.
Several studies have prospectively followed persons with transfusion-acquired NANBH from onset of acute
disease. In the USA, Koretz et al (1993) reported on long-term follow-up (mean of 16 y after disease onset) of
80 patients who developed TA-hepatitis in the 1970s. They found that eight patients (10%) in the entire
population had developed clinical evidence of hepatic failure. Life-table analysis showed that the probability of
developing clinical evidence of cirrhosis in patients with chronic HCV infection was 20 per cent after a mean
interval of 16 years. Two patients whose cirrhosis had been documented for over a decade had no evidence of
hepatic failure, suggesting the often indolent nature of cirrhosis in HCV-infected individuals. Also from the
USA, Di Bisceglie et al (1991a) reported on outcomes of subjects with acute NANBH post heart surgery.
Thirty-nine subjects were followed from between 1 and 24 years (mean 9.7 y). About 20 per cent developed
cirrhosis by the end of follow-up and 12 per cent developed end stage liver disease. No cases of HCC or liver-
related deaths were reported. Most patients with histological evidence of cirrhosis or CAH had minimal clinical
evidence of liver disease within the time frame of the study. From Europe, Hopf et al (1990) followed 86
patients in Germany for a mean of eight years (range 3-20 y). Clinical symptoms were noted in 4.7 per cent and
cirrhosis identified in 24 per cent. The development of cirrhosis required many years. In Italy, Tremolada et al
(1992) reported on 135 patients who developed NANBH mostly after cardiac surgery and who were followed
up for a mean of 7.6 years (range 1-15 y). Of the 65 patients who underwent biopsy at the end of follow-up, 32
per cent had developed cirrhosis. One subject (0.7%) developed HCC. Age was a significant correlation with
development of cirrhosis in this group. Mattsson et al (1993) reported on Swedish subjects who had acute
NANBH in 1978. After 13 years of follow-up, 8 per cent of subjects had cirrhosis with no cases of HCC and no
liver-related deaths. In summary, in the above studies at the end of follow-up, cirrhosis was identified in 8 to 32
per cent of subjects, HCC detected in 0.7 and 1.3 per cent in two studies and mortality from liver- related
disease ranged from 1.6 to 6 per cent.
In the National Heart and Lung Blood Institute study of TA-NANBH, Seeff et al (1992) followed post-TA-
hepatitis cases and controls from five major prospective studies that defined posttransfusion NANBH in the
1970s. Although there was a small but significant excess of liver-related mortality in the hepatitis population,
the study found little difference in overall mortality. The five studies were primarily of older individuals
undergoing open heart surgery. For most, their life expectancy was less than the 18 years follow-up interval in
Seeff et al (1992), independent of patient’s liver disease. Although HCV is generally persistent, it is indolent,
with a natural history measured in decades. Because so many deaths were caused by cardiac and other disease in
an older population and because the natural history of HCV is measured in decades, it is not a good study in
which to determine the outcome of chronic HCV infection in those infected at a younger age. More recently
(Seeff 1994) there have been morbidity data - 30 per cent of those with NANBH/HCV infection had evidence of
chronic hepatitis as compared with 1 per cent of66
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controls, and of the 40 patients who at the time of the survey had liver biopsies, two-thirds had severe
histological lesions including CAH, cirrhosis and HCC (Seeff 1994).
5.4.1 Studies of outcome of chronic hepatitis C virus infection in people with
already established chronic liver disease
Several studies have reported on outcomes in HCV-infected individuals with chronic hepatitis. Yano et al
(1993) reported 30 per cent cirrhosis and 15 per cent HCC on Japanese blood donors with chronic hepatitis
after a mean follow-up of eight years. The extremely high incidence of HCC in this group was also reflected by
Takahashi et al (1993) who followed 333 Japanese patients with chronic hepatitis for 11 years. Cirrhosis
developed in 42 per cent and HCC in 19 per cent. The very high rates of liver-related sequelae in these studies
undoubtedly reflect that in Japan chronic HCV is common and appears strongly related to HCC (Seeff 1997).
From the USA, Tong et al (1995) reported on 131 patients of whom 101 were biopsied (the others had signs of
cirrhosis and abnormal coagulation tests). The mean age of subjects at transfusion was 35 years (range 1-76 y)
and at the time of initial assessment, 57 years. The mean duration of follow-up after evaluation was 3.9 years
(range 1-15 y). Over 46 per cent of subjects had cirrhosis and 10.6 per cent had HCC. Liver-related deaths
during the course of the study were 15.3 per cent. The authors also identified posttransfusion chronic hepatitis at
13.7±10.9 years, cirrhosis 20.6±11.8 years and HCC 28.3±11.5 years later. Similar results were found by
Castells et al (1995) who studied serum samples from 191 consecutive patients diagnosed with cirrhosis and
HCC in a Barcelona hospital, Spain, between 1988 and 1993, using stored sera, and found 148 were positive for
anti-HCV on second-generation EIA (152 on third-generation EIA), confirmed by second-generation RIBA
(Dhillon and Dusheiko 1995). Only 14 (7.4%) were HBsAg positive, 8 (4%) of whom had dual infections. Of
the 29 anti-HCV-positive patients with a history of transfusion, the mean interval (± s.d.) between transfusion
date and diagnosis of cirrhosis was 24±12.5 years and that of HCC was 26.8±12.4 years. Poynard et al (1997)
assessed the natural history of liver fibrosis progression in HCV and the factors associated with this progression
by recruiting 2,235 patients with a biopsy sample compatible with chronic hepatitis. The median rate of fibrosis
progression per year was 0.133 fibrosis unit (95% CI 0.125-0.143) Three independent factors were associated
with an increased rate of fibrosis progression: age at infection >40 years, daily alcohol consumption of 50 g or
more, and male sex. There was no association between fibrosis progression and HCV genotype. The median
estimated duration of infection for progression to cirrhosis was 30 years (28-32 y), ranging from 13 years in
men infected after the age of 40, to 42 years in women who did not drink alcohol and were infected before the
age of 40. Without treatment, 377 (33%) patients had an expected median time to cirrhosis of less than 20 years,
and 356 (31%) will never progress to cirrhosis or will not progress for at least 50 years. Hu and Tong (1999)
investigated a total of 112 patients with compensated HCV-cirrhosis and a documented history of either
intravenous drug abuse or transfusion. The mean follow-up interval was 4.5 (2-7.7) years. The cumulative
probabilities for decompensation and development of HCC were 22.2 per cent and 10.1 per cent in five years,
with an estimated yearly incidence of 4.4 and 2.0 per cent, respectively. The incidence of decompensation was
significantly lower in patients treated with IFN, but age may have played a contributory role. In contrast, neither
HCC development nor mortality was significantly altered by IFN therapy. The authors conclude that once
decompensation develops disease is progressive. Further studies are required to determine the efficacy of IFN
on clinical outcomes in this group of patients.
These studies highlight the serious sequelae that can be expected in those with established HCV chronic
hepatitis. However, as they only report on individuals with established liver disease, and do not include those
with asymptomatic HCV disease who will not progress, they cannot give estimates of rates of progression to
sequelae. This can only be achieved through prospective follow-up studies with determination of disease onset
dates.67
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5.4.2 Studies in subjects with community acquired hepatitis C virus
Determining the natural history of community acquired HCV is difficult and little has been published to date. A
group in Melbourne reported pilot results (Rodger et al 1999) of a retrospective cohort study examining the
long-term outcomes of HCV in a cohort who acquired infection through IDU in the early 1970s. Stored serum
from 1971 to 1975 was found to be strongly reactive for antibody to HCV in 238 subjects. The pilot results
indicated that HCV-antibody-positive individuals followed up to date were at increased risk of liver-related
pathology, but few (7%) had progressed to cirrhotic liver disease after a mean follow-up of 25 years. This
differs from findings of transfusion-related studies and suggests, within the limitations of the study, that the
natural history of community acquired HCV may be more benign. The final results of the study are expected to
be published shortly. Another study also tested stored sera samples, this time of 10,000 airforce recruits in the
1950s (Seeff 1997), and is tracing the recruits. The results of this study are not yet published.
5.4.3 Other studies
HCV infection following administration of anti-D immunoglobulin has been reported. In Ireland, 417 (0.8%) of
53,178 recipients of anti-D in 1977 were found to be anti-HCV positive (Power et al 1995b). At follow-up 232
were assessed. Serum ALT was normal in 37.6 per cent and liver biopsy specimens revealed mild to moderate
chronic hepatitis in 38 per cent and severe hepatitis in 6 per cent. Only 2.4 per cent had features suggestive of
early cirrhosis (Seeff 1997). To assess progression of disease in this group, Albloushi et al (1998) followed 30
patients who underwent two liver biopsies about two years apart, 17 and 19 years after initial infection with the
infected immunoglobulin. In the initial 1994 biopsies, one patient showed cirrhosis (stage 6/6) and six patients
(20%) had developed moderate fibrosis (stage 3-4/6). There was no significant histological disease progression
between two biopsy specimens over two years. The results suggest that the prognosis in such cases could be
guardedly optimistic in this homogenous cohort of healthy women infected at a young age.
5.5 Hepatocellular carcinoma
HCC is one of the commonest carcinomas worldwide, although it is less common in Western countries than in
Asia, South Europe and Africa. An aetiological association between chronic HBV infection and HCC has been
known for some time, and is thought to be mediated partly through the capacity for HBV DNA to integrate into
host DNA. Although replicative intermediates of HCV RNA do not insert into cellular DNA, there is increasing
evidence to support a strong association between chronic infection with HCV and the occurrence of HCC.
Although the pathogenesis of HCV-related HCC is unknown, it almost always arises in association with
cirrhosis or chronic hepatitis. Because there is no evidence that the virus is directly carcinogenic, it appears that
HCV induces malignant transformation indirectly by causing chronic necroinflammatory hepatic disease and
continued regenerative attempts that eventually are responsible for tumour formation.
Evidence for the link between HCV infection and HCC is provided by case-control studies, case series and by
longitudinal studies (tables 31-39). The proportion of patients with HCC who have circulating antibody to HCV
shows a pronounced geographical variation. In regions where HBV infection is endemic and is the major risk
factor for HCC, antibody to HCV is present in the serum of a smaller proportion of patients (6-39%), with RRs
of 7 (95% CI 1.6, 39) in Taiwan and 6 (95% CI 0.5, 69) in Senegal. In Japan, Spain and Italy, antibody to HCV
is present in 47 to 83 per cent of the patients, with RRs of 52 (95% CI 24, 114) in Japanese and 69 (95% CI 15,
308) in Italian carriers of the virus. Comparatively low prevalences (13-35%) have been recorded for the
remaining geographical regions for which information is available, with RRs of 10.4 (95% CI 4, 26) in Greece
and 10.5 (95% CI 3.5, 31) in North America. For tables 31-39, see Tables section.68
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5.5.1 Interaction between hepatitis B and hepatitis C viruses in causation of
hepatocellular carcinoma
There is uncertainty regarding the interaction of HCV and HBV in hepatocellular carcinogenesis. Many reports
have suggested that anti-HCV antibodies are present appreciably more often in HBsAg-negative patients than
with HBsAg-positive patients with HCC (table 40) (Simonetti et al 1989; Hasan et al 1990; Saito et al 1990;
Jeng and Tsai 1991; Tanaka et al 1991; Bukh et al 1993a).
Table 40 Prevalence of hepatitis B virus markers and anti-hepatitis C virus among
people with hepatocellular carcinoma from different countries or regions
Country or
region
Reference Total no. of
cases
Percentage of people with: Percentage of anti-HCV(+)
in HCC in people with:
HBsAg+ Any HBV marker
(+)
Anti-HCV+ HBsAg+ HBsAg-
China Jeng & Tsai
(1991)
129 63 NM
A 37 24 60
France Ducreux et al
(1990)
74 NM 43 28 47 14
Italy Colombo et al
(1991b)
132 31 80 65 54 70
Italy Levrero et al
(1991)
167 32 68 58 28 72
Italy Trevisani et al
(1995)
166 20 47 72 47 78
Italy Simonetti et al
(1992)
200 62 NM 76 58 79
Japan Nishioka et al
(1991)
180 42 NM 15 76
Japan Shiratori et al
(1995)
205 11 71
Japan Tanaka et al
(1991)
91 21 NM 51 5 63
Mozambique Dazza et al
(1993)
189 66 98 37 NM NM
Southern
Africa
Kew et al (1990) 380 48 81 29 26 32
Spain Bruix et al
(1989)
96 9 NM 75 56 77
Taiwan Lee et al (1992) 326 75 97 13 4 37
Taiwan Lee et al
(1991b)
26 75 NM 13 35 55
Taiwan Yu et al (1991) 127 8 29
USA Hasan et al
(1990)
87 32 NM 45 14 53
ANM, not measured.69
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These results may provide some support for reports that HBsAg
 is cleared when superinfection with HCV
occurs, or suggest that HCV protects against superinfection with HBV which goes on to chronic HBsAg
carriage. Bukh et al (1993a) found that very few patients with HBsAg in serum had HCV detectable, despite the
presence of anti-HCV. There are also many reports which show that HBV DNA can be found in the liver tissue
of some patients who are HBsAg negative (Brechot et al 1982; Sakamoto et al 1988; Dodd 1995). A few reports
have not found any significant difference in HCV prevalence in patients with HCC related to the HBsAg status
(Bruix et al 1989; Colombo et al 1989; Vargas et al 1990), but there is a consistent trend to a higher prevalence
of HCV in patients who are HBsAg negative.
Of the many studies on HCC, relatively few have reported the risks for HCC in individuals positive for HBsAg
separately from those with anti-HCV and from those with both (Kaklamani et al 1991; Yu et al 1991; Chuang et
al 1992; Yuki et al 1992). Because HBsAg carriage is usually acquired early in life, the results suggest that
HCV superinfection in HBV carriers may synergistically increase the risk of HCC developing. However, there
are other studies which have reported that HBV and HCV act as completely independent risk factors for HCC
(Nalpas et al 1991; Simonetti et al 1992).
HBV and HCV can interact with chronic alcohol consumption, and there is circumstantial evidence of a high
prevalence of HBV and HCV infection in people with alcoholism. The high prevalence of HCV infection with
cirrhosis in people with alcoholism (40-50%), relative to those with minimal liver damage (about 20%) suggests
that HCV infection might be involved in the development of cirrhosis in some of these patients, and might also
account for the high prevalence of anti-HCV (50%) in people with alcoholism with HCC (Brechot 1996).
Coinfection with HBV and HCV might influence HCC at two levels: there is in vitro evidence for decreased
replication of both HBV DNA and HCV RNA in patients infected by two viruses. In vitro expression of the
HCV capsid also diminishes encapsidation of the HBV pregenome (Brechot 1996).
There is some evidence for an interaction between HCV and HBV in hepatocellular carcinogenesis, but this
remains to be proved (tables 41 and 42). There appears to be a negative correlation between markers for HBV
and HCV (figure 3). In most populations, HCC develops at an older age in patients with HCV-induced tumours
than in those with HBV-induced tumours.
Table 41  Effect of hepatitis C virus infection on risk of hepatocellular carcinoma in
hepatitis B-(HBsAg)-positive individuals
Country Reference No. HCC Control OR if anti-
HCV positive
95% confidence
interval
HCV +ve HCV  -
ve
HCV
+ve (%)
HCV
+ve
HCV-
ve
HCV
+ve (%)
Lower Upper
Italy Stroffolini et al (1992) 96 5 11 31 08 0 0.0 Undefined 5.58 Undefined
Taiwan CC Chang et al (1994) 34 1 23 4.2 01 0 0.0 Undefined 0.1 Undefined
Taiwan Tsai et al (1994c) 140 12 100 10.7 12 7 3.6 3.24 0.44 143.6
Taiwan Chuang et al (1992) 208 12 87 12.1 5 104 4.6 2.87 0.89 10.76
Combined M-H Weighted
Odds Ratio
478 30 221 12.0 6 221 2.6 4.55 2.15 19.470
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Table 42  Effect of hepatitis C virus infection on risk of hepatocellular carcinoma in
hepatitis B-(HBsAg)-negative individuals
Country Reference No. HCC Control OR if anti-
HCV positive
95% confidence
interval
HCV
+ve
HCV
-ve
HCV
+ve (%)
HCV
+ve
HCV
-ve
HCV
+ve (%)
Lower Upper
Italy Stroffolini et al
(1992)
68 38 11 77.6 13 6 68.4 1.59 0.4 5.89
Taiwan CC Chang et
al (1994)
156 4 10 28.6 4 138 2.8 13.8 2.15 83.4
Taiwan Lee et al
(1991a)
160 23 15 60.5 2 120 1.6 92 18.8 836
Taiwan Chuang et al
(1992)
304 13 16 44.8 8 267 2.9 27.12 8.74 85.4
Combined M-H
Weighted Odds Ratio
688 78 52 60.0 27 531 4.8 12 8.73 29.8
Figure 3. Interrelationship of hepatitis B and hepatitis C in hepatocellular carcinoma.
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One of the difficulties in attributing magnitude of risk associated with particular serostatus is that exposure or
infectivity as measured in the serum does not precisely reflect findings in liver tissue. For example, De Mitri et
al (1995) examined cancerous and noncancerous liver tissue and serum samples from 19 HBsAg-negative
patients with HCC without cirrhosis. Thirteen were HCV-RNA positive. Seven of 19 patients were HBV-DNA
positive in cancerous and noncancerous liver tissue. HCV antibody status did not match HCV-RNA status,
HBsAg-negative patients were not necessarily HBV-DNA negative, and HCC occurred in patients with HCV
without the intermediate step of cirrhosis. Liang et al (1993a) in the USA studied 91 HBsAg-negative patients
with HCC. These patients did not have other predisposing factors for HCC for evidence of HCV or HBV
infection, using PCR to detect HCV RNA and HBV DNA in serum and liver. HCV antibodies were measured
with second-generation immunoassays. Twenty-six (29%) of these patients carried low levels of HBV DNA in
either serum, liver/tumour tissue or both. The authors found that 53 of 91 patients (58%) exhibited evidence of
HCV infection. When the data were combined, 14 patients (15%) had evidence of HBV and HCV coinfection,
whereas 12 (13%) were infected with HBV alone and 39 (43%) had HCV only. Twenty-six (29%) had no
markers of HBV or HCV infection. All patients with identifiable viral markers had coexisting CLD. The authors
concluded that HCV or occult HBV infections account for most (71%) HCC of unknown pathogenesis in the
USA. Paterlini et al (1993), using a combination of serological and PCR assays, investigated the association
between HCV and HBV infections and primary liver cancer in 24 HBsAg-negative patients living in France.
Eleven of 22 patients tested had HBV DNA in the serum; 5 patients were anti-HBc positive and anti-HBs
positive. Patients with HBV viraemia had HBV DNA sequences in both tumorous and nontumorous liver
specimens. Selective loss of part of the HBV genome in the tumorous tissue of two of these patients suggested
HBV DNA persistence in clonally expanded malignant cells. The presence of HCV-RNA and HBV-DNA
sequences was tested for in serum and in tumorous and nontumorous liver samples. Twelve patients had anti-
HCV, and HCV-RNA sequences were found in the serum samples of all anti-HCV-positive patients and none of
the patients who were negative. Patients with HCV viraemia had HCV-RNA genomic sequences and presumed
replicative intermediates in both tumorous and nontumorous specimens. Sequence analysis of a hypervariable
region in the E2/NS1 gene of HCV showed significant variations between the viral molecules isolated from the
nontumorous, tumorous and serum samples. This eliminated the hypothesis of the contamination of the tumour
by nontumorous cells and serum particles and assessed that liver tumour cells did contain HCV-RNA genomes.
Only 4 of the 22 patients were negative for both viruses. Thelu et al (1992) tested 40 Caucasian patients with
HCC: 19 were anti-HCV positive and 21 were anti-HCV negative. Only 4/19 (21%) of anti-HCV-positive
patients were HCV-RNA positive: all four had C33-c-positive and C22-3-positive bands, but C100-3 and 5-1-1
bands were present in one and two patients, respectively. The only HBV marker was anti-HBcAb in two
patients. Only one of the patients who was anti-HCV negative had HCV RNA detected by PCR. The findings
suggest that HCV RNA is uncommon in the serum of Caucasian patients with HCC, which may be accounted
for by the contribution of alcohol to underlying cirrhosis in the patients or to the absence of viraemia at a final
stage of the disease. Diamantis et al (1994) studied paired samples (tumour, nontumour) from 38 patients using
PCR for HBV and HCV. Coinfection for HBV and HCV in liver was seen in nine patients, only three of whom
had anti-HCV in serum. One of these three was HBsAg negative in serum while the other two and four of the
other six from this group were HBsAg positive. One patient with anti-HCV in serum and no HBsAg had no
HCV RNA in liver tissue and HBV DNA was detected. Twenty-seven patients were infected with HBV only,
but only 25 of these had HBsAg detectable in serum. HCV was detected as the only agent in one patient. The
results suggest that in a hyperendemic area, HBV is closely associated with the development of HCC, but that
infection with HCV may play a secondary role. Even where PCR results between serum and liver are not
discordant, serum HCV genotyping may not reflect the viral population infecting the liver of a given patient
(Castillo et al 1995).72
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Table 43 Association of hepatocellular carcinoma with infection with hepatitis B virus or
hepatitis C virus
All patients were HBsAg negative.
Serum Liver Reference
HBV DNA 11/22 37/63 Paterlini et al (1993)
12/54 Not tested Ruiz et al (1992)
24/105 14/38 Liang et al (1992)
Not tested 5/12 Gerber et al (1992)
4/31 9/31 Sheu et al (1992)
Not tested 8/12 Unsal et al (1994)
3/22 11/22 Ramesh et al (1994)
HCV RNA 11/22 5/5 (HCV+) Paterlini et al (1993)
42/68 Not tested Ruiz et al (1992)
40/90 7/9 (HCV+) Liang et al (1992)
Not tested 11/20 Gerber et al (1992)
17/31 18/31 Sheu et al (1992)
Koike et al (1995) suggest an explanation for this. They measured HBV-DNA and HCV-RNA levels in the sera
of patients positive for both HBsAg and HCV antibody to characterise the state of dual infection with HBV and
HCV. Among 27 patients who showed evidence of double infection, 21 (77.8%) had detectable levels of only
either HBV or HCV genome in their sera, 2 (7.4%) showed none of the viral genomes, and 4 (14.8%) had both
HBV DNA and HCV RNA. In the 4 patients with both HBV DNA and HCV RNA, the titres of HCV RNA or
HBV DNA were lower than those in the patients with HCV RNA or HBV DNA alone. In some patients with
chronic hepatitis, the viruses appeared to replicate in turn in the course of the disease. Their results suggest that
the viruses show alternating dominance in replication in most patients who have dual infection with HBV and
HCV, probably due to interference of the viruses.
Studies seem to suggest that HBV-associated HCC tends to evolve more frequently in a noncirrhotic liver and
also at younger ages, and perhaps HCV-associated HCC emerges more often in an advanced cirrhotic liver in
older individuals and grows in a less aggressive manner (Okuda 1995). For example, in a series of 205
consecutive Japanese patients with HCC admitted during 1990-93, 71 per cent of the patients showed positivity
for HCV antibody alone, 13 per cent showed positivity both for HCV and HBV antibodies, 11 per cent were
positive for HBsAg alone and absence of both HCV and HBV antibody occurred in 4 per cent only (Shiratori et
al 1995). Positivity to both HCV antibody and HBsAg was demonstrated in 1 per cent only. Mean detection age
(± s.d.) of HCVAb-positive HCC as well as both HCV and HBV antibody-positive HCC was 62±7 years, in
contrast to 52±13 years in HCC with HBsAg (P<0.05). The male-to-female ratio among HCVAb-positive HCC
was 3.3:1, in contrast to 5.5:1 among the HCV/HBVAb-positive HCC and 7:1 among HBsAg-positive HCC,
but there was no significant difference in the gender distribution between these groups. More than 60 per cent of
HCVAb-positive HCC and HCV/HBVAb-positive HCC were classified into the stage of Child B and C,
whereas 65 per cent of HBsAg-positive HCC was at the stage of Child A. The severity of liver disease was
confirmed by liver histology, indicating that more than 70 per cent of the HCVAb-positive HCC and the
HCV/HBVAb-positive HCC showed cirrhosis, in contrast to 50 per cent among the HBsAg-positive HCC.
Three-year survival rate of HCVAb-positive HCC and HBV/HCVAb-positive HCC was 68 and 56 per cent,
respectively, in contrast to 47 per cent in HBsAg-positive HCC.73
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5.5.2 Time between exposure and development of hepatocellular carcinoma in
hepatitis C virus-positive patients
Blood transfusion
A history of blood transfusion may be associated with HCV infection, although blood transfusion appears no
longer to be a major route of HCV transmission. The mean time between first transfusion and the development of
HCC has been 25.2 years (USA, Yu et al 1990); 22 years (Japan, Saito et al 1990); 27 years (Japan, Nishioka et
al 1991); and 29 years (Japan, Kiyosawa et al 1990). Tremolada et al (1990) report the well-documented case of
HCV infection which progressed through CAH and cirrhosis to HCC 13 years after transfusion. Kiyosawa
described a case of a 70-year-old nonalcoholic man who developed HCC 18 years after chronic NANBH
following a blood transfusion, with five liver biopsies sequentially taken from year 5 to 15 showing, in order:
unresolved viral hepatitis, CPH, CAH, CAH with bridging necrosis and postnecrotic cirrhosis (Kiyosawa et al
1984). Close correlations have been demonstrated between blood transfusion, NANBH and anti-HCC in patients
with TA-HCC (Kiyosawa et al 1990).
Tanaka et al (1991) used cross-sectional data on seropositivity among 422 HCC patients, cancer registry data and
data on age-specific population prevalence to estimate the five-year age-specific incidence rates of HCV-linked
HCC. Using these risks, the cumulative risk (ie the probability of contracting HCC within the following 15 y in
50-y-old carriers) was estimated as 28 per cent for males and 6 per cent for females (Tanaka et al 1991).
Castells et al (1995) investigated the prevalence of anti-HCV and the interval between HCV infection and HCC
among 191 consecutive patients with cirrhosis and hepatocellular carcinoma. Of the 29 anti-HCV-positive
patients with previous transfusion, the interval between the date of blood transfusion and the diagnosis of hepatic
cirrhosis was (mean±s.d.) 24±12.5 years and that of HCC was 26.8±12.4 years, showing the slow sequential
progression from HCV infection through cirrhosis and HCC.
Prospective studies of hepatocellular carcinoma development
Ikeda et al (1993) prospectively studied 795 consecutive patients with viral or alcoholic cirrhosis for 2 to 17
years (median, 5.8 y). During the observation period, HCC developed in 221 patients. Cumulative appearance
rates of HCC were 19.4, 44.3 and 58.2 per cent at the end of year 5, 10 and 15, respectively. When classified by
the type of hepatitis virus infection, the appearance rates of HCC in 180 patients with only HBsAg and in 349
patients with only antibodies to HCV were: 14.2 and 21.5 per cent at year 5; 27.2 and 53.2 per cent at year 10;
and 27.2 and 75.2 per cent at year 15, respectively. A Cox proportional hazard model identified that α FP levels
(P<0.001), age (P<0.001), positive HCV antibodies (P<0.002), total alcohol intake (P<0.005) and indocyanine-
green retention rate (P=0.05) were independently associated with the appearance rates of HCC. Whereas age and
indocyanine-green retention rate were independent predictors for the appearance rate of liver tumour in the
subgroup of HBsAg-positive patients, α FP levels, age and past alcohol consumption were independent predictors
in the group of HCV antibody-positive patients. The authors believe these epidemiological results suggest that
some differences exist in the activity and modes of cancer promotion between HBV infection and HCV infection.
Ganne Carrie et al (1996) prospectively followed 151 hospitalised patients with histologically proven cirrhosis
from 1987-90 until June 1994 by which time 31 had developed HCC. Six variables summarised predictive
information of HCC: age greater than or equal to 50 years (P=0.01); male (P=0.01); large EV (P=0.03);
prothrombin activity <70 per cent (P=0.04); serum α FP levels greater than or equal to 15 ng/L (P=0.06); and
anti-HCV antibodies (P=0.08). A clinicobiological predictive score identified two groups of patients at low
(n=67; 3-y cumulative incidence, 0%) and high risk for HCC (n=84; 3-y cumulative incidence, 24%). The
predictive value of this score was confirmed using an independent population of 49 patients with cirrhosis.
Furthermore, liver large-cell dysplasia (LCD) had an additional predictive value in high-risk patients (P=10
-4),
which thus helped to define a subgroup at very high risk for74
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HCC (n=12; 3-y cumulative incidence, 72%). The authors concluded that in Western patients with cirrhosis, a
limited number of usual variables can identify a group of patients at high risk for HCC and that liver biopsy
allows for determination a subgroup of patients at very high risk for HCC.
Mechanism of carcinogenesis
The means by which HCV causes HCC has been an active area of research, and it seems likely that HBV and
HCV act via different mechanisms. HCV persists in hepatocytes during malignant transformation, and some HCC
appear to support replication and expression of HCV (Gerber 1993; Horiike et al 1993; Haruna et al 1994). One
mechanism suggested for carcinogenesis is that the cellular inflammatory infiltrates, present in the liver in both
chronic HBV and chronic HCV infection, are associated with premature hepatocellular death, possibly by
apoptosis, leading to regeneration of hepatocytes and, thus, an overall increase in the rate of proliferation and cell
turnover of the hepatocyte population. At the same time, inflammatory cells, particularly monocytes and
macrophages, present in the liver, generate free hydroxy radicals, which are capable of damaging cellular DNA,
and may be the proximate cause of malignant transformation. Much of the intrahepatic inflammatory response
may be nonspecific and cytokine-mediated (particularly IFN-γ). Although hypothetical, this mechanism of viral
carcinogenesis is consistent with the observation that HCC commonly develops in both HBV and HCV infections
against a background of chronic hepatic inflammation and cirrhosis (Lemon and Brown 1994).
Although in most cases the noncancerous tissue of HCC patients is cirrhotic, HCC can arise in HCV infection
without an intermediate step of cirrhosis (Sbolli et al 1990; Jeng and Tsai 1991; Levrero et al 1991; Simonetti et
al 1992), suggesting that HCV could be exerting some direct effect on the development of HCC. El-Refaie et al
(1996) reported four cases of HCV-RNA-positive, HBsAg-negative, HBV-DNA-negative HCC in patients
without cirrhosis in 66 consecutive cases of HCC undergoing surgical resection. Theise et al (1993) reported an
incidental small HCC in a patient with chronic HCV infection without cirrhosis. The existence of portal triads
and the Meyenburg complexes within the lesion and atypical subnodules suggested that the carcinoma has arisen
in the context of a macroregenerative nodule rather than the whole nodule being an early, spreading carcinoma.
They argue that macroregenerative nodules are precursor lesions in the development of HCC. Although often
thought of as being large cirrhotic nodules, the authors suggest that they may be lesions that develop in the
context of CLD, parallel to, but independently of, cirrhosis. Moreover, the development of carcinoma within the
nodule suggests that macroregenerative nodules may be involved in carcinogenesis in noncirrhotic livers.
HCC may be multicentric in occurrence, and patterns of loss of heterozygosity on chromosome 16 in multiple
HCCs suggest that they have an independent clonal origin. Multicentric tumours are associated with a low
disease-free three-year survival rate (Tsuda et al 1992; Takenaka et al 1994).
Mutant p53 has been found in a wide variety of human malignancies including carcinomas of the lung, breast and
colon. Laurent Puig et al (1992) examined immunohistochemically a large series of liver tumours from Caucasian
patients with different risk factors for expression of the p53 mutant to assess its prevalence and the relationships
between p53 overexpression and clinicopathological data. Nine of 58 specimens were found to have detectable
evidence of p53 gene mutation, and p53 was more frequent in patients with serological HBV and HCV markers
than patients without these markers (P=0.046). The authors concluded that p53-positive HCC is rare in patients
exposed to a low dietary aflatoxin intake and that p53 mutation seems to occur at a late stage of the tumorous
process and could contribute to an aggressive tumorous phenotype. Teramoto et al (1994) reported that p53
abnormalities in HCC correlated with the grade of cancer cell atypia which advanced with tumour growth. Using
PCR techniques on cancerous and noncancerous regions of the liver, patients who had been infected with either
HBV or HCV showed an incidence of p53 abnormalities (45%) higher than those infected by neither (13%).
However, the detection rate of these viruses was lower in the HCC region (33%) than that in the noncancerous
region (56%) in cases with mutated p53. There was a difference in pattern of p53 mutational changes in patients
depending upon whether they were75
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infected by HBV or by HCV. Two of three HBV-infected patients had a transversional change of nucleotide at
the G:C site to T:A. However, four of eight patients with HCV had a transitional change of nucleotide of p53,
indicating that HCV infections affect carcinogenic pathways causing p53 abnormalities independently. Yumoto et
al (1995) have also reported that loss of heterozygosity (LoH) on every chromosome and the p53 mutation is
observed more frequently in more advanced tumours. Genetic changes accumulated with the increase of the
histopathological grade, suggesting that the accumulation of genetic changes in multiple tumour suppressor genes
is involved in HCC progression (Yumoto et al 1995).
Tarao et al (1994) examined whether the pathogenesis of carcinoma that increased proliferation of tissue cells
correlates with the development of carcinoma, by increased rate of random mutations and by promotion. Patients
were studied by the in vitro uptake of bromodeoxyuridine in biopsied liver specimens and were followed
prospectively for 3 years. Nine of 14 (64.3%) of the cirrhotic patients with high-DNA synthesis activity
developed HCC in the 3 years, in contrast to only 2/14 (14.3%) of the cirrhotic patients with low-DNA synthesis
activity (P<0.05). Niu et al (1995) showed that HCV viral replication occurs both in the tumour tissue and
nontumour tissue of HCC. Viral replication was established by showing the presence of minus strand HCV RNA
by PCR amplification, after excluding residual reverse transcriptase activity of Taq polymerase. No minus strand
was found in serum-derived virion RNA. PCR amplified products from both tumour and nontumour parenchyma
were sequenced in the 5' noncoding region and shown to be identical. The finding of a conspicuous inflammatory
infiltrate of the tumour tissue was thought to reflect the presence of the virus.
Sullivan and Gerber (1994) sequenced part of the 5' untranslated region of HCV from the tumour tissue and the
surrounding nontumorous liver of three patients with HCC. No sequence differences between tumour-derived and
liver-derived HCV isolates were detected. Based upon the conservation of the 5' untranslated region of HCV -
not only in infected hepatocytes, but also in neoplastic cells - the authors suggest that the regulatory elements at
the 5' terminus of the viral genome are important in the pathobiology of HCV.
Based on histological criteria, regenerative nodules in cirrhotic liver have been generally considered to result
from hyperplastic proliferation of hepatocytes, but whether these nodules are hyperplastic or neoplastic has not
been determined definitively. Aihara et al (1994) undertook clonal analysis of regenerative nodules (n=76) and
HCC (n=7) induced by HCV infection. All carcinomas were monoclonal. Clonal analysis of regenerative nodules
showed that 43% (33/76) were monoclonal in origin. Adjacent monoclonal nodules showed inactivation of the
same allele of the phosphoglycerokinase gene. Because the gene allele is inactivated at random, it is unlikely that
each nodule happens to inactivate the same allele; it is more likely that monoclonal cell expansion is initiated
before the nodule is established by septum formation. The authors conclude that monoclonal cell expansion is
seen in many regenerative nodules in cirrhotic liver, indicating that certain genetic changes have already occurred
in these nodules.
Australian studies
There are few reports on HCC from Australia since the advent of testing for HCV. Brotodihardjo et al (1994)
from Westmead Hospital in Sydney, Australia, undertook a retrospective case-record review of clinical features
of all (122) patients discharged from their 900-bed tertiary-referral teaching hospital with a diagnosis of HCC
from January 1979 to March 1993. They aimed to examine the incidence of HCC in western Sydney over this
period, assess risk factors for the disease, and to consider the opportunities for improving HCV’s usually poor
outcome. They reported that the number of cases admitted each year at least doubled between 1979-85 and 1986-
92, an apparent increase affecting individuals born in Australia (50% of all patients) as well as immigrants.
Cirrhosis was found in 93 per cent at liver biopsy or autopsy. Excessive alcohol intake was an associated risk
factor for 46 per cent of Australian-born patients and for 13 per cent of those born in other countries. Among the
latter, HCC was associated with markers of HBV infection in 64 per cent. Since HCV tests became available in
1990, five of nine patients tested were anti-HCV positive. Screening of patients known to have cirrhosis detected
eight cases of early76
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HCC. The authors concluded that in Australian-born patients, alcoholic liver disease remains a major aetiological
factor and that the role of HCV requires further evaluation. Among immigrants, cirrhosis from chronic viral
hepatitis accounts for most cases. The authors suggested that prevention of cirrhosis caused by chronic viral
hepatitis should have the greatest long-term effect on prevention of HCC in Australia.
A Victorian study aimed to assess the prevalence of previously identified risk factors for liver disease and
infection with HBV and HCV in people with HCC recorded by state-based cancer surveillance (Victorian Cancer
Registry) and the feasibility of retrospective surveys in determining risk factors for HCC (Thompson et al 1997).
A retrospective mailed survey was undertaken of doctors notifying cases of HCC diagnosed in 1991 and 1992.
The study documented the high contribution of alcohol to HCC, particularly in Australian-born men. Low rates of
testing for HBV and particularly HCV at that time make interpretation of their contribution to HCC uncertain; no
cases of HCC due to HBV or HCV were reported in Australian-born patients. Higher rates of HBV carriage in
those tested were found in Asian and Mediterranean immigrants. Testing for HCV was known to have occurred
for less than one-quarter of subjects and assessment for multiple aetiological risk factors was very uncommon.
The authors concluded that the epidemic of HCV necessitates improved surveillance for the sequelae of long-
term infection. Alternative approaches to ongoing surveillance require cooperation from clinicians and adequate
resources for State cancer registries to supplement the existing passive reporting system with data on exposure.
Screening strategies for early detection of hepatocellular carcinoma
The prognosis for patients with HCC is poor. The five-year survival rate in patients who present with abdominal
pain and weight loss is less than 5 per cent, with mean survival measured in months (Wands and Blum 1991).
Studies have been undertaken in some countries with a high incidence of HCC to establish screening strategies
for early detection of HCC in an attempt to improve prognosis. Screening can be broadly divided into population-
based and clinic-based approaches; population-based screening programs have been successful in Japan, China
and the USA (Alaska); whereas clinic-based screening has been more relevant in Europe and other parts of the
USA (Wands and Blum 1991). Regular ultrasonography and measurement of tumour markers (serum α FP or
abnormal prothrombin) are screening tests, and may be supplemented by tests such as CT, magnetic resonance
imaging, celiac angiography and CT with angioportography when a tumour is suspected. HCC larger than 2 cm in
diameter show a higher frequency of vascular invasion and a higher recurrence rate after resection, so the
emphasis is on early detection before vascular invasion (Unoura et al 1993). It has not yet been confirmed in
controlled trials that screening has a beneficial effect on survival (Colombo et al 1991a; Sallie and Di Bisceglie
1994), and screening programs in patients with chronic hepatitis are hampered by a significant false-positive
detection of HCC.
Treatment of hepatocellular carcinoma
The treatment of hepatitis-related HCC is unsatisfactory, and made more difficult because most cases occur in
patients with cirrhosis, meaning patients tolerate surgery poorly. Only a minority of cases are suitable for surgical
resection, but this may improve survival in those with small, unifocal lesions. Systemic chemotherapy is generally
ineffective, with survival not being improved significantly over conservative management. Intra-arterial
chemotherapy with or without chemoembolisation has a reduced risk of toxicity related to chemotherapeutic
agents. Injection of pure ethanol into the tumour causes necrosis of the tumour; although this technique is
restricted to tumours less than 3 cm in diameter. Liver transplantation is an option but, unfortunately, limited by
availability of suitable donors, and the recurrence of HCV in grafts including severe hepatitis in some.77
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The prevention of virus-related HCC can be summarised (Sherlock 1994):
·  universal vaccination against HBV;
·  screening blood donors;
·  changing life styles, responsible alcohol consumption;
·  use of sterile syringes and needles; and
·  anti-viral treatment to prevent cirrhosis.
5.6 Hepatitis C virus and alcohol
Both HCV and alcohol are major causes of liver disease, serious morbidity, and mortality in various populations
worldwide. It is important to understand how these two factors interact. There has been no suggestion that HCV
infection increases the likelihood of high alcohol intake. However, there is strong circumstantial evidence that
high alcohol intake increases the likelihood of HCV infection and disease. Several questions arise in relation to
HCV and alcohol, as discussed in the following sections.
5.6.1 Association of hepatitis C virus infection and alcohol intake
Ideally, we would like to observe the incidence of HCV in a population-based sample of people in which an
accurate measure of alcohol intake over an extended period of time is recorded. There have been studies that
have attempted an approximation of this ideal from Portugal (Santos et al 1994) and Japan (Lin Chu et al 1990;
Shinzawa et al 1991). The Portuguese study demonstrated the difficulty of this approach, since the absolute
numbers of HCV-positive individuals was very small (3/659), as was the number of high-alcohol-intake
individuals, and observing sufficient numbers of HCV-positive high-alcohol-intake individuals in order to
meaningfully estimate the incidence would require a sample size very much larger. A population-based survey in
Japan (n=618) was performed in districts known to have a high rate of liver disease, and HCV-positive rates in
the two towns surveyed were 16.6 and 3.7 per cent (Shimizu et al 1992). The differences in the incidence of
HCV-positivity could not be explained by differences in alcohol intake. The second study (n=4,491) was
undertaken in people older than 35 in one town in Japan having routine health examinations, and 79 per cent of
the eligible population was examined during the study. Liver dysfunction was observed in 9.8 per cent of the
population, and 36.1 per cent of this group were HCV-positive (Shinzawa et al 1991).
A more common approach to the problem of estimating the rate of HCV infection in the general community and
in those with high alcohol intakes is to use convenience samples: the incidence in blood donors in a geographical
area compared to the incidence in a secondary-referral clinic or hospital for those being treated for the adverse
effects of high alcohol intake (Caldwell et al 1991; Blackmore et al 1992). In both instances, the patients with
high alcohol intakes already had alcoholic liver disease as an entry criterion. More often, the researchers simply
assume that the rate of HCV infection in the general population is very low. No studies compared patients with
high alcohol intakes but no liver disease, with a healthy control population. The studies were all cross-sectional
observations.
Despite the shortcomings of the studies, most published observations demonstrated a markedly raised prevalence
of evidence of HCV infection in those with high alcohol intake (table 44, see Tables section). The reported
prevalence of antibodies to HCV was 12 per cent in European and American studies in patients being treated for
the adverse effects of high alcohol intake without known alcoholic liver disease or only mild histological
changes. The similar prevalence in Japan was 22 per cent. However, several studies did not examine the liver
histology, and people with occult cirrhosis may have been included in these groups. In Northern Europe, the
prevalence of HCV antibodies in those with severe liver disease and HCC was 12 per cent, in France 32 per cent,
in Italy and Spain 36 per cent, in USA 18 per cent, and in Japan 65 per cent. This demonstrates that HCV
infection is a common problem in people78
Epidemiology of the hepatitis C virus - Chapter 5
with alcoholism, particularly in Japan and Southern Europe, and raises the question of increased susceptibility of
people with alcoholism to HCV infection.
It is clear that IDUs in many countries have high prevalences of HCV infection. Users of one type of drug are
frequently users of multiple drugs including alcohol, either concurrently or sequentially. Thus, some people with
high alcohol intakes have been IDUs, and this may account in some instances for the high rate of HCV in people
with alcohol abuse problems in the USA (McHutchison et al 1992; Caplan et al 1995; Mendenhall et al 1993b),
Sweden (Bell et al 1992; Verbaan et al 1993), Japan (Ishii et al 1992) and France (Jiang et al 1995). The
association may be valid in other countries also, but may not have been thoroughly investigated because of the
difficulties of gaining accurate histories of past IDU. Other forms of parenteral transmission, such as tattooing,
may be associated with high alcohol intake (Ishii et al 1992). High alcohol intake can be associated with violent
behaviours and also with medical interventions such as blood transfusion following haematemesis, both of which
could increase exposure to HCV.
An additional explanation for the association of high alcohol intake and HCV infection may be a methodological
bias: when high alcohol intake and HCV infection occur in the same person, the rate of progression of liver
disease may be higher (see section 5.6.2), and therefore those people may be more likely to be included in the
clinic-based prevalence studies than people with only high alcohol intake or HCV infection or neither.
Population-based incidence studies which include the subpopulations at risk of high alcohol intake and HCV are
required in order to measure the magnitude of this effect
5.6.2 Effect of hepatitis C virus and high alcohol intake
Most studies that attempt to establish the effects of hepatitis C virus and high alcohol intake have made cross-
sectional observations in specialist clinics serving people with the adverse effects of high alcohol intake, usually
alcoholic liver disease. The greater the degree of liver disease in these people, the higher the prevalence of HCV-
infection markers. The studies reported provide considerable circumstantial evidence that the presence of HCV
infection is associated with increased severity of liver disease in people with high alcohol intake. Combining the
results of the studies (tables 45 to 47) indicates an increased risk of liver disease in people with high alcohol
intakes with HCV infection (OR 5.8, 95% CI 3.6, 9.4), increased risk of cirrhosis in those with alcoholic liver
disease and HCV infection (OR 3.4, 95% CI 2.1, 5.5), and increased risk of HCC in those with alcoholic
cirrhosis and HCV infection (OR 2.5, 95% CI 1.5, 4.2). A multivariate analysis of risk factors in HCC
demonstrated that alcohol consumption and HCV infection were independent predictors of the disease. The
calculations need to be treated with caution, since they are based on potentially biased populations of uncertain
origin. However, they provide support for more definitive studies being performed in order to investigate the
interaction of HCV and alcohol on the development of liver disease.79
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Table 45 Effect of hepatitis C virus infection on risk of liver disease in people with high
alcohol intakes
Reference Disease present Disease absent n OR Lower CI
95%
Upper CI
95%
Exposure
present
Exposure
absent
Exposure
present
Exposure
absent
Caldwell et al (1993) 10 24 12 36 82 1.25 0.42 3.74
Chang et al (1994a) 37 86 1 43 167 18.50 2.88 767.3
Coelho Little et al
(1995)
17 23 6 54 100 6.65 2.12 22.9
Pares et al (1990) 36 59 1 44 140 26.85 4.1 1114
Shimizu et al (1992) 14 60 5 116 195 5.41 1.72 20.0
Combined 114 252 25 293 684 5.8 3.27 9.2
Table 46 Effect of hepatitis C virus infection on risk of cirrhosis in people with alcoholic
liver disease
Reference Disease present Disease absent n OR Lower CI
95%
Upper CI 95%
Exposure
present
Exposure
absent
Exposure
present
Exposure
absent
Gonzalez Quintela et
al (1995)
11 55 1 77 144 15.40 2.09 671.2
Pagani et al (1994) 28 50 17 79 174 2.60 1.23 5.6
Pares et al (1990) 26 35 10 24 95 1.78 0.67 4.82
Shimizu et al (1992) 14 25 1 35 75 19.60 2.6 851.8
Combined 79 165 29 215 488 3.41 2.05 5.8
Table 47 Effect of hepatitis C virus infection on risk of hepatocellular carcinoma in people
with alcoholic cirrhosis
Reference Disease present Disease absent n OR Lower CI
95%
Upper CI 95%
Exposure
present
Exposure
absent
Exposure
present
Exposure
absent
Pagani et al (1994) 32 23 28 50 133 2.48 1.15 5.4
Shimizu et al (1992) 14 10 14 25 63 2.50 0.78 8.1
Zarski et al (1993) 9 15 4 16 44 2.40 0.52 12.8
Combined 55 48 46 91 240 2.50 1.39 4.480
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5.6.3 Effect of abstinence from alcohol in people with hepatitis C virus
infection
This question has not been thoroughly addressed. One Japanese study demonstrated a fall in viral RNA levels
following in-hospital complete abstinence in patients with alcoholism infected with HCV (Sawada et al 1993).
One patient who resumed drinking alcohol showed subsequent rises in HCV-RNA levels. The implication of this
observation was that alcohol enhanced HCV replication, although it is possible that the effect was a reduction in
release of viral particles rather than reduced production. In people with alcoholic liver disease without evidence
of HCV infection, the levels of liver enzymes in the blood fall rapidly following abstinence from alcohol intake,
whereas in those people with alcoholic liver disease and HCV infection, normalisation of liver enzyme levels is
slower and less complete (Ishii et al 1993; Matsuda et al 1993; Nagata et al 1993; Yokoyama et al 1995).
Removal of the main toxic influence on the liver in the former group leads to fall in liver-damage markers,
whereas this is less complete when a second toxic influence is present. Nevertheless, improvement in markers of
liver damage occurs when people with alcoholic liver disease and HCV infection abstain from alcohol
consumption.
Histological improvement as measured by repeat liver biopsy was observed to occur more commonly after
alcohol abstinence or reduced intake in people with alcoholic liver disease with HCV infection, although a
minority of patients deteriorated despite abstinence (Yoshida et al 1991). Another study confirmed this, and
showed that improvement in histology was greatest in those with fewest markers of HCV infection (Ishii et al
1993). These observations would be consistent with various levels of toxic activity of both alcohol and HCV
infection producing a range of interactions. These observations suggest that abstinence from alcohol intake
reduces progression of liver damage in HCV-infected people.
However, very few studies have been performed, and of these, almost all have been performed in Japan. No
studies have been published that directly measure the therapeutic effectiveness of abstinence from alcohol on
clinical end-points. The influence of alcohol on the effectiveness of IFN therapy has not been investigated. Thus,
although there is a therapy available that might reduce the effect of HCV infection on mortality and morbidity
from liver cirrhosis and HCC that has not been thoroughly investigated in long-term follow-up, there should be an
unwillingness to recommend a change in lifestyle that might cause additional stress and social disruption to an
infected person, if that alcohol abstinence proves to have no influence on health outcomes in people with
alcoholic liver disease and HCV infection. It is important that the effect of abstinence on long-term outcomes
should be investigated. An even more important question is whether there is any benefit in abstaining from
alcohol in HCV-infected individuals whose alcohol consumption is light or moderate.
5.7 Extrahepatic manifestations of hepatitis C virus infection
Gumber and Chopra (1995) reviewed the extrahepatic manifestations of HCV infection identified by mid 1995.
They identified conditions where strong evidence for an association exists of a direct pathogenic effect of HCV
(essential mixed cryoglobulinaemia, Willems et al 1994), membranoproliferative glomerulonephritis and
porphyria cutanea tarda), conditions where good evidence of an association exists but which falls short of proof
of pathogenic effect of HCV (Mooren corneal ulcers and autoimmune thyroiditis), and conditions where evidence
suggests the possibility of an association with HCV (the Sjögren syndrome, lichen planus and idiopathic
pulmonary fibrosis).
A common feature of most of these conditions is that they represent abnormal immune-system activity. HCV is
found in peripheral monocytes of most people chronically infected with HCV (Zignego et al 1995). In addition,
36 to 54 per cent of people with HCV CLD are reported to have cryoglobulins that precipitate HCV antigens
(Pawlotsky et al 1995a). These cryoglobulins consist of either a monoclonal antibody (type II) or polyclonal
antibodies (type III) complexed with anti-Ig(G or M) antibodies, which precipitate when cooled. The
cryoglobulins bind and concentrate81
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HCV virions in the blood. Precipitation of the cryoglobulins in different tissues can lead to skin lesions,
vasculitis, peripheral neuropathy, myopathy, and autoimmune hepatitis, among others. About 20 per cent of
people with HCV-associated cryoglobulinaemia have symptoms, typically a triad of purpura, weakness and
arthralgia. Cryoglobulinaemia is also associated with non-Hodgkin’s lymphoma (Pioltelli et al 1996; Zignego et
al 1996) and membranoproliferative glomerulonephritis (Pozzato et al 1994b).
Thus, chronic HCV infection can infect both liver and immune cells. The ongoing presence of virus stimulates
the immune system including B-cells leading to large quantities of HCV antibodies being produced, which
themselves become antigenic targets for antibody production. Neoplastic change can occur in the B-cell lines.
This process is likely to progress slowly over years or decades, so the possibility of HCV infection may be
overlooked by patient and doctor. The patient may eventually present in many different ways, and there is the
danger that the underlying diagnosis of HCV infection is missed, delaying specific therapy and risking cross-
infection to other patients using the same health facilities. In particular, patients in whom membranoproliferative
glomerulonephritis is the dominant presentation may progress to renal failure and be placed on dialysis, risking
cross-infection of other dialysis patients unless scrupulous infection control is practiced. Alternatively, people
who present with arthralgias and myopathy may be treated with surgery, local steroid injection or acupuncture,
with the risk of transmission to others.
5.8 Paediatric hepatitis C virus infection
In adults, HCV is known to be transmitted through parenteral exposure, primarily through receipt of blood or
IDU in about 50% of cases (Alter 1994; Alter 1995a). Other cases of HCV infection, without a reported source of
parenteral exposure to HCV, are so-called ‘sporadic cases’ of HCV infection. The possibility of sexual
transmission has been suggested for sporadic cases. The extent to which parenteral exposure and community-
acquired HCV infection contribute to HCV infection in children is not known. The outcome of chronic HCV
infection in children is also not well described (Doherty 1993).
5.8.1 Prevalence of hepatitis C virus infection in children
Prevalence of HCV infection is low in children without parenteral risk factors for HCV infection (table 48, see
Tables section). HCV seroprevalence measured by second-generation EIA in school children in Brazil, Italy,
Japan and Taiwan indicated that HCV seroprevalence was less than 0.5 per cent. HCV seroprevalence among
children transfused during surgery or with orthotopic liver transplantation was much higher than that in children
without parenteral risk factors. In Taiwan, HCV seroprevalence was 4 per cent among children transfused during
open heart surgery, prior to the introduction of HCV-antibody screening of blood donors. The highest HCV
seroprevalence was recorded among multiply-transfused children such as children with thalassaemia or
haemophilia or in children surviving malignant disease. In two studies carried out in Italy, HCV seroprevalence
among thalassaemic children was about 55 per cent whereas among children with haemophilia in Canada and
Australia, HCV seroprevalence was 63 and 74 per cent, respectively. Among children with NANBH and without
underlying conditions which may contribute to liver disease, HCV seroprevalence ranged from 36 per cent in
Taiwan to 74 per cent in children in Italy. In almost all children with HCV infection, a history of parenteral
exposure to HCV was documented.
5.8.2 Natural history of hepatitis C virus infection in children
A few papers have described aspects of the natural history of HCV infection over a relatively short time (table
49, see Tables section). Although about 60 per cent of children appeared to progress to chronic HCV infection,
measured by persistent elevation of ALT, limited evidence of liver damage was available for most children.
Children with thalassaemia had the highest rate of cirrhosis but this may be due to treatment and immunological
factors.82
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5.8.3 Interferon treatment in children with hepatitis C virus infection
In three small studies, IFN treatment in children appeared to be effective in limiting progression to more
advanced liver disease (table 50, see Tables section). However, further studies need to be carried out to confirm
these results.
HCV infection is rare in children except for those with parenteral exposure to HCV. Although the available
studies of the natural history of HCV infection in children were limited by the small numbers of children included
and the relatively short duration of follow-up, they suggest that in most children, HCV infection is chronic but
severe active hepatitis and cirrhosis were rare.
5.9 Coinfections
5.9.1 Coinfection with hepatitis B virus
There is a complex relationship between HBV and HCV which, in terms of pathogenesis, is explored elsewhere
in this report. Interaction with acute infection is also complex. Acute HCV infection can enhance the clearance of
HBsAg in those chronically infected with HBV (Sheen et al 1994). Acute HBV/HCV coinfection may inhibit the
development of chronic HBV infection, whereas the onset of HBV infection may reduce the severity of HCV
infection but not its progression to chronicity (Mimms et al 1993). And in a study of people with cirrhosis, 80 per
cent had evidence of both HBV and HCV exposure, although most were negative for HBsAg (Villa et al 1995b).
As discussed elsewhere, although HBV and HCV seem to inhibit each other at the molecular level (Francois et al
1994; Ohkawa et al 1994), they seem also to enhance each others’ cytopathic effects (Alberti et al 1995). For
instance, concurrent HBV and HCV infection confers the greatest risk of HCC (Bertorp 1994).
5.9.2 Coinfection with human immunodeficiency virus
HIV and HCV share similar routes of transmission so individuals at risk of contracting one virus are at risk of the
other. Prevalence of HCV in those with HIV varies according to exposure risk. In IDUs, prevalence of HCV in
those who are HIV infected ranges from 52 to 95 per cent (Quan et al 1993; Francisci et al 1995). In homosexual
or bisexual men, who do not inject drugs, the prevalence ranges from 0 to 12 per cent (Quan et al 1993; Wright et
al 1994b).
HCV infection of a person already infected with HIV can lead to a prolonged and/or increased HCV viraemia.
For instance, Horvath and Raffanti (1994) found that HCV RNA was quantifiable in 79 per cent of HIV-infected,
HCV-seropositive IDUs compared with only 43 per cent of HIV-uninfected; Cribier et al (1995) found mean
HCV-RNA levels to be much higher in HIV coinfected people than in those with only HCV infection.
One possible result of this effect is that transmission of HCV from coinfected people may be more efficient.
Lissen et al (1993) examined the stable heterosexual partners of index cases who were either HIV/HCV
coinfected or only HCV infected, and found that HCV prevalence was 2.2 times higher in the partners of the
coinfected than in those infected by HCV alone. Their conclusion was that the efficiency of sexual transmission
of HCV is enhanced by concurrent HIV infection.
However, there is some evidence that HIV infection has a deleterious effect both on immune response to HCV
and, as a result, on serological diagnosis of HCV exposure. Several studies have found higher rates of
indeterminate reactivity to HCV antibody in those with HIV infection than in those without. For example, in one
study of people all of whom were HCV-PCR positive, 14.7 per cent of those with HIV infection were
seronegative or indeterminate compared with only 4 per cent of those without HIV (Cribier et al 1995).
The effect of HIV/HCV coinfection on pathogenesis and disease progression is still not fully understood. HCV
does not appear to adversely influence survival in, or severity of, HIV infection (Quan et al 1993; Wright et al
1994a,83
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1994b). One study found an inverse relationship between CD4 count and the severity of liver damage, suggesting
immunomediation is important in the process of hepatic damage caused by HCV (Guido et al 1994).
There appears to be an increase in the incidence of liver disease in coinfected individuals (Sanchez-Quijano et al
1995; Soto et al 1997). Telfer (1994) reported that the risk of HCV-infected people with haemophilia developing
hepatic decompensation after 20 years was 10.8 per cent, and in HCV/HIV-infected individuals the risk increased
21-fold. The authors conclude that HIV infection in those with HCV accelerates progression to cirrhosis and
hepatic decompensation, and speculate that this is probably due to enhanced HCV replication in the presence of
immune deficiency. Eyster et al (1993) report on a cohort of people with haemophilia. In those coinfected, 9 per
cent had liver failure after 10 years of HCV infection compared to 0 per cent in those infected only with HCV. In
a UK cohort of coinfected people with haemophilia, Martin (1989) reports that 18 per cent of deaths were due to
liver failure and 44 per cent developed cirrhosis over 12 years. This is significant as the expected prevalence of
cirrhosis in mono-infected subjects should be 10 to 20 per cent (Seeff 1997) and mortality due to HCV-related
liver disease in people with haemophilia infected only with HCV is uncommon (Eyster et al 1993).
The hypothesis for the more severe liver disease seen in coinfected individuals has been well documented, that is,
 progressive HIV-induced immunosuppression giving rise to an increase in HCV replication which correlates
with increased liver damage (Beld et al 1998a). Sherman et al (1993) reported that whereas HCV-RNA levels
increased four-fold in those who were HIV negative, they increased 58-fold during the same time period in
coinfected subjects. The same study also showed a significant correlation with declining CD4 T cell counts and
raised ALT levels.85
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6 Treatment
6.1 Therapy for hepatitis C virus infection
6.1.1 Interferon therapy in the management of hepatitis C virus infection:
efficacy, predictors of response and effect on natural history
Although some people with chronic HCV infection develop a sustained response following IFN  therapy, the
proportion of responders, factors predictive of response and optimal therapeutic regimes need to be clarified. Of
even greater importance is whether IFN therapy can alter favourably the natural history of HCV infection
(Terrault and Wright 1995a).
This section summarises information on the efficacy of IFN therapy in the management of acute and chronic
HCV infection, including factors predictive of response. It also explores the question of the effect of therapy on
the natural history of HCV infection, and outlines further areas for research.
Information abstracted from published reports included type of trial, number of participants, inclusion and
exclusion criteria, baseline characteristics including liver histology, type, dose and duration of IFN therapy,
initial, complete and sustained response rates, and predictive factors for response. Studies were broadly divided
into randomised and nonrandomised trials.
6.1.2 Interferon therapy for chronic hepatitis C virus infection
Inclusion criteria among published trials were similar. These included elevated ALT levels (1.5-2 times greater
than normal) for more than six months, age greater than 18 years, and anti-HCV  except for early studies among
patients with NANBH. Liver biopsies to document chronic hepatitis were performed on most study participants.
Exclusion criteria were also remarkably standard including presence of HBsAg, HIV antibody, evidence of other
CLD, current drug or high alcohol intake, decompensated cirrhosis, pregnancy, and several biochemical and
haematological parameters. In addition to patients with CPH and CAH, most studies included patients with
compensated active cirrhosis.
Recombinant IFN-α2a was the predominant formulation of IFN, although recombinant IFN-α2b and natural IFN-
α were used in some trials. Earlier trials of IFN efficacy among persons with NANBH and HCV infection
included a control or placebo arm, but, in later randomised trials, dose and duration of IFN therapy were
compared.
Randomised controlled trials demonstrated a clear benefit (based on normalisation of ALT level) of IFN therapy,
with complete response (normal ALT level at completion of therapy) rates of 38 to 69 per cent and sustained
response (normal ALT level 6-12 months posttherapy) rates of 19 to 40 per cent in trials where 3 million units
(MU) or more of IFN were used, compared with no significant response among control patients (table 51) (Davis
et al 1989; Di Bisceglie et al 1989; Diodati et al 1994a; Fernandez et al 1995; Rumi et al 1995). IFN doses of 2
MU  or less gave sustained response rates of 10 per cent or lower (Davis et al 1989; Douglas et al 1993).
Subsequent randomised studies that compared IFN regimes of different doses and duration produced complete
response rates of 27 to 70 per cent, with sustained response rates of 8 to 49 per cent (table 51) (Alberti et al 1993;
Attili et al 1994; Caporaso et al 1993; Chemello et al 1995a; Negro et al 1995; Poynard et al 1995). These studies
also appeared to demonstrate improved response for longer durations (12-18 months) (Chemello et al 1995a;
Poynard et al 1995) and higher doses (6 v. 3 MU) (Caporaso et al 1993; Chemello et al 1995a) of IFN therapy.86
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Table 51 Randomised trials of the efficacy of interferon therapy for treatment of chronic
hepatitis C virus infection
Country Reference No. of
subjects
Therapy IR
A/CR
B
(%)
SR
C
(%)
Comments
France Poynard et al
(1995)
n=303
CPH/CAH
(n=225)
CIRR
D (n=75)
IFN-α2b
(1) 3 MU
E 6/12
(2)1-3 MU
18/12*
(3) 3 MU 18/12
38/30
41/27
49/45
8
10
22
Histological improvement (at
18/12): 39% (1), 48% (2), 70% (3)
*3 MU 6/12 then 1 MU 12/12
Randomisation occurred at 6/12
Italy Alberti et al
(1993)
n=234
CPH (n=66)
CAH (n=119)
CIRR (n=49)
IFN-α2a
3-6 MU 12/12*
3 MU 12/12
6 MU 6/12
IFN-α (natural)
3 MU 6/12
70/67
58/53
70/70
56/56
44
27
33
12
SR: CPH 33%; CAH 35%; CIRR
9.5%
* 6 MU 6/12, 3 MU 6/12
86% +ve anti-HCV antibody
Italy Attili et al
(1994)
n=62
CAH
IFN-α2a
3 MU 3/12
3 MU 6/12
63
63
10
30
Italy Caporaso et
al (1993)
n=81
CAH/CIRR
IFN-α2a
3 MU 6/12
6 MU 6/12
50
64
28
41
CR: CAH 68%; CIRR 32%
Italy Diodati et al
(1994a)
n=60
CAH (n=60)
IFN-α2a
1-6 MU 12/12*
Controls
67 /47
3/3
27
3
Histological improvement : 28%
at 18/12
 * 6MU 1/12, 3MU 3/12, 1MU
8/12
Italy Negro et al
(1994)
n=135
CPH (n=44)
CAH (n=71)
CIRR (n=18)
IFN-α2a
6 MU 9/12
6 MU 3/12 x 2*
46
47
17
10
14/14 SRs tested -ve HCV-RNA
* 2 3/12 cycles separated by 6/12
with no therapy
Italy Rumi et al
(1995)
n=67
CPH (n=21)
CAH (n=30)
CIRR (n=23)
IFN-α2a (Rof)
3-6 MU 12/12*
Controls
69
0
40
6
Histological improvement: IFN,
80%; controls, 32%
8/14 CRs -ve HCV-RNA (23%
CR)
ALT normal + HCV-RNA-ve: CPH
40% (4/10); CAH 29% (4/14);
CIRR 0% (0/11)
* 6MU 2/12, 3MU 10/12
Japan Yokosuka et
al (1995)
n=66
CPH/CAH
(n=61)
CIRR (n=5)
IFN-α2a
3 MU 12/12
3 MU 2/12
Placebo 2/12
67*
32
4
67*
4
4
*57% (12/21) HCV-RNA -ve
Spain Fernandez et
al (1995)
n=148 IFN-α2a 6 MU
12/12
IFN-α2b 5 MU
12/12
Controls
63
57
0
25
19
0
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Country Reference No. of
subjects
Therapy IR
A/CR
B
(%)
SR
C
(%)
Comments
USA Davis et al
(1989)
n=166
CPH (n=27)
 CAH (n=41)
CIRR (n=83)
IFN-α2b
3 MU 6/12
1 MU 6/12
Controls
38
16
4
19
8
Histological improvement : 3
MU=52% (24/46); 1 MU=29%
(14/48)
USA Di Bisceglie
et al (1989)
n=41
CPH (n=3)
CAH (n=31)
CIRR (n=7)
IFN-α2b
2 MU 6/12
Placebo 6/12
62/33
15/5
10
Histological improvement: 90%
(40% among placebo group)
USA Douglas et al
(1993)
n=32
CPH (n=4)
CAH (n=15)
CIRR (n=10)
IFN-α2a
1.5 MU 6/12
Controls
25
6
6 HCV-RNA -ve in 43% of CRs
AIR=normal ALT level during therapy.
BCR=normal ALT at completion of therapy.
CSR=normal ALT 6/12-12/12 following therapy completion.
DCIRR=cirrhosis.
EMU=million units of interferon: regimes given three times per week unless otherwise stated
Nonrandomised studies have been limited by the combination of patients treated with different IFN regimes and
the relative lack of follow-up; three studies provided no information on sustained response rates. Complete
response rates varied from 31 to 69 per cent, while sustained response in those studies with available information
ranged from 22 to 41 per cent (table 52).88
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Table 52 Nonrandomised trials of the efficacy of interferon therapy for treatment of
chronic hepatitis C virus infection
Country Reference No. of
subjects
Therapy IR
A/CR
B
(%)
SR
C
(%)
Comments
France Pawlotsky et
al (1994)
n=36 IFN-α2a
3 MU
E 6/12 47/33 10/12 CRs had negative HCV-RNA
at 6/12
Italy/Japan Pozzato et al
(1995)
n=57
CPH/CAH
/CIRR 
D
IFN-α2a
3-6 MU 6/12* 53 30 6 MU 1/12, 3 MU 5/12
A
Japan Aiyama et al
(1994)
n=65
CAH
IFN-α2a
IFN-α, IFN-β
3-10 MU 3/12-
6/12
75 41 20% -ve HCV-RNA 6/12
posttherapy
Japan Kanai et al
(1992)
n=96 IFN-α2a
3 MU 6/12* 31 First week 6 MU daily
A
CR: Genotype II(1b) 20%; III(2a)
67%;
IV (2b) 33%
Japan Kanai et al
1995
n=126 IFN-α2a
3 MU 6/12* 50 First week 6 MU daily
A
HCV-RNA negativity at 6/12=33%
CR (HCV-RNA -ve): genotype
II(1b) 20%; III (2a) 69%; IV (2b)
25%
Japan Orito et al
(1994)
n=55
CAH
IFN-α2a
6-9 MU 6/12* 69 22 9 MU daily 2/52, 6 MU x3/week 
22/52
A
Japan Urushihara
et al 1994
n=31 IFN-α2a 81 35 10/11 SRs -ve HCV-RNA
Japan Yoshikawa
et al (1994)
n=156
CPH (n=20)
CAH 2a
(n=96)
CAH 2b
(n=40)
IFN-α2a 9 MU
or
IFN-α (natural)
3 MU 6/12
69 28 SR: CPH 35%; CAH 2a 35%; CAH
2b 5%
AIR=normal ALT level during therapy.
BCR=normal ALT at completion of therapy.
C SR=normal ALT 6/12-12/12 following therapy completion.
DCIRR, cirrhosis.
EMU=million units of interferon: regimes given three times per week unless otherwise stated;
In studies where HCV-RNA detection by PCR was performed, response rates based on clearance of HCV
viraemia were generally lower compared with rates based on normalisation of ALT (Aiyama et al 1994; Negro et
al 1994; Chemello et al 1995c; Kanai et al 1995; Yokosuka et al 1995). One study that produced a sustained
response of 41 per cent based on a normal ALT six months posttherapy gave a sustained response of 20 per cent
when HCV-RNA negativity was included in the definition (Aiyama et al 1994).
In contrast, a response classified on the basis of histological improvement noted on repeat liver biopsy tended to
be higher than that based on ALT normalisation, with improvement of between 48 and 90 per cent at completion
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therapy (Davis et al 1989; Di Bisceglie et al 1989; Chemello et al 1995a; Poynard et al 1995; Rumi et al 1995).
However, in the two studies where control or placebo participants underwent repeat liver biopsies, histological
improvement was also seen in 32 to 40 per cent (Di Bisceglie et al 1989; Rumi et al 1995).
6.1.3 Predictors of response to interferon therapy
The strongest predictors of response to IFN therapy appear to be HCV genotype and baseline HCV-RNA level
(table 53). The poor response to genotype 1b (II) has been demonstrated in several studies (Aiyama et al 1994;
Chemello et al 1995c; Poynard et al 1995; Pozzato et al 1995), whereas the benefit of lower HCV viraemia
(baseline HCV-RNA level, table 53) in promoting response also appears significant (Aiyama et al 1994;
Yoshikawa et al 1994; Kanai et al 1995; Negro et al 1995; Yokosuka et al 1995). Other factors which may be
important are age, disease duration and liver histology, with younger age, shorter duration of disease and absence
of cirrhosis appearing to predict improved response. Factors which appear not to influence response to IFN
therapy are gender, HCV exposure category, and baseline ALT level (table 53).
Table 53 Studies showing possible predictive factors for response to interferon therapy
in treatment of chronic illness caused by hepatitis C virus
Predictive factors References supportive No association Higher response
Age Chemello et al (1995c), Piccinino
et al (1993), Poynard et al (1995)
Aiyama et al (1994), Pozzato et al
(1995), Saracco et al (1993)
Younger age
ALT level (baseline) Pozzato et al 1995 Aiyama et al (1994), Di Bisceglie
et al (1989), Kanai et al (1995),
Saracco et al (1993)
Anti-HCV core IgM Negro et al (1995), Pawlotsky et al
(1994)
Absent IgM
Disease duration Chemello et al (1995c), Fernandez
et al (1995), Par et al (1995)
Shorter duration
Dose of IFN therapy Davis et al (1989) (3 v. 1 MU)
Chemello et al (1995a) (6 v. 3 MU)
Caporaso et al (1993) (6 v. 3 MU)
Enriquez et al (1995) (10 v. 5 MU)
Aiyama et al (1994)
Alberti et al (1993) (3 v. 3-6 MU)
Aach et al (1991)
Lin et al (1995) (3 v. 5 MU)
Higher dose
Duration of IFN therapy Chemello et al (1995a) (12/12 v.
6/12)
Yokosuka et al (1995) (12/12 v.
2/12)
Poynard et al (1995) (18/12 v.
6/12)
Saracco et al (1993) (12/12 v.
6/12)
Aucella et al (1995) (6/12 v. 3/12)
Lin et al (1995) (24/12 v.  6/12)
Craxi et al (1992) (12/12 v. 6/12) Longer duration
Exposure category Aiyama et al (1994), Kanai et al
(1995), Pozzato et al (1995),
Saracco et al (1993)
Gender Par et al (1995) Aiyama et al (1994), Alberti et al
(1993), Chemello et al (1995c),
Kanai et al (1995), Piccinino et al
(1993), Pozzato et al (1995),
Saracco et al (1993)
Table continued overleaf90
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Predictive factors References supportive No association Higher response
HCV genotype Chemello et al (1995c) (2, 3)
Orito et al (1994) (serotype II)
Pozzato et al (1995) (I,III,IV)
Aiyama et al (1994) (III)
Poynard et al (1995) (non-1b)
Kanai et al (1992) (III)
Non-1b (II) genotype
HCV-RNA level
(baseline)
Aiyama et al (1994), Kanai et al
(1995), Negro et al (1995),
Yokosuka et al (1995), Yoshikawa
et al (1994)
Low HCV-RNA level
Liver histology Aiyama et al (1994), Alberti et al
(1993), Caporaso et al (1993), Lin
et al (1995), Piccinino et al (1993),
Poynard et al (1995), Rumi et al
(1995), Saracco et al (1993),
Yoshikawa et al (1994)
Chemello et al (1995c), Kanai et
al (1995), Pozzato et al (1995),
Reichard et al (1994)
Noncirrhosis, less
severe CAH
Neutralising anti-IFN
antibodies
Diodati et al (1994b) Absence of anti-IFN
antibodies
No. of HCV genotypes Villa et al (1995a) Single genotype
Serum iron level Archer et al (1992) Lower serum iron
Type of IFN Chemello et al (1995c) (rec.v. nat) Aiyama et al (1994) (α v. β) Recombinant
Table 53 continued overleaf
6.1.4 Interferon therapy for acute hepatitis C virus infection
Randomised controlled trials of IFN therapy in acute HCV infection (table 54) were performed within
posttransfusion prospective cohorts. The trials uniformly demonstrated more rapid transaminase resolution and
initial reduction in progression to chronic infection among treated patients. Follow-up appeared to demonstrate a
relatively limited long-term benefit as level of chronic infection and ALT abnormality rates converged among
treatment and control groups. However, a recent meta-analysis of interferon therapy for acute HCV infection,
with the addition of further studies, estimated an approximately 30 per cent increased long-term response rate
(Quin 1997). The optimum duration of therapy appeared to be 12 weeks, with higher doses (6-10 MU) providing
increased response rates (Quin 1997).
Table 54 Randomised trials of interferon therapy in acute hepatitis C virus infection
Adapted from Hoofnagle (1994).
Reference No. of subjects Response (normal ALT at 12/12) (%)
Interferon Placebo
Alberti et al (1991) 22 57 37
Omata et al (1991) 20 64 11
Rumi et al (1992) 45 61 42
Viladomiu et al (1992) 28 57 3191
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6.1.5 Effect of interferon therapy on progression of hepatitis C virus infection
The primary goal of IFN therapy should be to decrease HCV-related morbidity and mortality. Although about 50
per cent of people develop an initial response to IFN therapy, the lack of long-term follow-up has impaired the
ability of studies to determine the benefit of IFN therapy in altering the natural history of HCV infection.
However, two studies have provided preliminary evidence that progression of chronic HCV infection may be
delayed by IFN therapy. In a randomised trial of six months v. 18 months IFN-α2b therapy (Poynard et al 1995),
progression to cirrhosis was 16 and 7 per cent, respectively, during 19 to 42 months of follow-up. Although not
statistically significant, this halving of progression rate to cirrhosis with prolonged therapy suggests a true effect
of IFN therapy on the natural history of chronic HCV infection.
The second study was a randomised controlled trial of the effect of IFN-α on incidence of HCC among patients
with compensated cirrhosis (Di Bisceglie et al 1991b). Patients were randomised to IFN-α (6 MU for 3-6 months)
or symptomatic treatment. Although only 16 per cent of IFN-treated patients cleared HCV RNA, the rate of
progression to HCC during two to seven years of follow-up was 4 per cent as compared with 38 per cent in the
control group (P=0.002).
6.1.6 Recent advances in therapy for chronic hepatitis C virus infection
The long-term response rate to interferon therapy of 15 to 20 per cent is obviously suboptimal, and has almost
certainly contributed to a poor uptake of treatment for chronic HCV infection. Recent studies, however, have
provided optimism that therapeutic advances are approaching. A randomised placebo-controlled study of the
addition of ribavirin to interferon therapy demonstrated a sustained response rate (absence of viraemia 6 months
posttherapy) of 36 per cent in those treated with the combination therapy compared to 18 per cent in the
interferon monotherapy group (Reichard et al 1998). This followed to smaller studies which have also
demonstrated a higher sustained response rate for the combination therapy (Chemello et al 1995b; Lai et al
1996).
Trials are also underway to investigate the efficacy of pegylated forms of interferon which would require less
frequent dosing (once per week v. standard 3 times per week), and the use of induction dosing with standard
interferon (daily dosing for the initial month of therapy).  Other classes of therapies such as protease or helicase
inhibitors are under investigation, but will be several years before they reach phase III clinical trials.
6.1.7 Interferon therapy trials and use in Australia
A randomised trial of IFN-α2b therapy among 230 patients with histologically proven chronic HCV infection
compared three regimes: 3 MU for six months, 5 MU for six months, and 3 MU for two years (Lin et al 1995).
The complete response rate (normal ALT at therapy completion) was 64 and 58 per cent for patients treated with
5 MU and 3 MU, respectively, while the sustained response rate (normal ALT 6 months posttherapy) was higher
among patients treated for two years (32% v. 17%; P<0.001). Histological stage of disease was the strongest
predictor of response, with a complete response rate of 75 per cent among noncirrhotic patients as compared to
42 per cent among those with cirrhosis (P<0.001). Although HCV exposure category was a significant predictive
factor for response to IFN therapy in univariate analysis (complete response rates: IDU 71%; blood transfusion
56%; sporadic 43%; P<0.01), it was not independent of histological stage in multivariate analysis.
There are several chronic HCV trials currently recruiting patients in Australia. These include trials investigating
the effect of high dose induction interferon (6-9 MU daily for 1 month) (AUSHEP 07), pegylated interferon
(multinational), and the efficacy of combination interferon and ribavirin therapy for prior interferon
nonresponders (AUSHEP 06) and for treatment-naive patients (AUSHEP 08).92
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Requirements for prescription of IFN therapy in Australia under the S100 scheme include evidence of chronic
HCV infection (positive anti-HCV antibody, abnormal ALT), and absence of current high alcohol intake or
current IDU. Excluded from therapy are patients with cirrhosis on liver biopsy and current IDUs, the latter group
constituting the largest proportion of people with chronic HCV infection in Australia. IFN therapy available
under the S100 scheme consists of 3 MU three times per week for 12 months. Recent changes to the S100 criteria
included the removal of HIV coinfection and IDU in the previous 12 months as exclusion criteria, and the
increase in recommended therapy duration from six to 12 months.
6.1.8 Discussion
Pooled information from randomised trials of IFN therapy demonstrate a complete response rate to standard
regimes (3 MU for 6 months) of about 50 per cent with a sustained response rate of 20 per cent. There is
preliminary evidence that more aggressive IFN regimes, including higher doses (6 MU) and/or longer duration
(12-24 months) of therapy can provide greater and more sustained response rates. The most important predictive
factors for response to IFN therapy are HCV genotype, baseline HCV-RNA level and less advanced histological
liver disease. However, if these persons are those least likely to progress to advanced liver disease, targeting of
them for IFN therapy may not be a reasonable or cost-effective approach.
Evidence suggests that IFN therapy may be able to significantly alter the natural history of HCV infection and
thus reduce long-term morbidity and mortality. These studies need to be replicated in the case of the apparent
reduction of HCC among persons with cirrhosis, and provide longer term follow-up in the case of assessing
progression of CAH and CPH to cirrhosis. The increased response rates with combination interferon and
ribavirin should translate into significant reductions in chronic HCV progression. However, combination therapy
is currently only available through a compassionate access scheme.
Future research should include determination of the benefit of interferon and ribavirin combination therapy in
people with compensated cirrhosis and people with HIV/HCV coinfection, and the effect of combination therapy
in reducing risk of progression to HCC.
6.2 Liver transplantation
In patients with CLD secondary to HCV, the indications for transplant referral are based upon the presence and
severity of hepatic decompensation. Patients with cryptogenic cirrhosis should be investigated for HCV infection.
Anti-HCV testing may be insufficient, and examination of both serum and liver for HCV RNA may be required.
HCV often coexists with other forms of CLD. End-stage cirrhosis related to HCV is a common reason for liver
transplantation, although viraemia is known to persist in most cases (Gane et al 1996). Initial graft dysfunction
often resolves but liver damage can continue to occur and may lead to recurrent cirrhosis. Recurrence of HCV in
the graft can occur within four weeks after liver transplantation for HCV-induced cirrhosis (Konig et al 1992) and
acute lobular hepatitis occurs in most patients who are viraemic within the first year (Ascher et al 1994); most of
those with histological disease at two to three years follow-up will only have mild hepatitis. Feray et al (1992)
proved that the posttransplant infection was recurrence rather than a new infection by showing HCV-RNA
sequence homology pretransplant and posttransplant. In a few patients there is rapid clinical and histological 
progression resulting in subacute liver failure (Lim et al 1994; Schluger et al 1996). There remains a concern that
chronic hepatitis leading to graft loss and decreased patient survival may become more common in the later
posttransplant period (>5 y). The relatively short follow-up periods in patients with documented HCV infection
prior to liver transplantation means that whether chronic hepatitis occurs later has not been clearly established.93
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Gane et al (1996) investigated the effect of persistent HCV infection after liver transplantation on patient and
graft survival and the effects of the HCV genotype and degree of human lymphocyte antigen (HLA) matching
between donor and recipient on the severity of recurrent hepatitis. A group of 149 patients with HCV infection
who received liver transplants between 1982 and 1994 were followed for a median of 36 months; 623 patients
without HCV infection who underwent liver transplantation for end-stage CLD were used as a control group. A
total of 528 liver-biopsy specimens from the HCV-infected recipients were reviewed, including 82 obtained one
year after transplantation as scheduled and 39 obtained at five years as scheduled. In addition, biopsy specimens
were obtained from 91 of the HCV-negative patients five years after transplantation. Cumulative survival rates
for the 149 patients with HCV infection were 79 per cent after one year, 74 per cent after three years, and 70 per
cent after five years, comparable with rates of 75, 71 and 69 per cent, respectively, in the HCV-negative
transplant recipients (P=0.12). Of the 130 patients with HCV infection who survived more than six months after
transplantation, 15 (12%) had no evidence of chronic hepatitis on their most recent liver biopsy (median follow-
up, 20 months), 70 (54%) had mild chronic hepatitis (median, 35 months), 35 (27%) had moderate chronic
hepatitis (median, 35 months) and 10 (8%) had cirrhosis (median, 51 months). Graft loss occurred after a median
of 303 days in 27 of the 149 patients, including five with HCV-related cirrhosis and three with HCV-related
cholestatic hepatitis. Infection with HCV genotype 1b was associated with more severe graft injury, whereas the
primary immunosuppressive regimen used and the extent of HLA mismatching between donors and recipients
had no significant effect on this variable.
Feray et al (1995) have also studied the influence of the genotypes of HCV on the severity of recurrent liver
disease after liver transplantation. They recognised that the clinical relevance of genotypes remains elusive, and
that liver transplantation for HCV-related cirrhosis offers a unique opportunity for prospective studies of this
issue. Sixty anti-HCV-positive liver recipients with precise virological and histological assessments had HCV
genotype determined with both type-specific capsid primers and a line probe genotyping assay. They found that
HCV genotype 1b was the predominant type before transplantation (40/60 patients); after liver transplantation,
acute hepatitis and CAH developed more frequently in these patients than in patients infected by other genotypes
(31/40 and 24/40 v. 8/20 and 4/20 patients). Actuarial rates of acute hepatitis and CAH were 77 and 59 per cent,
respectively, three years after transplantation in patients infected by type 1b and 40 per cent (P=0.008) and 22
per cent (P=0.004) in those infected by other types. There was no statistical relationship between the level of
HCV viraemia and HCV genotypes both before and after transplantation. In contrast, after transplantation, serum
HCV-RNA values were significantly increased in patients who developed hepatitis after transplantation. This
study provides direct evidence that HCV 1b is associated with more aggressive recurrent liver disease than other
genotypes.
Schluger et al (1996) described a progressive, severe cholestatic form of hepatitis occurring in 10 of 135 patients
with HCV infection who received liver transplants (Schluger et al 1996). The 10 patients experienced severe
recurrent HCV infection; 1 died, 1 was awaiting retransplantation, and 8 underwent retransplantation. All 10 
developed severe progressive cholestatic hepatitis, with a mean rise in bilirubin to 24.7 mg/dL at the time of
retransplantation. Histology at initial recurrence showed mild hepatitis without evidence of rejection. The failed
grafts showed either cirrhosis or confluent hepatic necrosis. The onset of cholestasis preceded retransplantation
by less than five months, and suggests that a minority of patients with recurrent HCV infection after undergoing
liver transplantation develop a severe progressive cholestatic hepatitis and liver failure.
In summary, after liver transplantation for HCV-related cirrhosis, persistent HCV infection can cause severe graft
damage, and such damage is more frequent in patients infected with HCV genotype 1b than with other genotypes.
After five years, the rates of graft and overall survival are similar between patients with, and those without, HCV
infection.94
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6.2.1 Hepatitis C virus in other transplantation events
HCV can also be acquired de novo in the peritransplant period, from donor organs or transfused blood products,
and the course of disease may be altered by immunosuppressives in the posttransplant period. The size of the
inoculum, ability of the organ to sustain replication, procurement and preservation techniques, and posttransplant
immunosuppression may all affect the risk of infection. There is some debate about whether it should be
permissible to use organs from HCV-infected donors for HCV-infected recipients.
6.2.2 Mechanism of liver injury
The mechanism of liver injury in HCV-infected transplant recipients is thought to be via direct viral cytopathicity
and host-mediated immunity. Among the factors which may influence viral-host interactions are: level of
viraemia before transplantation, viral genotype, coinfection with other heterotrophic viruses, amount of
immunosuppression in the posttransplant period and host immunocompetence.
6.2.3 Fulminant hepatitis
Another important, if uncommon, reason for liver transplantation is fulminant hepatitis, of which viral hepatitis is
the most common cause. The extent to which HCV contributes to FHF has been discussed previously. HCV alone
may not be causally responsible for all cases of FHF in which it is found, but acts either as a cofactor or
represents an ‘innocent bystander’ in liver failure due to another aetiology (Terrault and Wright 1995b). An
interaction with HBV/hepatitis D virus (HDV) appears to exist.
Haratake et al (1993) looked at predictable factors for estimating prognosis of patients after resection of HCC.
One hundred and forty cases of HCC with hepatic resection were observed from 1 to 11 years, and the
relationship among various clinicopathological factors, including the mitotic index and anti-HCV, and prognosis
was evaluated. Age at the time of operation, positive results for HBV surface antigen or anti-HCV, accompanying
cirrhosis, and the degree of tumour necrosis due to transarterial embolisation did not influence the prognosis
significantly. Patients with HCV-related cases had a better prognosis than patients with HBV-related cases, and
patients with a single and small carcinoma (<2 cm) had a significantly better prognosis than those who had larger
and/or multiple tumours. A better prognosis also was observed in the carcinomas with no histological  invasion
into portal vein branches, low Edmondson grades and low mitotic activities when compared with the counterpart
of each group. The mitotic index was correlated best with prognosis in the current study and was a simple
examination which was a helpful factor in predicting prognosis.
6.2.4 The Australian Liver Transplant Registry
(From: Australian Liver Transplant Registry 8th Report. From the Combined Registries of the Australian Liver
Transplant Centres, data to 31 December 1995).
The Australian Liver Transplant Registry (Australian Liver Transplant Registry 8th Report) collates the data on
all liver transplants undertaken in Australia. The number of new patients receiving a liver transplant has steadily
increased from the mid 1980s to the mid 1990s (figure 4).95
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Figure 4. Number of new patients receiving liver transplants per million within the Australian population.
From Australian Liver Transplant Registry 8
th Report.
Until the end of 1995, a total of 890 patients (650 adults and 240 children) had received 974 liver transplants in
Australia. Paediatric patients are most commonly transplanted for biliary atresia (72%) or metabolic disorders
(14%), although 7 per cent are transplanted following FHF. The effect of viral hepatitis infections is seen in adult
patients. Chronic HCV infection as a cause has increased dramatically over the past few years, whereas
transplantation for HBV has remained fairly steady from year to year (figure 5).96
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Figure 5. Percentage of liver transplantations as a result of infection with hepatitis B virus and hepatitis C
virus.
The actuarial survival figures for the 60 adult patients who have received liver transplants for HCV is 87 per cent
at one year, 87 per cent at three years and 79 per cent at five years, better than the figures for all liver transplants
combined. Recurrent infection in the graft accounts for some graft losses and patient deaths, and may occur as
early as six months after transplantation.
6.2.5 Patients infected with hepatitis C virus referred to Royal Prince Alfred
Liver Clinic: characteristics and outcomes
Levy et al (in press) from the Royal Prince Alfred Hospital in Sydney have analysed their experience in assessing
and transplanting patients referred to their Unit with HCV-associated cirrhosis. This Unit is the largest liver
transplant centre in Australia, and has transplanted nearly half of the HCV infected patients up to the end of
1995.
Twenty-eight of 63 patients (44%) referred received transplants. Of patients referred, 86 per cent were male and
35 per cent consumed alcohol in the harmful/hazardous range, 13 per cent were infected with HBV and 7 per cent
had HCC. The reason for the male preponderance in referral is unknown. The routes of infection were considered
to be: 26 (41%) IDU; 8 (13%) via blood transfusion; 2 (3%) via tattoo, and in 27 (43%) there was no known risk
factor (sporadic). Patients whose acquisition of infection was considered ‘sporadic’ were more likely to have
been born outside of Australia (Egypt 9, Italy 7, Australia 6, other countries, 5) and were an average of 10 years
older than those with HCV acquired via IDU (P<0.001). Alcohol consumption in the harmful range meant
referral at an average age 12 years younger than in those who abstained.97
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Between mid 1994 and the end of 1995, 21 per cent of patients referred for assessment and 31 per cent of
patients transplanted had an underlying diagnosis of HCV cirrhosis. Of the 34 patients accepted for
transplantation, four died while on the waiting list and two were to be transplanted. Among those not accepted for
transplantation are those with ongoing drug dependence (5) and psychological/psychiatric contraindications (2).
HCC developed in one patient in the 18 who had transplantation deferred; and two died of decompensated liver
failure. Three-year survival was 84 per cent. Chronic-HCV-related graft dysfunction occurred in 56 per cent (15
patients), of whom 10 had asymptomatic transaminitis, two had cholestatic hepatitis and three had severe HCV
infection that progressed onto chronic rejection. HCV genotype 1b tended to be associated with HCV graft
dysfunction (5/6 type 1b v. 10/16 in non type 1b).99
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7 Hepatitis C virus infection in
Australia
Detailed information on the size of the HCV epidemic in Australia is lacking. The two main sources of
information both provide very partial and biased perspectives on the numbers and characteristics of people
infected with, or becoming infected with, HCV in Australia: surveillance for HCV infection; and studies of
particular population groups. With the former, the problems revolve around participation in testing and in the
difficulties of identifying incident cases; with the latter, estimating the sizes of the populations at risk and
deriving representative samples. Further work is needed in these areas to quantify the HCV epidemic in Australia,
information vitally necessary to underpin every aspect of the public health response.
7.1 Surveillance data
Between 1991 and 1997, over 57,000 diagnoses of HCV infection were reported to the National Notifiable
Diseases Surveillance System (NNDSS) maintained by the Commonwealth Department of Health and Aged Care
(CDNANZ, pers. comm. 1998) in States other than New South Wales and South Australia. A further 46,900
HCV diagnoses have been reported in New South Wales to the end of 1997 (Robert Menzies, pers. comm. 1998)
and 7,500 in South Australia (STD Control Branch, pers. comm. 1998), the only two States in Australia that
forward details of incident HCV diagnoses to the NNDSS, making a total of over 110,000 HCV diagnoses in
Australia to the end of 1997. Of annual total notifications to the NNDSS during this period, 67 to 78 per cent of
HCV diagnoses were in the age range 20-39, with a male to female ratio of between 1.6 and 1.7 (Crofts et al
1997a). A second system of reporting by sentinel laboratories (CDI Laboratory Reporting Scheme, Lab VISE)
received 18,124 reports of diagnosis of HCV exposure from 1990 through September 1995, of which only 11.8
per cent had accompanying risk factor information (Crofts et al 1997a). Of the cases with such data, 86.4 per cent
gave the risk as a history of IDU.
These data reflect patterns of testing and of notification far more than they do patterns of infection and
transmission, although they are, of course, based on the latter. Such data reveal nothing about the incidence rate
for HCV infection in either the general population or any special subgroups. As a response, the Communicable
Diseases Network Australia New Zealand undertook a trial enhanced surveillance program for incident infection
in 1995 (Andrews and Curran 1996). Based on notification of cases, enhanced callback to assist classification of
cases into incident or pre-existing was undertaken with somewhat different emphases by different States and
Territories. In the preceding two years, 73 cases (0.4% of all notified cases) had been classified as incident
(Crofts et al 1997a); in 1995, under enhanced callback, this rose to 138 cases (0.8% of all notified cases)
(Andrews and Curran 1996). This is an annual rate of 7.8 incident cases per 100,000 per year, but the authors of
this report point out that this is an unreliable estimate because of, among other factors, ‘variance in the methods
used, response bias, and the presence of duplicates among the total HCV notifications’ (Andrews and Curran
1996). The major limitation of this type of surveillance for incident cases, however, is that most acute HCV
infections are either asymptomatic or cause nonspecific symptoms which do not get classified as hepatitis and
are, therefore, not investigated further (Locarnini and McAnulty 1996). This rate is stated as 75 per cent: ie only
25 per cent of acute cases are icteric (van der Poel et al 1994), but this figure is derived from studies of TA-HCV
infection in which those infected received higher infectious doses than would be the case in those infected as a
result of IDU. Anecdotal information suggests that the rate of development of jaundice among those IDUs acutely
infected with HCV is much lower than 25 per cent.100
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7.2  Population sizes and prevalence
7.2.1 Blood donors
The prevalence of antibodies to HCV among blood donors has decreased since testing for HCV antibody was
introduced in 1990 from 0.7-0.8 per cent in 1987-89 in selected hospitals in Western Australia and New South
Wales (Ismay et al 1995), to 0.45 per cent overall and 1.0 per cent in first time donors in Sydney in 1990-91
(Archer et al 1992), to 0.05 per cent in 1994 (Melbourne Red Cross Blood Transfusion Service, unpublished).
These rates are likely to be increasingly unrepresentative of the general population because of the selection
process involved in donating blood, but they provide a lower boundary of around 100,000 Australians having
been exposed to HCV. HCV incidence has been estimated among repeat blood donors in Victoria to be 1.0 per
100,000 (Whyte and Savoia 1997).
7.2.2 Injecting drug users
Published HCV prevalence studies among IDUs in Australia show a range of prevalences between 8 and 94.3 per
cent (Crofts et al 1997a). The lower figure is from a study in Perth of recent initiates to IDU; the upper from a
study of entrants to methadone maintenance programs in 1994. Most of the cross-sectional surveys of Australian
IDUs have found prevalences of HCV antibody between 50  and 70 per cent. Using these data and estimates of
the numbers of people who have ever injected drugs in Australia, Crofts et al estimated in 1993 that there were
approximately 80,000 people in Australia chronically infected with (not simply exposed to) HCV as a result of
IDU (Crofts et al 1993). Subsequently the same authors have raised this estimate to 130,000 on the basis of
newer knowledge of the proportions of people exposed who become chronically infected (Crofts et al 1996).
The incidence of HCV among IDUs in Australia has also been measured in several studies. These rates vary from
14 to 38 per 100 person-years, depending on the population studied (Crofts et al 1997a). Using a rate of 20 per
100 person-years, Crofts et al estimated in 1993 that between 8,000 and 10,000 new infections were occurring
per year among IDUs (Crofts et al 1993). They have subsequently revised this figure, using an average incidence
rate of 15 per 100 person-years, to around 6,000 new infections in Australian IDUs per year (Crofts et al 1997a).
In a combined analysis, based on two cohorts of IDUs in Melbourne and one in Sydney, the incidence of HCV
infection among IDUs in the 1980s and early 1990s was estimated to be around 15 new infections per 100 person
years of follow-up (Crofts et al 1997a). These studies also provided an indication, although not statistically
significant, of a reduction in HCV incidence among IDUs from around 18 infections per 100 person years in
IDUs who started injecting before 1987, to 13 infections per 100 person years in IDUs who started injecting
since then. This indication coincides with the introduction of needle and syringe exchange programs, and other
preventive campaigns, that were aimed at reducing the risk of HIV infection among IDUs. Further evidence of
declining incidence in some populations of IDUs in Australia is beginning to accrue (see section 4.1.12).
7.2.3 Antenatal patients
Two studies of HCV antibody prevalence among women receiving antenatal care in Victorian hospitals using the
first-generation assay found prevalences of 0.3 and 0.4 per cent (Fairley et al 1990; Williamson et al 1990). A
study in South Australia found an overall prevalence of 1.1 per cent (17/1537) in an unselected consecutive series
of antenatal patients (Garner et al 1997).101
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7.2.4 General population
No data have been published on the prevalence of HCV among the general population in Australia, but there has
been one population-based survey (as yet unpublished) of the prevalence of risk behaviours and of participation in
testing for HCV. In a phone survey of the adult Victorian population, Watson et al found that 11.4 per cent reported
having been tested for HCV, 15 per cent reported having had a blood transfusion prior to 1990, 4.4 per cent
reported ever having had a tattoo and 2 per cent reported having ever injected drugs (R Watson et al, pers. comm).
7.2.5 Estimates of hepatitis C virus prevalence and incidence
It has been estimated, based on both direct and modelling approaches, that there were around 190,000 people living
with HCV antibodies in Australia in 1997 (plausible range 140,000-240,000) (Hepatitis C Virus Projections
Working Group 1998). HCV incidence in 1997 was estimated using a mathematical model to be 11,000 new
infections (8,500-13,500), 91 per cent  of whom were exposed through injecting drugs.
Of all people living with HCV antibodies in Australia in 1997, it was estimated that:
·  8 per cent were exposed to HCV through IDU, 7 per cent through receipt of blood, and 13 per cent through
other transmission routes;
·  47,000 (35,000-60,000) had cleared their HCV infection;
·  134,000 (101,000-167,000) had chronic HCV infection, and therefore were at risk of developing cirrhosis;
·  8,500 (4,000-13,000) were living with HCV-related cirrhosis;
·  80 (40-130) people developed HCV-related HCC during 1997; and
·  among those people exposed through IDU, 49 per cent were currently injecting.
Projections of the number of people living with HCV-related cirrhosis, or the number of incident cases of
HCV-related HCC, indicated that the numbers of both would more than double by 2010.
7.3 Conclusions
The available data suggest that to the end of 1997 about 140,000 to 240,000 people living in Australia have been
exposed to HCV at some time, most as a result of IDU. This, together with the surveillance and survey data, suggest
that between 46 and 79 per cent of those who have been exposed have been tested for HCV. Of those exposed,
101,000 to 167,000 could be expected to be chronically infected and at risk of end-stage liver disease. Mathematical
models suggest that about 11,000 new HCV infections occurred in Australia during 1997, most as a result of IDU.
However, these data are uncertain, partly at least because the sizes of the populations at risk are generally unknown.
Further work enabling better estimates of the numbers of people infected and becoming infected with HCV is
necessary.
Control of the epidemic of HCV in Australia clearly depends on control of the epidemic among IDUs, the only
remaining core group for HCV in this community. There is some suggestive evidence of declines in incidence of
HCV among some populations of IDUs, beginning in the late 1980s, and perhaps accelerated from 1993 onwards,
but even if these are real phenomena, current HCV incidences in other populations remain extremely high. It has
been argued that current strategies are effective in decreasing HCV incidence among IDUs, but that, given the high
prevalences the virus has reached in these populations before the institution of control strategies, the dose of current
efforts - needle and syringe availability and disposal programs, substitution therapy and peer education - is
inadequate (Crofts et al 1999). It would seem that an increase in current strategies, combined with investigation of102
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new approaches - for example, primary prevention of IDU, support for transitions from injecting to other methods of
administration of drugs, and specific HCV-peer education programs - will be necessary to control this ongoing
epidemic in Australia (Crofts and Wodak 1999).103
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Table 4 Prevalence of hepatitis C virus among injecting drug users
Region/ country Reference Number
in
sample
Population % HCV
positive
% PCR
positive
HIV HBV core
antibody
HBV surface
antigen
Assay
generation
Year of
sample
Asia
China, Ruili County Cheng (1993) 79 HIV-infected 92 68
China, Yunnan Li et al (1994) 507 DRCs
A 94.9 66.5
China Ye (1993) 177 92.2
Japan, Hiroshima Ichimura et al (1995) 47 74.5 44.7 2.1 57.4
Malaysia Sinniah & Ooi (1993) 85
Taiwan Wu et al (1991) 703 82.2
Taiwan Lee et al (1991a) 115 53
Taiwan Chen et al (1990) 58 IDUs 81
Thailand, Chiang
Mai
Apichartpiyakul et al
(1994)
29 82.8 PCR assay
Vietnam, Hanoi Nakata et al (1994) 200 30.5
Vietnam, HCMC Nakata et al (1994) 67 86.6
Australia/New
Zealand
Australia MacDonald et al (1998) 20 Trawler crew 55.0 0.0 96
NSW, Sydney Bell et al (1990) 172 MMT clients
B 1 88-90
NSW, Sydney van Beek et al (1994) 201 Primary care 58.7 7.2 48.0 2 91-92
NSW, Sydney van Beek et al (1998) 1078 Primary care 45.0 2.5 2 92-95
Victoria Crofts et al (1995) 1428 Prison entrants 64.0 1 91-92
Victoria Crofts et al (1994) 303 Cohort study 68.0 50.0 4.5 47.0 1.8 2 91-92Region/ country Reference Number
in
sample
Population % HCV
positive
% PCR
positive
HIV HBV core
antibody
HBV surface
antigen
Assay
generation
Year of
sample
Victoria Fairley et al (1990) 61.9
Victoria, Melbourne Thomson et al (1998) 95 HAV/HBV +ve 90.4 2 71-75
NZ, Christchurch Chetwynd et al (1995) 116 MMT 84.2 75.9 2 93
NZ, Wellington Chetwynd et al (1995) 92 Treatment
centre
77.2 2 92-94
NZ, Wellington Robinson et al (1995) 92 Treatment 77.2 92-94
New Zealand Kemp et al (1998) 241 Varied 63.9 94
New Zealand McKenna et al (1994) 19 21.1 30
New Zealand Woodfield et al (1993) 110 72.7
New Zealand Woodfield et al (1994) 74
Europe
Austria Pont et al (1991) 151 Prison 75.5 18.0 67.5 1 85-90
Belgium, Ghent Vanderschueren et al
(1991)
81 46.9 90
Denmark Westh et al (1993) 126 97.6 88-89
France, Nice Quaranta et al (1994) 97 HIV-infected 78.3
France Rey et al (1995) HIV-infected 94
France Lucidarme et al (1994) 104 72.1 1.0 32.7 5.8
France Ranger et al (1991) 73.5
Germany, Mainz Hess et al (1990) 84.5 19 0
Germany, Hamburg Trubner et al (1991) 282 Deceased IDUs 40.1 88-90
Germany, Hamburg Gaube et al (1993) 80
Germany Batz and Reymann (1997) Treatment 63 48 96Table 4 continued overleaf
Region/ country Reference Number
in
sample
Population % HCV
positive
% PCR
positive
HIV HBV core
antibody
HBV surface
antigen
Assay
generation
Year of
sample
Germany Weber et al (1995) 78.9 91-93
Greece Malliori et al (1998) 375 Prison 80.6 0.3 62.7 2 94-95
Iceland, Reykjavik Love & Stanzeit (1994) 152 62.5
Iceland Love et al (1996) 41 M 76.4
F 33.3
Ireland, Dublin Smyth et al (1995) 272 Treatment
centres
84.2 2 92-93
Ireland, Dublin Smyth et al (1998) 735 Treatment 61.8 1.2 1.0 2 92-97
Italy, Cagliari Coppola et al (1994) 255 Treatment
centres
81.2 32.9 7.4 2 91
Italy, Catanzaro Grob & Joller Jemelka
(1990)
41 63.4
Italy, East Sicily Cacopardo et al (1992) 175 58.3
Italy, Naples Rezza et al (1996) 713 Treatment
centres
63.1 1.3 2 91-93
Italy, Padova Chiaramonte et al (1991) 70
Italy, Rome Girardi et al (1990) 80 MMT 67.5 47.5 86.2 1 89
Italy, Rome Patti et al (1993) 645 10 MMT centres 63.4 71.3 9.3 2 90-91
Italy, Tivoli Ciuffreda et al (1994) Hospital 80.9
Italy, Veneto Galeazzi et al (1995) 227 Cohort study 75.3 52.0 0.9 2 92
Italy Corona et al (1991) STD patients 39.5
Italy Salvaggio et al (1993) 151 Female IDUs 74.2
Italy Francisci et al (1995) 72 82Region/ country Reference Number
in
sample
Population % HCV
positive
% PCR
positive
HIV HBV core
antibody
HBV surface
antigen
Assay
generation
Year of
sample
Netherlands,
Amsterdam
Van den Hoek et al (1990) 304 Cohort study 73.7 1 85-89
Norway, Oslo Grinde et al (1997) 144 HAV-infected 81 43
Norway Rollag et al (1993) 37 70.3
Poland, Gdansk Smiatacz et al (1991) 46 71.7 45.7 78.3
Poland Laskus et al (1992b) 100 Unselected 78 69
Poland Halota et al (1991) 80 63.8 75 85
Portugal Santos et al (1994) 33.3
Portugal, Lisbon Gloria et al (1991) 135 83 0.7 81
Scotland, Glasgow Goldberg et al (1998) 77 95
Spain, Baleares Payeras Cifre et al (1992) 110 Patients 86 36 53
Spain, Galdacamo de Miguel et al (1994) 45 IDUs 88.9
Spain, Valencia Anon et al (1995) Prison 90 (‘around’)
Spain, Valencia Bolumar et al (1996) 1056 Current IDUs 85.5 2 90-92
Spain Garcia Bengoechea et al
(1995)
Hospital patients 85.7
Spain Decarvalho et al (1996) 265 Various 75.6 50.2 67.5 90-91
Sweden, Malmo Widell et al (1991) 172 79.7 1 87-89
Sweden Sonnerborg et al (1990) 89 83 1 90
Sweden Krook et al (1997) Prison,
treatment
92 75 94
Switzerland, Geneva Chamot et al (1990) 262 MMT 64 36 74 1 90
Switzerland, Zurich Grob & Joller Jemelka
(1990)
45 90Table 4 continued overleaf
Region/ country Reference Number
in
sample
Population % HCV
positive
% PCR
positive
HIV HBV core
antibody
HBV surface
antigen
Assay
generation
Year of
sample
Switzerland, Zurich Chamot et al (1990) 382 Various 48 15 56 1 90
UK, East Anglia Majid et al (1995) Rural IDUs 59 44 1.0 22
UK, North West Lamden et al (1998) 773 Treatment 67 48 92-96
Middle East
Israel, Jerusalem Maayan et al (1994) 51 Drug
rehabilitation
54 26
North America
Canada, Calgary Anand et al (1992) 50 (about)
Canada, Montreal Roy et al (1997) 200 Street youth 26.5 16.2 96
Canada, Ontario Stratton et al (1998) 92 Semi-rural 46.7 5.4 23.1
Canada, Ontario Lior et al (1998) 94 Prison 52.1 2.2 18.7 97
Canada, Vancouver Patrick et al (1998) 1080 Field 85 23 96-97
Canada, Vancouver Strathdee et al (1997) 1006 Field 88.0 23.2 96-97
USA, Baltimore Fingerhood et al (1993) 687 Treatment
centre
63.2 4.2 29.7 1 90-91
USA, Baltimore Donahue et al (1991) 225 Cohort study 85 18 8
USA, Baltimore Garfein et al (1996) 312 Cohort study 76.9 20.5 65.7 88-89
USA, Baltimore Garfein et al (1998) 229 Young IDUs 37.6 94-96
USA, California Tennant & Moll (1995) 389 Op treatment
C 93.6 73.6 3.5
USA, California Zeldis et al (1992) 585 72 1.0 71.0
USA, San Francisco Buchbinder et al (1994) 92 Gay IDUs 25.0 1 83-84
USA, San Francisco Osmond et al (1993a) 64
USA, Seattle Hansen et al (1997) 787 Treatment 88.9 1.2 66.0 94-96Region/ country Reference Number
in
sample
Population % HCV
positive
% PCR
positive
HIV HBV core
antibody
HBV surface
antigen
Assay
generation
Year of
sample
USA, Seattle Hagan et al (1999) 2462 Treatment + 85.7 68.3 3 94-96
USA Kelen et al (1992) 175 Inner city A&E
D 82.9
South America
Argentina, Buenos
Aires
Fainboim et al (1996) 234 HIV +ve 92.3 72.6 19.2 94-95
Brazil, Santos Delgado Iribarren et al
(1993)
110 75 62 75
ADRCs, Drug Rehabilitation Centre.
BMMT, methadone maintenance therapy.
COp, outpatients.
DA&E, Accident and Emergency.Table 13 continued overleaf
Table 13 Hepatitis C virus and haemodialysis: prevalence and associations
Site Reference Number Prevalence (%) % PCR
Total HD CAPD Total HD CAPD HCV+ HCV-
No. of
transfusions
Duration Other associations/factors
Argentina Curciarello et al (1994) 219 35.6
Argentina Fernandez et al (1996) 31 0 12.9
Argentina Sartori et al (1993) 48 59 Y
Brazil Cendoroglo Neto et al
(1995b)
309 185 124 35.1 33.9 Y Y HBV
Brazil Vanderborght et al
(1995)
433 398 35 65 (range
47-82)
17 Prevalence 2.9% among dialysis
staff
Chile Castillo et al (1993) 26 54 N Y
Chile Ibarra et al (1995) 56 0
Croatia Jankovic et al (1994) 101 38 Y Y Prevalence 0% in 75 dialysis staff
Czechoslovakia
(the former )
Korcakova (1995) 629 (47
centres)
31 (range
6-60)
Denmark Bukh et al (1993b) 340 8.2 96.4 2.6
Egypt Abdel Wahab et al
(1994)
46.2
Egypt el Gohary et al (1995) 70.4
England Corcoran et al (1994) 66 13.6 N Y
France Courouce et al (1995) 128 42 98 0
France Dussol et al (1995) 984 23.6 Y Y Female, kidney grafts, HBV,
HD >> CAPD
Transfusional and nosocomial risks
France Simon et al (1994) 217 39.6 82.6
France Chauveau et al (1993) 115 54 Y Y
Germany Seelig et al (1994) 1515 23.1 76 4.1Site Reference Number Prevalence (%) % PCR
Total HD CAPD Total HD CAPD HCV+ HCV-
No. of
transfusions
Duration Other associations/factors
Germany Weber et al (1995) 8.1
Hong Kong Chan et al (1993) 51 21.6 72.7 2.5
Indonesia Hadiwandowo et al
(1994)
58 76
Ireland Conlon et al (1993) 266 1.7
Israel Golan et al (1996) 120 76 44 21.7 30.3 6.8 Y Y Ethnicity
Italy Aucella et al (1995) 80 35 62.5 2
Italy Boero et al (1995) 75 40 80 0
Italy Castelnovo et al (1995) 127 48 79 52 14 2.2
Italy Fabrizi et al (1994) 235 77.9 41
Italy Incandela et al (1994) 88 13.6 Y N HBV
Italy Petrosillo et al (1995) 1002 39.4
Italy Puoti et al (1995)
Japan Fujiyama et al (1995) 548 30.3%
overall.
35.4% in
transfused
25.7%
among non-
transfused
Y Y Prevalence 2.3% among dialysis
staff
Japan Hayashi et al (1994a) 357 55.5 86.4
Japan Hayashi et al (1994b) 310 51.9
Fukuoka
Japan Hayashi et al (1994b) 143 9.1
Okinawa
84.5Table 13 continued overleaf
Site Reference Number Prevalence (%) % PCR
Total HD CAPD Total HD CAPD HCV+ HCV-
No. of
transfusions
Duration Other associations/factors
Japan Irie et al (1994) 485
152 w/o
trans-
fusion
38.6
31.2
YY
Y
Japan Nakayama et al (1996) 2132 29.9 with
transfusion
7.6 w/o
transfusion
Y Y Duration not assoc in females w/o
transfusion
Japan Tsuyuguchi (1994) 584 22.0 55.9 Y
Japan Yamaguchi et al (1994) 1423 22.2 Y Y
Lithuania Ambrozaitis et al (1995) 48.3 Prevalence 7.9% among dialysis
staff
Oman al Dhahry et al (1993) 102 26.5
Pakistan Kumar et al (1994) 68 46 Y>4 Y>1y Females, reused dialyzer
Poland Polz et al (1995) 57
Poland Slizien et al (1995) 67 61.2 HBV
Romania Boscan et al (1995) 61 79 Y HBV
Russia Shakhgil’dian et al
(1994a)
269 25 Y
Russia Shakhgil’dian et al
(1994b)
25
Saudi Arabia Huraib et al (1995) 1147
(22 HD
centres)
68 (range
14.5-94.7)
Y Y Male, ethnicity
Scotland McIntyre et al (1994) 483 3.9 Y Y HD>CAPD
South Africa Cassidy et al (1995) 103 21 Y Y Prevalence 0% in dialysis staffSite Reference Number Prevalence (%) % PCR
Total HD CAPD Total HD CAPD HCV+ HCV-
No. of
transfusions
Duration Other associations/factors
Spain Anon. (1995c) Higher in HD than CAPD
Prevalence higher in nurses than in
other staff
Spain Garcia Valdecasas et al
(1994)
107 25.2
Spain Oliva et al (1995) 43 43 63
Taiwan Hou et al (1995) 44 Prevalence 5.4% in family members
Taiwan Chou et al (1993) 87 44.8
Thailand Luengrojanakul et al
(1994)
221 55 20 0
Tunisia Hmida et al (1995) 235 45.1 Y
Tunisia Jemni et al (1994) 63 42 Y Y
Turkey Akpolat et al (1995)
Turkey Paydas et al (1994) 56 23.2 Y Y
USA DuBois et al (1994) 208 21 77 0 High levels of viraemia, especially in
males
USA Kuhns et al (1994) 63 25 75 4.3
USA Tokars et al (1994) 170,028
(2,170
centres)
8.1 Prevalence 1.6% among dialysis
staff
USA Tokars et al (1994) (2,304
centres)
9.7 Prevalence 1.6% among dialysis
staff
Vietnam Nakata et al (1994) 28 54Table 23 continued overleaf
Table 23 Prevalence of anti-hepatitis C virus in sexual partners of anti-HCV-positive people
Country Reference Assay Risk factor No. of
people
% with
antibody
Comments
Canada,
Ottawa
Scully et al
(1993)
EIA
RIBA
Sexual partners of HCV+ 29 0 One husband-wife pair were positive, but both were IDU
England Hallam et al
(1993)
EIA2 Sexual partners of HCV+ people
with haemophilia
104 2.9 56% of index cases were HIV positive. All those who developed HCV had other risk
factors for HCV (1 IDU, 2 had undergone surgery pre HCV screening).
Europe,
America,
and
Australia
Brettler et al
(1992)
EIA2, RIBA Sexual partners of HCV- infected
person with haemophilia
106 3
Finland Kolho et al
(1991)
EIA1 Sexual partners of HCV- infected
people with haemophilia
30 3 This one result was indeterminate
France David et al
(1995)
EIA2
RIBA 2
Sexual partners of HCV+ 104 10.6 In 8/11, other risk factors were present (3.2% if no other risk). General population
levels about 1% in this region.
Germany Brackmann et
al (1993)
EIA1/2 Household contacts of HCV+
people with haemophilia
228 0.4 Only one positive; not clear if this was a sexual contact or not
Germany Meisel et al
(1995)
EIA2/3,
RIBA2/3
Husbands of HCV+ 94 0 Women were infected by immunoglobulin
Hong Kong GC Chan et al
(1992)
EIA1 Sexual partners of HCV positive 11 0 All heterosexual
Italy, Naples Coltorti et al
(1994)
EIA2 RIBA2 Spouses of HCV+ with chronic
hepatitis.
100 27 Only 1.9% of 260 children positive. In spouses, correlated with duration of marriage.
Italy, Bari Napoli et al
(1993)
EIA2 RIBA2 Spouses of HCV infected 108 34 Rate in children was 2%, 14% in siblings, 17% in other cohabitants, 45 family
members of 16 negative controls had no HCV
Italy Gabrielli et al
(1994)
EIA, RIBA2 Sexual partners of HCV+ positive
IDU
84 29
13
0
In 7 couples where both were HIV+
In 47 couples where index HIV+, exposed HIV-
In 30 couples where both HIV-. No effect of condom use.Country Reference Assay Risk factor No. of
people
% with
antibody
Comments
Italy Marino et al
(1994)
EIA2 Sexual contact with HCV+ person
(86)
159 18 72/86 anti-HCV-positive patients had unknown risk factors. Rate higher than in other
household contacts (3.1%). No mention of IDU.
Japan Oshita et al
(1993)
? Spouses of HCV+ 75 24 Much higher than other family members
Japan Setoguchi et
al (1994)
EIA2, HCV
RNA
Sexual partners of those with liver
disease due to HCV
83 24 24% is no higher than the background rate in this community
Netherlands Bresters et al
(1993)
EIA2, HCV
RNA
Sexual partners of viraemic
individuals
50 0 Median duration of sexual partnerships 13 years
Spain,
Seville
Lissen et al
(1993)
EIA2 RIBA2 Heterosexual partners of HCV+ 147 7.4 9.2% if also HIV+, 4.1% if HIV negative
Spain Diaz et al
(1995)
? Sexual partners of HCV+. 126 1.6 1.6% is no different to the prevalence of HCV in blood donors in this area.
Seroconcordant couples had shared toiletry items.
Spain, 
Seville
Soto et al
(1994)
EIA2, RIBA2 Heterosexual partners of HCV+ 423 7.1 1.2% in blood donors. Higher if index case coinfected with HIV (9.1%).
Spain Garcia
Bengoechea
et al (1994)
? Sexual partners of patients with
chronic HCV
161 4.7 Nonsexual household contacts 2.5%
Sweden Shev et al
(1995a)
EIA2 Sexual partners of HCV+ blood
donors
22 23 In seroconcordant partnerships the exposed individual more likely to be HSV2
positive. No difference in syphilis serology.Country Reference Assay Risk factor No. of
people
% with
antibody
Comments
Taiwan Kao et al
(1992)
? Sexual partners of HCV positive 48 21 Older age and longer duration of marriage were risk factors.
USA Eyster et al
(1991)
EIA1, WB Sexual partners of HCV+
haemophiliacs
194 2.6 3% in partners of men with HIV+/HCV+, 0% in men with HIV-/HCV+
USA, San
Francisco
Osmond et al
(1993b)
RIBA2 Sexual partners of HCV+ 31 6 2 women with no parenteral risk and with an infected male partner were infected,
compared to no women with HCV- partners
USA,
Michigan
Gordon et al
(1992)
RIBA2 Sexual partners of HCV positive
with chronic hepatitis
42 2 90% of partners reported frequent unprotected sex with their partners. Only case of
transmission was a woman who reported razor sharing.Table 24 Rate of mother-to-infant transmission of hepatitis C virus in published studies
Transmission rates refer to numbers of infants, not number of mothers
Country Reference Assay No. of
children
Transmission
rate (%)
Risk factors
Australia Latt et al (1994) EIA2,
HCV RNA
25 12 No mothers HIV infected
England Kudesia et al (1995) EIA2,
HCV RNA
13 0 1 mother coinfected with HIV
France Roudot Thoraval et al
(1993)
EIA2,
RIBA2, HCV
RNA
18 0 All HIV negative; 8 mothers HCV-RNA-positive
France Marcellin et al (1993) EIA2,
HCV RNA
10 0 All mothers HIV negative, normal liver transaminases. 5 mothers HCV-RNA positive.
Germany, Berlin Meisel et al (1995) 231 1.3 Mothers infected by immunoglobulin. No children developed apparent or chronic hepatitis.
Italy, Florence Resti et al (1992) EIA, RIBA2,
HCV RNA
22 23 All HIV negative. 12/22 mothers HCV-RNA positive. 5/12 babies born to HCV-RNA-positive mothers infected.
Italy,  Milan Paccagnini et al
(1995)
EIA2,
HCV RNA
70 20 12% if mother HIV negative (17), 23% if positive (53). Rate of vertical transmission higher if vaginal delivery
(32%) than by caesarean section (6%). 4 of HCV infants became HIV infected.
Italy, Milan Zuccotti et al (1995) EIA, HCV
RNA
37 16 31% in 13 mothers who were HCV-RNA positive and had HIV, and 25% of the 8 with HCV RNA alone. 0%
in mothers who were HCV-RNA negative. Only infants born to mothers infected with subtype 1b or 3a
acquired HCV.
Italy Novati et al (1992) EIA1
RIBA,
HCV RNA
8 13 All mothers HIV infected
Italy Giovannini et al
(1990)
EIA1 25 44 All mothers infected with HIV. Infection of children defined by persistence of anti-HCV antibody beyond 6
months of age. All 11 children infected with HCV were also infected with HIV.
Italy Zanetti et al (1995b) EIA?,
RIBA?,
HCV RNA
116 7 0/94 cases of transmission in HIV- mothers, but 8/22 (36%) in HIV+ mothers who had higher levels of HCV
RNA (transmission was 44% in HIV+ HCV RNA+ mothers). No transmission in 71 breastfed babies of HIV-
mothers. No transmission in HCV-RNA- mothers.
Italy Giacchino et al (1995) EIA2,
HCV RNA
31 6 No mothers infected with HIV. Transmission in HCV-RNA-positive mothers was 10%.Country Reference Assay No. of
children
Transmission
rate (%)
Risk factors
Japan Ohto et al (1994) EIA2,
HCV RNA
54 6 11% transmission in HCV-RNA positive mothers, 0% in HCV-RNA negative mothers.
Japan Uehara et al (1993) EIA2,
HCV RNA
12 8 Seven mothers HCV-RNA positive. One case of transmission in a HCV-RNA-positive mother. May have been
breast milk transmission (initially HCV-RNA negative, later positive).
Japan,
Hiroshima,
Moriya et al (1995) 87 2.3 All mothers were HCV-RNA positive but had no evidence of hepatitis.
Scotland Lam et al (1993) EIA2, RIBA 66 6 Forty-eight of 56 mothers were coinfected with HIV, and 59% of mothers were HCV-RNA positive. Infection
defined by repeated EIA2 positive after 6 months of age. No association between HIV and HCV infection.
Spain Alvarez (1992) EIA1
RIBA1
22 4.5 All mothers HIV infected. The one child who was HCV infected was also HIV infected. Mother had advanced
stage HIV disease.
Sweden Wejstal et al (1993) EIA1/2,
RIBA2,
HCV RNA
21 5 All mothers were positive for HCV RNA
Taiwan Lin et al (1994) EIA2,
HCV RNA
15 7 One case of transmission was from a mother with very high levels of HCV RNA (10
10 copies/mL)
Taiwan Ni et al (1994b) EIA2 11 18 No comment on HCV RNA in mothers. All HIV negative.
USA Thaler et al (1991) EIA1,
RIBA1, HCV
RNA
10 80 Five mothers coinfected with HIV. 8 mothers HCV RNA positive, transmission occurred in all.
USA Reinus et al (1992) EIA,RIBA,
HCV RNA
24 0 Four mothers coinfected with HIVTable 25 Prevalence of anti-hepatitis C virus in household contacts of anti-HCV-positive people
Country Reference Assay No. and type of
index cases
No. of contacts Prevalence of
antibody (%)
Background prevalence, specific risk factors
Germany Brackmann et al
(1993)
EIA1, EIA2,
some
RIBA2
HCV-infected
people with
haemophilia
228 0.4 12% of household contacts were anti-HBc positive
Italy, Bra Napoli et al (1993) ? HCV infected 108 2-34 Prevalence 0% in family members of negative controls.
Rate in children 2%, siblings 14%, other cohabitants 17%, spouses 34%.
Italy,
Naples
Vegnente et al
(1994)
EIA2
RIBA2
44 children with
chronic HCV
77 parents
56 sibs
14
0
No horizontal spread in children
Italy,
Naples
Coltorti et al (1994) EIA2 RIBA2 Chronic HCV
hepatitis
100 spouses
260 children
27
1.9
Italy,
Piacenza
Buscarini et al (1993) EIA2
RIBA2
Chronic HCV
disease
HCV-infected
donors
107
30
14.9
0
Prevalence in blood donors 1.7%.
8 infected children, families had used reusable syringes. Mean age of infected
children and sexual partners older than HCV negative.
Italy Marino et al (1994) EIA2 HCV infected 159 8.8 Rate higher in those who had sexual relationship with index case (18%) than
those who did not (3.1%)
Japan,
Fukoaka
Hayashi et al (1995) EIA2 General population
survey
Children
Men
Women
18
22 in wives
35 in husbands
Community prevalence 20%, ranged from 0 if <19 to 31% if 60-69
Japan, Iki
Island
Nakashima et al
(1995)
EIA2 General population
survey of 1122
people
53 children
51 men
44 women
5.7
33 wives
39 husbands
Community wide prevalence was 14% of 1122. Zero prevalence in 312 people
under 20. All positive children of positive mothers were older than 20 and all had
undergone surgery.
Japan,
Kanazawa
Honda et al (1993) EIA2 Chronic HCV 88 23 23% (5/22) of positive fathers, 29% (4/14) positive mothers, 30% (3/10) positive
siblings, 19% (8/42) spouses
Japan,
Osaka
Oshita et al (1993) EIA2 HCV infected 219 12 Control group rate 2%, volunteer blood donors 1.5%.
24% in spouses, 5% in children, 9% in 34 others. Positivity increased with age.
Only 1/33 children aged < 20 positive. No spouses aged < 40 pos.Country Reference Assay No. and type of
index cases
No. of contacts Prevalence of
antibody (%)
Background prevalence, specific risk factors
Japan Goto et al (1994) EIA1, EIA2 HCV liver disease 118 12.7 Blood donor prevalence 1.1% (3.1% at age >50).
Prevalence 13% father-child pairs (3/24), 18% mother-child pairs (3/17), 25%
sibling pairs (2/8), 16% husband-wife (6/38) pairs.
Korea Kim et al (1994) EIA2 HCV infected 181 2.2 1% in controls. No evidence of familial clustering. History of acupuncture and
transfusion associated with HCV risk.
Spain,
Oviedo
Riestra et al (1992) EIA 120 HCV infected 302 4.3 0.78% in blood donors. Positives were 1 mother, 7 sexual partners, and 5 sons.
Positive contacts older, longer ‘contact time’ (mean of 29 years). Higher risk if
index had cirrhosis.
Spain,
Oviedo
Riestra Menendez et
al (1991)
EIA1 225 HCV infected 530 4.9 0.78% in blood donors. Prevalence increased with age, contact time. No higher if
sexual relationship.
Spain Camarero et al
(1993)
EIA2
RIBA?
27 children with
HCV infection
80 1 1 brother positive (age 15). No history of drug abuse. There is no mention of
whether this brother may have had a blood transfusion.
Spain Garcia Bengoechea
et al (1994)
EIA2
RIBA2
Chronic HCV 401 2.5 Sexual contacts 4.7%, others 2.5%.
Of non-sexual contacts, rate was higher in parents (4.2%) than in siblings (2.7%)
or offspring (1.1%).
Taiwan Hou et al (1995) ? HCV infected
haemodialysis
patients
186 5.4 Not significantly different from that of age-matched adults
Taiwan Huang et al (1993) EIA2 27 HCV RNA+
renal dialysis
patients
86 8.1 Spouses 10%, others 7.6%
Taiwan Kao et al (1992) ? HCV infected 186 5.4 Higher than background prevalence
Thailand Pramoolsinsap et al
(1992)
EIA1 29 HCV liver
disease
20 spouse
72 other
10
4
Prevalence in blood donors 0.4-1.5%.
Positive contacts older (all aged >40).Table 31 Studies of hepatocellular carcinoma in Italy
Reference Place/test type Type of
study
Definitions Results Conclusions
Colombo et al
(1989)
Specialist Unit in
hospital
Stored sera, 1st 
generation RIA
Descriptive
case series
Cases: consecutive cases of HCC=238
diagnosed by histology, sera on 132.
Comparison: chronic liver disease patients
Chronic hepatitis=139
Posttransfusion=19
Cirrhosis+transfusion=82
Cryptogenic=38
Proportion HCC who were HCV+=0.65
Proportion cirrhosis who were HCV+=0.74
Recorded alcohol consumption, blood
transfusion, HBsAg+ had no effect on the
proportion of HCC patients who were HCV+ (**
actually 70 v. 54%)
HCV common in both the HCC and chronic
liver disease groups
Colombo et al
(1991b)
Stored sera
EIA or RIA ?1st
generation
Cases
series of
HCC and
NANBH
CLD
HCC=132
Chronic NANBH & cirrhosis=139
Controls=untreated haemophiliacs (11),
housestaff (15); miscellaneous liver
diseases (11)
HCC: 65% anti-HCV+ (similar frequency if
HBsAg+ or -). Chronic hepatitis & cirrhosis:
71/72% anti-HCV+. Miscellaneous disease:
18% anti-HCV+
Healthy control groups 8% anti-HCV+
High prevalence of anti-HCV in patients with
HBsAg+ cirrhosis. (53% of all those with
HBsAg; 16.7% of all HCC patients had dual
infections). Suggests patients infected by both
viruses are more likely to develop serious liver
disease.
Colombo et al
(1991a)
Specialist Unit in
hospital
Stored sera, 1st
generation EIA
Prospectiv
e case
series of
447
patients
with
cirrhosis
HCC found in 30 (7%) at baseline and 29
(7% of patients free of tumour at baseline)
during follow-up (mean 33 months)
Baseline prevalence of HCC was 7% with
yearly incidence of 3% throughout follow-up.
The major single cause of HCC was HCV but
for many cases there was a multifactorial
aetiology.
A viral aetiology for 62% of HCC
Coltorti et al
(1994)
Naples, Italy Case
series
Cirrhosis=536
HCC+cirrhosis=122
Cirrhosis: 23.6% HBsAg+; 63.1% anti-HCV
HCC+Cirrhosis: 21.3% HBsAg+; 83.2% anti-
HCV
Age >57 y, male sex, HCV infection and
duration of cirrhosis contribute to progression
of HCC in cirrhotic patients.
Patients with anti-HCV-positive HCC had a
significantly longer duration of cirrhosis than
anti-HCV-negative ones.
Cumulative frequency of HCC was higher in
anti-HCV-positive patients, independently of
cirrhosis duration.Reference Place/test type Type of
study
Definitions Results Conclusions
Curley et al
(1995)
1st and 2nd
generation EIA
Descriptive
case series
Prospective study of 416 patients with
chronic hepatitis (340 HCV, 69 HBV, 7
both) screened for HCC
Initial screening identified symptomatic HCC in
33 patients (7.9%);+3 others identified in 1st
year of follow-up.
Most HCC found in subset of patients with
liver biopsies showing severe CAH, cirrhosis
or both.
Farinati et al
(1992)
EIA generation
not specified,
some checked
by RIBA (90%
concordance)
Cases
series
97 patients with histologically proven HCC Overall presence of anti-HCV was
64%Prevalence was significantly lower in
HBsAg+ patients
Gentilini et al
(1994)
Florence
2nd generation
EIA, and PCR
for HCV RNA
Cases
series of
HBV or
HCV
cirrhotic
patients
405 patients, followed for up to 15 years Cumulative occurrence rates (%) for HCC at 5,
10 and 15 y:
HCV: 4.6, 24.0, 56.2
HBV: 6.5, 23.4, 31.9 (no significant difference
between HBV and HCV)
Cumulative occurrence rates were significantly
higher in males
Most important predisposing factor for the
onset of HCC is cirrhosis.
Females may be relatively protected from
HCC (by hormonal or immunological factors)
that are lacking after the fertile period.
Simonetti et al
(1992)
Sicily
Referral based
hospital
EIA, RIBA
Case-
control -2
studies
I. Cases: 212 patients with HCC (197 with
cirrhosis)
Controls: Chronic nonhepatic diseases
2. Cases: 197 patient with HCC+cirrhosis
Controls: Pair-matched controls with
cirrhosis but not HCC
I. 71% of HCC patients were anti-HCV+ cf. 5%
with nonhepatic chronic disease (OR=42; 95%
CI 22, 95). Anti-HCV was an independent risk
factor for HCC (OR=69; 95% CI 15, 308).
HBsAg (OR=8.7, CI, 1.5, 50) and anti-HBc
(OR=4.2, CI 1.7, 11) were also risk factors for
HCC. No significant interaction was found
between anti-HCV and HBV markers
2. 74% of patients with HCC and cirrhosis were
anti-HCV+ cf. 62% of those with cirrhosis alone
(OR 1.8; 1.1-2.8). Anti-HCV and HBsAg were
independent risk factors for HCC
HCV is a risk factor for HCC
HCV infection acts independently of HBV
infection and of alcohol, age or gender.
Stroffolini et al
(1992)
Four hospitals
2nd generation
EIA
Samples frozen
& tested within
months of
collection
Case
control
Cases: Newly diagnosed HCC=65
Controls: Gender & age matched,
consecutively admitted to same hospital
with nonhepatic chronic diseases
Prevalence of markers (OR compared to no
markers)
anti-HCV alone:
  Cases 59%; controls 13%; OR=21.3 (8.8,
51.3)
HBsAg+ alone:
 Cases 17%; controls 6%; OR=13.3 (5.5, 32.2)
anti-HCV plus HBsAg
 Cases 8%; controls 0%; OR=77.0 (3.8, 1421)Table 32 Studies of hepatocellular carcinoma in Greece and Turkey
Reference Place/test type Type of study Definitions Results Conclusions
Hadziyannis et
al (1995)
Athens, 2
hospitals
2nd generation,
RIBA confirmed
Case control Cases: 65 consecutive incident
cases of HCC
Controls: matched on age and
sex
1. 65 metastatic liver disease
2. 65 cases with ENT admissions
HCC: anti-HBs=61.5% HCV=12.3%
1. MLC: anti-HBs=12.3% HCV=4.6%
2. ENT: anti-HBs=6.1% HCV=0%
OR HCC v. both controls:
  HBsAg: 18.8 (95% CI 8.2, 43.2)
  anti-HCV: 7.7 (95% CI 1.7, 35.1)
Insufficient cases to examine whether there is
an interactive effect of HBV and HCV in
development of HCC
Kaklamani et al
(1991)
Athens
Hospitals
1st generation
EIA on stored
sera
Case control
(Record review
of patients 1976-
84)
Cases: 185 HCC diagnosed by
histology (108) or αFP (77)
Controls:
1. Accident orthopaedic
admissions (432)
2. MLC (35)
Prevalence of HCV (%):
HCC=39
MLC=3
Control=7
For HCV: RR for HCC=6.3 (95% CI 3.7, 11.0)
For HBsAg+: RR=11.4 (95% CI 6.7, 19.4)
For HbsAg+ HCV: RR=20.0 (95% CI 2.5, 157.5)
RR of HCC in hospitalised Greek people with
HCV is 6.3.
RR is even greater if coinfection with HBV
HCV has an interactive role in the origin of
HCC
Ozyilkan et al
(1994)
Turkey Case series,
prevalence study
Cases: HCC=25 (histology)
Also looked at 127 patients with
cirrhosis
Prevalence anti-HCV: 1/25=4%
Prevalence HBsAg+: 19/25=76%
Low prevalence of HCV in HCC patients may
reflect the low carriage of HCV in the Turkish
population
Tzonou et al
(1991)
Athens
Stored sera
1st generation
Case control
Patient interview
Cases: HCC=185
Controls: 432 hospital controls
Anti-HCV RR=6.2 (95% CI 3.6, 10.6)
Rate ratio is higher in subjects HBsAg+ (RR 20.0 v.
4.4)
RR is higher for subjects with pre-existing cirrhosis
(11.4 v. 4.4)
The association between presence of HCC
and HCV is highly significant
Zavitsanos et al
(1992)
Athens
hospitals1st &
2nd generation
EIA on stored
sera, RIBA
confirmation
As above As above Prevalence of HCV
HCC=13.3%
MLC=0%
Controls=1.4%
For HCV: RR for HCC=10.4 (95% CI 4.2, 26.0)
Association between HCC and HCV is
increased when a 2nd generation assay is
usedTable 33 Studies of hepatocellular carcinoma in Spain
Reference Place/test type Type of study Definitions Results Conclusions
Bruix et al
(1989)
Hospital Liver
and Virus Unit
Stored sera, 1st
generation EIA
Descriptive case
series
Cases: Consecutive cases HCC=96
diagnosed by histology (74);
ultrasound/computerised axial
tomography/αFP (22)
Comparison groups:
1. Cirrhosis without HCC (ultrasound,
αFP)
2. Hospital surgical admission not due
to liver disease
Proportion HCC who were HCV+=0.75
Proportion cirrhosis who were HCV+=0.556
Proportion surgery unit control who were
HCV+=0.073
Recorded alcohol consumption, age, sex,
blood transfusion had no effect on the
proportion of HCV+
High prevalence of HCV in this group with
HCC in Spain
Castells et al
(1995)
Barcelona
University liver
clinic
2nd or 3rd
generation EIA,
RIBA
Case series of
HCC in cirrhosis
patients
191 consecutive cases of HCC HBsAg+ in 14 patients (7%), 8 had dual
infection
Anti-HCV in 152 patients (79.5%)
No significant difference in anti-HCV
prevalence by HBsAg+ status (but lower if Ag+,
81.3 v. 57%)
29 patients had a history of blood transfusion
before diagnosis of hepatic cirrhosis
Mean interval (± s.d.) between date of
transfusion and diagnosis of HCC was
29.4±12.6 y in nonalcoholic (n=21) cf.
22.7±14.9 y in alcoholics (n=8) (‘alcoholic’ is
not defined)
Before anti-HCV testing was available, the
aetiology of chronic liver disease was
attributed to excessive alcohol in 100/191
patients.
Trend to shorter interval between blood
transfusion and HCC in alcoholic patients.
Prevalence of anti-HCV in patients without a
history of previous transfusion was 55.4%.
Ruiz et al
(1992)
University liver
clinic
2nd generation
EIA, nested
PCR
Case series Cases: 70 patients with HCC
(cirrhosis 65; CAH 1, normal liver 4)
19 had histories of alcohol abuse
(>80 g/day)
HBsAg+ 17%; HBV markers 37%
anti-HCV 63% HCV RNA found in 42/68=62%
No viral marker 16%
HCVis more prevalent than HBV in HCC
patients in Spain.
Most HCC patients have a viral marker.Table 34 Studies of hepatocellular carcinoma in Japan and Korea
Place and
reference
Test type Type of study Definitions Results Conclusions
Chiba, Japan
Takano et al
(1995)
University
Hospital
1st generation
EIA, 2nd
generation after
liver biopsy
Prospective
study of chronic
hepatitis
patients: divided
in CPH, CAH2a
& CAH2b based
on liver biopsy
anti-HCV+:=124
HBsAg+=127
Seven with markers of both excluded
Incidence of HCC in HCV+ patients (13) was
2.6 times that of HBV patients (5).
7.7% of cases in HCV patients cf. 40% of cases
in HBV patients did not have cirrhosis
The prevalence of genotypes in HCC patients
was the same as in the total number of followed
HCV patients
Despite similar population prevalence of HBV
(1.5%) and HCV (1.3%) about 80% of cases
of HCC within the institution are HCV-assos’d.
Therefore, the authors argue, the incidence of
HCC in HCV carriers is higher than in HBV
carriers.
Fukuoka,
Japan
Tanaka et al
(1991)
Hospitals
1st or 3rd
generation on
stored sera,
RIBA
confirmation
Case control
Interview
Cases: 91 HCC diagnosed by
histology (30), angiography (58) or
ultrasound/CT (3)
Controls
1.Cirrhosis, same age, sex
(Histo 24; laparoscopy 14; clinical/CT
37)
2. Population (Public health centre)
controls, age matched
Prevalence HCV
HCC=68%
Cirrhosis=64%
Controls=7%
For HCV: RR for HCC=52.3 (95% CI 23.9,
114.3)
For HBsAg+: RR=15.3 (95% CI 2.0, 7.0)
If HCV+ and cirrhosis: RR=64.4 (27.4, 151.4)
Negative correlation between HCV and HBsAg
infection
Attributable fraction of HCV for HCC=0.49
(0.39-0.60)
Negative correlation between HBV and HCV
is unexplained
Heavy alcohol remains a risk but the increase
was moderate to slight (RR for HCC=2.2; for
cirrhosis=1.4).
Japan
Tomimatsu et
al (1993)
Surgical unit
Stored sera,
repeat reactors
on 2nd
generation EIA
Descriptive case
series
Prevalent cases of HCC diagnosed
histologically=121
Prevalent cases of CC diagnosed by
histology=13
Combined HCC+CC=7
Proportion HCC who were HCV+=0.703
Proportion CC who were HCV+=0.308
Proportion HCC+CC who were HCV+=0.714
HCV is increased in HCC and combined
HCC/CC in Japan
Japan
Ikeda et al
(1993)
Prospective
cohort study of
cirrhosis
795 consecutive patients with viral or
alcoholic cirrhosis, followed for 2-17 y
(median 5.8 y). Cumulative
appearance rates of HCC were 19.4,
44.3 and 58.2% at 5, 10 & 15 y,
respectively.
The appearance rates of HCC in 180 patients
with only HBsAg and in 349 patients with only
antibodies to HCV were 14.2 and 21.5% at 5
years, 27.2 and 53.2% at 10 years and 27.2
and 75.2% at 15 years, respectively
αFP levels, age and past alcohol consumption
were independent predictors in the group of
HCV-positive patientsTable 34 continued overleaf
Place and
reference
Test type Type of study Definitions Results Conclusions
Japan
Kiyosawa et al
(1990)
University
hospital
Stored sera
tested on 1st
generation EIA
Retrospective
cohort NANBH
CLD patients
Chart
review/interview
and family
interview
Cases: All HCV+ (nonHBV) patients
with biopsy-proved chronic liver
disease=205
Comparison: All HCV- patients
admitted with biopsy-proven CLD.
(excluded CLD other causes)=26
RR HCC of HCV Ab+=6.31
Prevalence of HCV in NANBH=90%; in
HBV=19%
Prevalence of blood transfusion in
NANBH=41%; in HBV=5%
Prevalence of HCV in HCC. NANBH=94%;
HBV=35%
Mean interval (± s.d.) to development of HCC
from blood transfusion in those with
HCV=29±13.2 y
86% of HCC patients had cirrhosis
Close association between HCC and HCV
positivity.
High frequency of blood transfusion in this
group (other causes had been excluded).
Prolonged interval between transfusion and
HCC
14-60+ y lag between putative infection and
tumour development suggests chronic
inflammation &/or hepatic regeneration may
play a role in carcinogenesis.
Japan
Nishioka et al
(1991)
5 hospitals
Serum from
HCC throughout
Japan, 1st
generation EIA
Prevalence
study, case
series
Cases: HCC by histology with
available sera, excluding those
transfused after HCC diagnosed=180
(HBsAg+=75)
Comparison group: Historical data re
seroprevalence in blood donors
Proportion HBsAg-ve HCC who were
HCV+=0.762
Proportion HBsAg+ve HCC who were
HCV+=0.147
Proportion blood donors HCV+=0.012
(HBsAg+ and HBcAb markers same in HCV- &
HCV+)
Transfusion associated with 39% of HCV+ cf.
4.7% HCV-ve.
High prevalence of HCV (76.2%) in this group
of patients with HCC.
Past alcohol consumption was an
independent predictor for the appearance rate
of HCC in HCV+ positive but not HBsAg+
patients.
Nagasaki
Prefecture,
Japan
Hamasaki et al
(1993)
Stored sera
Serial 1st , 2nd
generation EIA,
then PCR
Marker
prevalence
study over time,
hospital case
series
Cases: 253/295 patients with HCC
admitted to hospital between 1976
and 1990 (those with stored sera)
More than 90% of patients positive for HBsAg
or HCV.
Serial changes with HBsAg+ prevalence
peaking in 1982-84 and thereafter decreasing;
HCV prevalence in cases increasing in last 6 y
Familial clustering found
Only 23% of HCV+ patients had received
blood transfusions.
Osaka, Japan
Pyong et al
(1994)
Koreans living in
Osaka
Case control Cases: 90 hospital admissions with
newly diagnosed HCC
Controls: 249 hospital patients
matched for age group
Cases: Prevalence HCV=74.4%;
HBsAg+=16.7%;
41.1% of cases were heavy drinkers
Controls: Prevalence HCV=8.0%;
HBsAg+=3.6%
Adj OR: HCV=92.4 (95% CI 33.8, 252);
HBsAg+=58.2 (95% CI 15.3, 221)Place and
reference
Test type Type of study Definitions Results Conclusions
Osaka, Japan
Tsukuma et al
(1993)
Stored sera
1st generation
EIA
Prospective
study of 917
patients with
cirrhosis (240) or
chronic hepatitis
(677)
917 patients with cirrhosis (240) or
chronic hepatitis (677)
Follow-up for 35.7± 13.0 months (range 5-52),
HCC developed in 52 patients.
3-y cumulative risk of HCC was 12.5% for 240
patients with cirrhosis at enrolment and 3.8%
for 677 patients with chronic hepatitis.
Risk of HCC increased in patients with HbsAg.
Rate ratio 6.92 (95%CI 2.92, 16.39) and 4.09
(1.30, 12.85) in patients with anti-HCV.
Risk of liver cancer in men was 1.33 times
that in women.
Positive association between risk of liver
cancer and age at enrolment.
Use of 1st generation assay may
underestimate the rate ration for HCC.
Pusan, Korea
Park et al
(1995)
2nd generation
EIA
Prevalence
study in CLD
and HCC
patients
Controls: anti-HCV=1.6%; HBsAg+=5.2% , No
HCV/HBV marker=30.3%
Chronic hepatitis: anti-HCV=24.3%
HBsAg+=63.4%, No HCV/HBV marker=4.2%
Cirrhosis: anti-HCV=18.9% HBsAg=47.3%; No
HCV /HBV marker=8.0%
HCC: anti-HCV=14.3% HBsAg=61.1%, No
HCV/HBV marker=3.7%
Current or previous HBV infection is still the
major cause of chronic hepatitis, cirrhosis and
HCC in Korea.
Tokyo, Japan
Shiratori et al
(1995)
Hospital series
HCV PHA
(Dinabbott kit)
Case series,
prevalence
study
Cases: 205 consecutive patients with
HCC
70.7% positive for anti-HCV alone, M:F
ratio=3.3:1
12.7% positive for HCV and HBcAb, M:F=5.5:1
11.2% HBsAg+ alone, M:F=7.1
1.0% HCVAb and HBsAg+
4% no HBV or HCV marker
Cirrhosis and severe chronic hepatitis present
in 69.3 and 24.8% of HCV Ab cases.
Interval after blood transfusion in HCV+ cases
was ~30 y; 35-45 y if transfused before 20 y of
age.
Less cirrhosis if HBsAg+ (50% cf. >70% in
anti-HCV+), patients younger (52 cf .62 y),
M:F ratio higher.
3 y survival was higher in HCV related HCC.
Tokyo, Japan
Saito et al
(1990)
Specialist
hospital units
Stored sera , 1st
generation EIA
Descriptive case
series.
Record review
Cases: All HCC diagnosed clinically
and pathologically=253
Other cancer patients with available
sera (including 5 with liver
metastases)=148
Proportion HCC who were HCV+=0.545
Proportion HCC who were HBsAg+=0.202
Proportion HCC who were HCV+ and HBsAg
+=0.008
Recorded alcohol consumption no effect on the
proportion of HCV+
Blood transfusion reported in 35.8% of HCC
with HCV.
HCV is associated with 55% of HCC,
especially high where no HBV markers.
Toyama, Japan
Watanabe et al
(1994)
Stored sera
?1st generation
HCV PCR in
those with HCC
Prospective
study of patients
with chronic
hepatitis and
cirrhosis
167 patients with anti-HCV+ chronic
liver disease: 86 with chronic
hepatitis and 81 with cirrhosis
Longer follow up in hepatitis
patients(mean 53.8 v. 36.6 months)
13/81 (16.0%) hepatitis patients developed
HCC
56/86 (65%) patients with cirrhosis developed
HCC
A close relationship between oncogenicity and
HCV activity. Hepatitis activity index (HAI)
score was not demonstrated.Table 35 continued overleaf
Table 35 Studies of hepatocellular carcinoma in Taiwan
Reference Place/test type Type of study Definitions Results Conclusions
Chang et al
(1994)
Taiwan,
community
setting
Stored sera,
repeat reactors
2nd generation
EIA
Nested case
control
Questionnaire
and structured
interview
Cases: 38/55 newly diagnosed cases
of HCC with sera available
Controls: healthy men in community
cohort, matched 4:1 by age, date of
recruitment and residence
Prevalence of HCV
HCC=13.2%
Controls=2.6%
RR for HCC if HCV+=7.9 (95% CI 1.49, 41.8)
RR for HCC if HBsAg+=26.5 (7.9, 88.6)
Attributable fraction to HCC.
HCV=0.152, HBsAg+=0.636
HCV infection is causally related to HCC in
Taiwan although the attributable fraction is
less than for HBV
Chang et al
(1992)
Taiwan
Hospital series
1st generation
EIA
Case series Consecutive hospital admissions with
cirrhosis (138) or HCC (306).
Cases were those with cirrhosis or
HCC who had pre and
posttransfusion stored sera, who
received >10 transfusions between
1987 and 1990.
30 patients were selected
HCC: HBsAg+=42.9%; Cirrhosis:
HBsAg+=57.1%;
5/30 (16.7%) were anti-HCV+ prior to
transfusion
7/25 (28%) became anti-HCV+ after
transfusion
Seroconversions to HCV were much higher in
those who were HBsAg- (66.7 cf. 15.8%)
The aetiological role of HCV is not so
important in Taiwan as in Western countries.
Transfusion might result in an overestimated
pathogenic effect of HCV in cirrhotic patients
and those with HCV.
Chuang et al
(1992)
Hospital &
community
anti-HCV+ on
EIA
Case control Cases - 128 HCC diagnosed on
histology
Controls - 384 community participants
in gallstone study, matched for age
and sex
Prevalence HCV
HCC=19.5%
Controls=3.3%
Relative risk (95% CI) cf. HBsAg-ve, anti-HCV -
ve
HBsAg+: 68% HCC v. 27.1%, RR=13.96 (7.82,
24.92)
HCV+: 10.1% HCC v. 2.1%, RR=27.12 (9.83,
74.83)
HBsAg+/anti-HCV+: HCC 9.4% v. 1.3,
RR=40.05 (12.57, 127.6)
HBV and HCV were highly associated with
HCC.
The two viruses contribute independent but
synergistic effects to the pathogenesis of
HCC.
Lee et al (1992) Hospital series
?1st generation
EIA
Case series Cases of histologically proven
HCC=26
Controls: MLC=35
` Mean age of patients (± s.d.) with:
HBsAg+=55.5 ± 11.9 y
anti-HCV=65.1 ± 6.0 yReference Place/test type Type of study Definitions Results Conclusions
Tsai et al
(1994a)
Hospital
Stored sera, 2nd
generation EIA
x2
Case control Cases: 102 hospital patients with
HCC
Controls: 1. Age/sex matched,
nonhepatic hospital controls=102
2. Age/sex matched healthy
community controls=204
Prevalence of HCV
HCC=34.3%
Nonhepatic disease=10.7%; Healthy
control=2.4%
Prevalence of HBsAg+
HCC=77.4
Nonhepatic disease=16.6%; Healthy
control=19.6
anti-HCV: OR=3.4, 95% CI 2.1, 5.6
HBsAg+: OR=5.6, 95%CI 3.6, 8.5
Dual infection in 18 (17.6%) patients
Calculation of incremental ORs showed no
interaction between HBV and HCV - ‘they act
independently and without interaction’
Tsai et al
(1994c)
Hospital series
2nd generation
EIA
Case control Case control
HCC=150
Control: community acquired,
matched for sex and age
Association with HCC HBsAg+ OR=14.9 (4.2,
39.9)
anti-HCV OR=12.8 (7.1, 23.2)
Being HBsAg+ and HCV+ had an OR=3.3 cf.
HBV+ HCV-ve
Both HBV and HCV infection are independent
risk factors for HCC. There was no interaction
between HBV and HCV in the development of
HCC.
Tsai et al
(1994b)
Hospital
Stored sera
2nd generation
Case control Cases: 102 HCC patients with
nonalcoholic underlying cirrhosis
Controls: 1. 102 age group/sex
matched nonalcoholic cirrhotic
patients
2. 102 age/sex matched, nonhepatic
disease controls
anti-HCV+ prevalence
All patients (102):
HCC=40/102 cf. 1. 28/102 & 2. 11/102 patients
The prevalence of anti-HCV in controls (10.7%)
was significantly lower than that in HCC (OR
4.34, 95% CI, 61.7-79.3) or cirrhosis (OR=3.13,
95% CI 1.38, 7.21)
HBsAg+ patients (72)
anti-HCV+: HCC=20/72 cf. 1. 16/76 and 2. 2/17
patients
No difference in prevalence of anti-HCV+ in
HBsAg+ patients
HBsAg-ve patients: 2. Controls=10.5% (4.6-
16.4%)
HCC=66.7% (57.5-75.7%) OR=16.88 (5.44,
54.88)
Cirrhosis=46.1% (36.5-55.7%) OR=7.23 (2.29,
23.32)
Male sex and increasing age are associated
with higher anti-HCV prevalence.
HCV is an independent risk factor for HCC.
Additive effect modification of HBsAg and
anti-HCV as risk factor for HCC &/or liver
cirrhosis.Reference Place/test type Type of study Definitions Results Conclusions
Yu et al (1991) Two major
teaching
hospitals
anti-HCV on EIA
Case control Cases: Newly diagnosed HCC=127
Controls: Community controls
matched for age, gender, ethnicity
and residence
Anti-HCV:
HCC: 11.0% Controls: 1.6% OR 7.0 (95% CI
1.6, 30.8)
HBsAg+/HBeAg-:
HCC: 67.7% Controls: 14.2% OR 17.2 (6.8,
43.4)
HBsAg+/HBeAg+:
HCC: 18.9% Controls: 2.4% OR 28.1 (6.4,
124.1)
Both HBsAg and anti-HCV remained
significant risk factor in a multivariate model.
Data show a considerably higher prevalence
of anti-HCV in HBsAg- (29.4%) than in
HBsAg+ (8.2%) HCC patients.
Synergistic effect on HCC when both HBsAg+
and anti-HCV were present.
Alcohol smoking and peanut consumption
frequency interacted as risk factor with anti-
HCV.Table 36 Studies of hepatocellular carcinoma in China
Reference Place/test type Type of study Definitions Results Conclusions
Ito et al (1993) Hospital patients
Stored sera, 1st
generation EIA
Descriptive
seroprevalence
study
Recorded clinical
information
Cases: HCC patients with available
sera=16
Comparison: 1. Viral hepatitis
Acute=89; chronic=246; cirrhosis=44
2. Blood donors=451
Proportion of HCC patients who were
HCV+=0.06
Proportion acute hepatitis patients who were
HCV+=0.0
Proportion chronic hepatitis who were
HCV+=0.03
Proportion HCC patients who were HBsAg+=0.87
Proportion blood donors HCV+=0.007
HCV accounts for a low proportion of hepatitis
and HCC (but small group with HCC)
Jeng & Tsai
(1991)
Hospital patients Descriptive case
series
Cases: Prevalent cases HCC
diagnosed by histology=129. All
HBsAg+ and 12 month of HBsAg+
patients
Control: Healthy on physical check-up,
no HCC on ultrasound
Proportion HBsAg-ve HCC who were HCV+=0.60
Proportion HBsAg+ve HCC who were HCV=0.24
Proportion HCV+ in healthy controls=0.0
48/129 (37.2%) HCC patients were positive for
anti-HCV
HCV may play a role in the
immunopathogenesis of HCC
Okuno et al
(1994)
Guangxi
Province,
Southern China,
Stored sera
2nd generation
EIA
Case series Cases: 186 patients with HCC
diagnosed by histology (25),
ultrasound, CT, αFP (161)
Prevalence HCV
10/186=5.4% (9 also HBsAg+, only 1 HBsAg-)
Prevalence HBsAg+=70.4%
54 (29.0%) neither HBsAg+ nor anti-HCV
HCV does not play a very important role in the
development of HCC in Guangxi
Yuan et al
(1995)
Shanghai
2nd generation
EIA
Nested case
control
Cohort 18,244 men
Cases: Incident cases of HCC=76
Controls: Matched for age, time of
blood sample collection, residence=410
HBsAg+=48/76
anti-HCV+ 1 case; 1 control; RR 5.0 (0.3-79.0)Table 37 Studies of hepatocellular carcinoma in the United States of America
Reference Place/test type Type of study Definitions Results Conclusions
Di Bisceglie et
al (1991b)
Stored sera, 1st
generation EIA
Descriptive case
series
Cases: consecutive cases HCC
diagnosed by histology=99
Comparison: cancer patients in same
institution at some time=98
Prevalence HCV
HCC=13.0%
Controls=2.0%
HCC if HCV+: RR=7.3 (95% CI 1.8, 48.2)
HCC if HBsAg+: RR not calculable;
estimate=17.3
Attributable fraction of HCV for HCC=0.114
Estimated attributable fraction of HBV for
HCC=0.067
Hasan et al
(1990)
Miami Hospital
Liver Unit
1st generation
EIA anti-HCV
positive
Retrospective
prevalence
study
Record Review
Cases - 59 HBsAg-ve HCC
diagnosed by histology (51) or
ultrasound/CT & αFP (8)
Comparison groups
1. HCC with HBsAg+ -28
2. Blood donors - 200
3. Cryptogenic cirrhosis - 76
Prevalence HCV in HBsAg-ve HCC=53%
HBsAg+ve: Presence of HCV=14%
Blood donors=0.5%
Cryptogenic cirrhosis=42%
HCV is prevalent among HCC patients, but
causal relationship is unknown.
Time relationship of exposure (HCV) and
outcome (HCC) is unknown.
Liang et al
(1993a)
Miami Hospital
Sensitive PCR,
three sets of
HCV and HBV
primers
Cases series
Prevalence
study
Cases: 91 HBsAg- patients with no
other predisposing factors for HCC
29% low levels of HBsAg in serum, liver/tumour
tissue
58% HCV infected
13% infected with HBV alone
15% HBV/HCV coinfection
43% HCV markers only
29% no identifiable viral markers
HCV and occult HBV infection accounts for
most (71%) of the HCC cases of unknown
pathogenesis in the USA
Mangia et al
(1994)
Stored sera
Immunoblot,
PCR for HCV
RNA
Case series Cases: 87 patients with HCC anti-HCV detected in 16% by EIA; only 57%
confirmed by RIBA and an additional 4 -ve on
1st gen were positive. HCV RNA detected in 6 -
all +ve on RIBA
HCV plays a less important role in HCC than
in Europe and JapanTable 38 Others studies of hepatocellular carcinoma
Reference Test type Type of study Definitions Results Conclusions
France
Ducreux et al
(1990)
Stored sera
tested on 1st
generation EIA
Case series
comparison
without HCC
Cases: 74 cases HCC diagnosed by
histology (48), ultrasound/CT & αFP
(11) and ultrasound/CT/clinical (15)
Proportion of HCC with HCV Ab=0.28
Proportion of cirrhotic controls with HCV
Ab=0.20
Proportion of HCC with HCV+/ HBV+=0.47
Proportion of HCC with HCV+/ HBV-=0.14
Proportion of cirrhotic controls with
HCV+/HBV+=0.27
Proportion of cirrhotic controls with HCV+/
HBV-=0.16
No differences in rates of HCV Ab between
HCC and cirrhosis cases
France, Paris
Ganne Carrie
et al (1996)
Hospital
Stored sera, 3rd
generation EIA
Prospective
cohort study of
cirrhosis
31/151 patients hospitalised with
histological cirrhosis developed HCC
Age ≥  50 years (P=0.01)
Male (P=0.01),
Large oesophageal varices (EV) (P=0.03)
prothrombin activity <70% (P=0.04)
serum α-FP ≥  15 ng/L (P=0.06)
anti-HCV antibodies (P=0.08).
Liver large cell dysplasia had an additional
predictive value in high-risk patients
It is possible to identify by liver biopsy a
subgroup at high risk for HCC. May be a basis
for intensive screening or preventive
measures.
India, New
Delhi, Ramesh
et al (1992)
Hospital-based
2nd generation
EIA
Seroprevalence
study
CAH=85
Cirrhosis=44
HCC=53
CAH: HBsAg+=44.7%; anti-HCV=15.3%
Cirrhosis: HBsAg+=61.4%; anti-HCV=18.0%
HCC: HBsAg+=28.0%; anti-HCV=15.1%
Low prevalence of HCV among patients with
HCC and CLD in India cf. Japan and Europe.
When HBV cases were excluded, only 14.6%
of CLD/HCC cases had HCV.
Rwanda
Mets et al
(1993)
Stored sera
2nd generation
EIA
Case series Cirrhosis=79
HCC=26
Voluntary blood donors=54
Prevalence of anti-HCV
Cirrhosis=48%; HCC=38%; Controls=17%
84% of cirrhosis & 54% of HCC patients were
HBsAg+
Prevalence of anti-HCV antibodies was
significantly higher for cirrhosis patients who
had been in contact with HBV but who had no
persistent infection with HBsAg.
Saudi Arabia
Al Kawari et al
(1992)
Frozen sera
1st generation
Cross-sectional
seroprevalence
study
Anti-HCV+
Volunteer blood donors=1.5%
Antenatal=1.0%
Chronic liver disease (HBsAg+)=14.0%
Chronic liver disease (HBsAg-)=37.5%
HCC (HBsAg+)=12.5%
HCC (HBsAg-)=42.3%
Overall seropositivity of 30.4% in 181 liver
disease patients is lower than that reported
from European countries.Reference Test type Type of study Definitions Results Conclusions
Scotland
Haydon et al
(1995)
Hospital cases
Frozen sera, 3rd
generation RIBA
Case series Cases: 65 patients with HCC 13 patients (20%) had chronic HCV infection,
all were negative for HBsAg+
All had histologically confirmed background
cirrhosis
Genotype 1b in 8 patients, genotype 4 in 2
Study supports the role of specific HCV
genotypes, particularly 1b.
Strong association between chronic HCV
infection, cirrhosis and hepatocarcinogenesis.
Time from probable HCV transmission to
HCC development ranged from 19 to 49 y
(mean± s.d., 38 ± 11).
South Africa
Kew et al
(1990)
Stored sera
tested on 1st
generation EIA
Case series with
comparison
group
Recorded data
on HBsAg+ and
Ab
Cases: 388 histological HCC
Comparison: ‘healthy’, matched for
age, gender, rural/urban origin
Proportion of HCC with HCV Ab=0.29
Proportion of controls with HCV Ab=0.007
Proportion of HCC with HB+=0.81
Proportion of controls with HB+=0.55
Prevalence of HCV higher in the group with
HCC than in apparently healthy controls.
HCV prevalence higher in HBsAg-ve than
HBsAg+ patients (34 v. 26%).
Sweden,
Goteborg
Wejstal et al
(1993)
2nd generation
EIA, RIBA
Case series Cases: 5 patients (4 post-transfusion
& 1 spontaneous NANBH)
For 4 posttransfusion cases, the mean interval
from time of transfusion until diagnosis was
15.8 ± 7.4 y
Chronic hepatitis preceded development of
HCC, and cirrhosis was present in all patients
when HCC was diagnosed
Switzerland, 
Zurich, Garson
et al (1992)
Hospital
Frozen sera,
2nd generation
EIA, RIBA
confirmation
Case series Cases: 40 patients with histologically
confirmed HCC
Serological evidence of HCV in 14/40 (35%)
12/14 PCR-RNA +ve
7 of the 14 had evidence of previous HBV
infection, 2 gave histories of high alcohol
consumption
Ongoing viral replication is present in most
HCC patients with anti-HCV
Thailand, North
East 
Srivatanakul et
al (1991)
?1st generation
EIA
Case control Cases: HCC from 3 hospitals=73
Controls: hospital controls, matched
for age, sex & educational level
HBsAg+ OR=12.0 (95% CI 2.9, 50.4)
HBV marker OR=5.3 (CI 1.8, 15.2)
anti-HCV+ OR=1.3 (CI 0.2, 8.7)
Infection with HCV in Thailand appears to be
rare
Vietnam, Hanoi
Cordier et al
(1993)
EIA ? generation Case control
Hospital
Cases: Male HCC=152
Controls: Hospital, matched for
gender, age, hospital and place of
residence=241
HBsAg: cases 92.6%, controls 18.3%, OR 61.7
(30, 128)
Anti-HCV: cases 2.0%, controls 0.8%, OR 2.0
(0.3, 17.4)
If HBsAg- HCV+: cases 3 (27.3%), controls 2
(1.0%)
OR=38.1 (2.8-1443)
HBV infection plays the major role in HCC in
VietnamTable 39 Effect of hepatitis C virus infection on risk of hepatocellular carcinoma
Country Reference n HCC Control Odds ratio
HCV+ve HCV-ve %HCV+ve HCV+ve HCV-ve %HCV+ve If anti-HCV positive Lower 95% CI Upper 95% CI
Italy Stroffolini et al (1992) 164 43 22 66.2 13 86 13.1 12.9 5.59 30.5
Italy Simonetti et al (1989) 424 151 61 71.2 11 201 5.2 45.2 22.4 97.6
Japan Pyong et al (1994) 339 66 24 73.3 38 211 15.3 15.3 8.23 28.5
Japan Tanaka et al (1991) 501 46 45 50.5 12 398 2.9 33.9 16.1 74.8
Taiwan Chuang et al (1992) 512 25 103 19.5 13 371 3.4 6.93 3.26 15.2
Taiwan Tsai et al (1994a) 204 40 62 39.2 11 91 10.8 5.34 2.44 12.4
Taiwan Yu et al (1991) 254 14 113 11.0 2 125 1.6 7.74 1.71 71.22
Taiwan Tsai et al (1994c) 300 35 115 23.3 3 147 2.0 14.9 4.49 77.1
Taiwan CC Chang et al (1994) 190 5 33 13.2 4 148 2.6 5.61 1.12 29.5
USA Di Bisceglie (1994) 197 13 86 13.1 2 96 2.0 7.26 1.56 67.5
Combined Mantel-Haenszel (M-H)
Weighed Odds Ratio
3085 438 664 39.7 109 1874 5.5 14.5 12.3 21.1Table 44 continued overleaf
Table 44 The prevalence of markers of hepatitis C virus infection in clinic populations with different levels of alcoholic liver disease
Population Reference Assay Individuals without a
high-alcohol intake
(controls)
People with alcoholism Individuals with
noncirrhotic alcoholic
liver disease
Individuals with
alcoholic liver disease
Individuals with alcoholic
cirrhosis
Individuals with
hepatocellular carcinoma
No.
of
+ve
No.
of -ve
Total % No.
of
+ve
No.
of  -
ve
Total % No. of
+ve
No. of
-ve
Total % No.
of
+ve
No.
of -
ve
Total % No.
of
+ve
No. of
-ve
Total % No. of
+ve
No. of
-ve
Total %
France Halimi et al
(1991)
EIA 29 135 164 18
France,
Bobigny
Deny et al
(1994)
EIA2 +
RIBA2
36 128 164 22
France, Paris Pagani et al
(1994)
E I A 1 77 99 61 8 2 85 07 83 63 2 2 3 5 5 5 8
Germany,
Heidelberg
Goeser et
al (1994)
HCV
RNA(P
CR)
20 61 81 25
Germany,
Stuttgart
Bode et al
(1995)
EIA2 12 118 130 9
Italy,
Bologna
Brillante et
al (1991)
EIA 15 26 41 37
Italy, Bormio Marioni et
al (1991)
EIA 7 33 40 18
Italy, Brescia Nalpas et al
(1991)
EIA2 46 59 105 44
Japan,
Fukuoka
Ishii et al
(1992)
EIA2 80 146 226 35
Japan,
Matsumoto
Shimizu et
al (1992)
EIA +
RIBA
5 116 121 4 0 35 35 0 14 25 39 36 14 10 24 58
Japan, Tokyo Yamauchi
et al (1993)
EIA
P22+C
100
40 23 63 63Population Reference Assay Individuals without a
high-alcohol intake
(controls)
People with alcoholism Individuals with
noncirrhotic alcoholic
liver disease
Individuals with
alcoholic liver disease
Individuals with alcoholic
cirrhosis
Individuals with
hepatocellular carcinoma
No.
of
+ve
No.
of -ve
Total % No.
of
+ve
No.
of  -
ve
Total % No. of
+ve
No. of
-ve
Total % No.
of
+ve
No.
of -
ve
Total % No.
of
+ve
No. of
-ve
Total % No. of
+ve
No. of
-ve
Total %
Japan Ishii et al
(1993)
EIA2 46 4 50 92
Poland,
Szczecin
Boron
Kaczmarsk
a et al
(1994)
EIA2 2 229 231 1
Poland,
Warsaw
Lasku s et
al (1992)
EIA 35 109 144 24
Scotland,
Glasgow
Blackmore
et al (1992)
EIA2 50 304,9
62
305,0
12
0 . 0 2 06 0 6 00
Spain,
Barcelona
Pares et al
(1990)
EIA +
RIBA
1 44 45 2 10 24 34 29 26 35 61 43
Spain,
Santiago de
Compostela
Gonzalez
Quintela et
al (1995)
EIA 1 77 78 1 11 55 66 17
Sri Lanka De Silva et
al (1994)
EIA2 74 0 4 7 1 5
Sweden,
Malmo
Verbaan et
al (1993)
EIA2 +
RIBA2
45 265 310 15
Sweden,
Stockholm
Bell et al
(1992)
EIA2 29 172 201 14
Taiwan, 
Tainan
Chang et al
(1994a)
EIA2 1 43 44 2 37 86 123 30Population Reference Assay Individuals without a
high-alcohol intake
(controls)
People with alcoholism Individuals with
noncirrhotic alcoholic
liver disease
Individuals with
alcoholic liver disease
Individuals with alcoholic
cirrhosis
Individuals with
hepatocellular carcinoma
No.
of
+ve
No.
of -ve
Total % No.
of
+ve
No.
of  -
ve
Total % No. of
+ve
No. of
-ve
Total % No.
of
+ve
No.
of -
ve
Total % No.
of
+ve
No. of
-ve
Total % No. of
+ve
No. of
-ve
Total %
USA,
Cincinatti
Mendenhall
et al
(1993a)
EIA2 +
 RIBA2
40 256 296 14
USA, Florida Coelho
Little et al
(1995)
EIA2 +
RIBA2
6 5 4 6 0 1 0 1 72 34 04 3
USA, Los
Angeles
McHutchiso
n et al
(1992)
EIA +
RIBA
18 121 139 13
USA, Miami Caldwell et
al (1991)
EIA 2 177 179 1.12 11 26 37 30
USA, Virginia Caldwell et
al (1993)
EIA 
C100-3
12 36 48 25 10 24 34 29Table 48  Prevalence of hepatitis C virus antibody in children
Country Reference Year of
enrolment
Sample No. of
children
Age at
enrolment
(years)
Screening
assay
HCV
antibody
(%)
Comments
Australia Leslie et al (1992) Jan. 1980-
Nov. 1981
Children with haemophilia
attending the Royal Children’s
Hospital in Melbourne
31 mean 9 EIA1 74.2 In Feb 1987 - Jan 1990,
HCV prevalence was 68% in children
< 10 y old.
Austria Fink et al (1993) Not reported Children surviving malignant
disease
203 Not reported EIA1 20.2 HCV antibody was associated with the
number of blood product transfusions
and with chronic NANBH
Belgium Pastore et al
(1995)
Mar. 1984-
Sept. 1993
Children who had had orthotopic
liver transplantation, monitored for
hepatitis C infection
249 Not reported EIA2 6.4 HCV antibody was detected in 11.2%
(11/98) and in 3.3% (5/151) of
children whose transplantation
occurred prior to, or after the
introduction, in January 1990, of HCV
antibody screening, respectively
Brazil Martins et al
(1995)
Sept. 1990-
Dec. 1993
Public day care centres
Public primary school students
Home-based street adolescents
Homeless adolescents
280
607
391
100
< 9
Mean 11.5
s.d. 3.1
-
-
EIA2 0.0
0.2
1.0
3.0
HCV antibody prevalence increased
with age from 0% in children 9-12 y
old to 6.9% in children 17-20 y old.
Exposure to HCV through blood
transfusion, tattooing or IDU
accounted for 72% of cases.
Cameroon Ngatchu et al
(1992)
Not reported Students from 6 primary schools
in the city of Kumba
696 4-14 EIA1 14.5 HCV antibody prevalence increased
with age, from 6.6% in children 4-6 y
old to 17.5% in children more than 11
y old
Canada Blumberg et al
(1995)
Mar. 1990-
June 1994
People with haemophilia
diagnosed and reported to the
national registry within 2 y of the
study (March - June 1992)
884 Not reported EIA2 63.3 Prevalence of HCV antibody
increased with age, from 2% in
children < 5 y old, to 27% in children
5-9 y old and to 74% in people 10 y or
olderTable 48 continued overleaf
Country Reference Year of
enrolment
Sample No. of
children
Age at
enrolment
(years)
Screening
assay
HCV
antibody
(%)
Comments
Egypt Khalifa et al
(1993)
Nov. 1990-
Feb. 1991
Consecutive outpatients with
haematological disorders
Consecutive hospitalised patients
with non-haematological disorders
Consecutive outpatients with
acute illnesses
84
84
84
mean 7.0
s.d. 3.7
mean 7.4
s.d. 4.0
mean 6.2
s.d. 3.7
EIA2 54.8
0.0
0.0
HCV antibody was associated with the
duration of illness, number and
volume of transfusions, higher ALT
level (after exclusion of cases of acute
leukemia), clinical jaundice
France Dussaix et al
(1993)
Mar. 1986-
Mar. 1991
Children surviving orthotopic liver
transplantation
149 Not reported EIA1+2 9.4 6 children (4%) had HCV infection
prior to liver transplantation and 8
(5.4%) were diagnosed with HCV
infection following liver transplantation
Italy Lai et al (1993) Jan. 1980-
Dec. 1987
Children newly diagnosed with
thalassemia major with no history
of blood transfusion or of liver
disease and no evidence of
exposure to HBV followed
prospectively
135 mean 2.4
s.d. 1.9
EIA1+2 55.6 HCV antibody was detected in 90% of
children with NANBH.
Risk of NANBH was associated with
the number of units of blood
transfused.
Italy Resti et al (1992) Not reported Children with beta-thalassaemia
major who had been transfused
78 mean 7.7
s.d. 3.1
EIA1 56.4 HCV antibody prevalence in acute and
chronic NANBH was 83.3 and 82.9%,
respectively
Italy Bortolotti et al
(1992)
1976-1990 Children with chronic NANBH and
without underlying conditions,
seen at 4 paediatric centres
33 mean 5.6  s.d.
3.9
EIA1 48.5 HCV antibody was detected in 88% of
children with parenteral exposure and
in 33% of children without parenteral
exposureCountry Reference Year of
enrolment
Sample No. of
children
Age at
enrolment
(years)
Screening
assay
HCV
antibody
(%)
Comments
Italy Romano et al
(1994)
May 1987-
Nov. 1989
Students in public and private
schools in 2 northern cities, 2
southern cities and in Sardinia
2,749 3-19 EIA2 0.36 HCV antibody prevalence was 0.2% in
the northeast and 0.6% in Sicily and
Sardinia
Italy Bortolotti et al
(1994b)
1991-93 Children with chronic NANBH and
without underlying systemic
conditions, seen at 7 paediatric
centres
43 mean 8.5
s.d. 4.1
EIA2 74.0 HCV antibody detected in 93% of
children with parenteral exposure and
in 40% of children with unknown
exposure
Italy Iorio et al (1993) 1987-91 Children with chronic NANBH and
without underlying systemic
conditions
33 mean 3.6 RIBA2 39.4 69% (9/13) of children with HCV
antibody were considered to have had
parenteral exposure and 23% (3/13)
were sporadic cases
Italy Locasciulli et al
(1991)
1969-89 Children with chronic liver disease
who had completed chemotherapy
for leukemia
50 mean 5.8 EIA1 46.0 Persistent HCV antibody was
associated with persistent elevation of
serum glutamic pyruvic transaminase
Italy Arico et al (1994) 1977- 92 Children who had completed
chemotherapy for acute
lymphoblastic leukemia
102 mean 10.5 EIA-2 29.4 14 children without detectable HCV
antibody had HCV RNA, resulting in a
prevalence of HCV exposure of 43%
Italy Dibenedetto et al
(1994)
Jan. 1986-
Sept. 1992
Children diagnosed with acute
lymphoblastic leukemia in first
continuous complete remission
90 0-14 EIA2 32.2 Almost all children with HCV antibody
(97%) had abnormal liver function test
results, 5 (17%) had evidence of
chronic liver disease
Japan Tanaka et al
(1992)
1986-1990 Primary and junior high school
students in Matsumoto City
1,442 6-15 EIA1 0.0 No cases of elevated serum
transaminase
Japan Matsuoka et al
(1994a)
Jan. 1983-
June 1992
Children in Tokushima prefecture
who received a blood transfusion
during open heart surgery
226 2-19 EIA2 9.7 HCV antibody was detected only in
children (22/161, 13.7%) who received
blood or blood products prior to the
introduction, in November 1989, of
screening for HCV antibody
Taiwan Ni et al (1994a) Oct. 1990-
Dec. 1992
Children transfused during open
heart surgery, enrolled
retrospectively
Children transfused during open
heart surgery, enrolled
prospectively prior to the
introduction of HCV-antibody
screening
Children transfused during open
heart surgery, enrolled
prospectively after the
introduction, in July 1992, of HCV-
antibody screening
196
38
56
mean 4.9
s.d. 3.1
mean 5.4
s.d. 4.0
Not reported
EIA2 4.1
5.3
0.0
Of 8 children with persistent HCV
antibody, ALT levels returned to
normal over 2 y of follow upCountry Reference Year of
enrolment
Sample No. of
children
Age at
enrolment
(years)
Screening
assay
HCV
antibody
(%)
Comments
Taiwan Chang et al
(1993)
Not reported Infants and children with various
liver diseases
Apparently healthy infants and
children
195
748
<15
<1-15
EIA2 1.0
0.1
HCV antibody prevalence was 4.4%
(1/23) in children with HCC and 16.7%
(1/6) in children with NANBH
Taiwan Hsu et al (1991) July 1979-
June 1989
Children with chronic NANBH 27 median 5.4 EIA1 36.4 A higher proportion of cases with a
history of transfusion and with chronic
NANBH had HCV antibody
United
Kingdom
Myers et al
(1995)
1976-91 Children from Nottingham and
Sheffield with haematological
malignancy transfused at a single
transfusion centre
98 mean 10.5 EIA2 1.0 At 9 y posttransfusion, the only case
of HCV antibody was positive for HCV
RNA and had elevated
transaminases. Liver biopsy indicated
mild hepatitis
USA Nowicki et al
(1994)
Not reported Children surviving orthotopic liver
transplantation for at least 6
months
62 mean 5.3 EIA2 5.1 At a median of 3 y following
transplantation, HCV RNA was
detected in 6.2% of children
USA Jonas et al (1992) Not reported Patients undergoing either
haemodialysis or peritoneal
dialysis at the Jackson Memorial
Medical Centre, Miami
27 mean 20.9 EIA1 18.5 HCV antibody was detected only in
patients who had been transfused.
HCV antibody was associated with
older age (25.9 vs 19.7), longer
duration of haemodialysis and number
of units of blood transfusedTable 49  Natural history of hepatitis C virus infection in children
Country Reference Year of
enrolment
Sample Number of
children
Age at
enrolment
(years)
Number of
months of
follow up
Outcome
Italy Bortolotti et al
(1993)
1983-93 Children with chronic HCV infection and
without underlying systemic diseases
37 Not reported mean 40.8
s.d. 38.4
10% were symptomatic, 3% had ALT
normalisation, 0% developed liver
failure
Italy and Spain Bortolotti et al
(1994a)
1978-82 Children with chronic HCV infection and
without underlying systemic conditions,
identified incidentally on routine
screening
77 mean 4.4
s.d. 2.9
Posttransfusion
mean 81.6
s.d. 37.2
Sporadic
mean 73.2
s.d. 46.8
Most children remained
asymptomatic during follow-up. Liver
histology was consistent with inactive
liver disease in > 60%. Severe active
hepatitis and cirrhosis were
infrequently associated with chronic
HCV infection.
Italy Lai et al (1993) Jan 1980-Dec
1987
Children newly diagnosed with
thalassaemia major with no history of
blood transfusion or of liver disease and
no evidence of HBV, followed
prospectively
135 mean 2.4
s.d. 1.9
mean 69.6
s.d. 24.0
Of 83 children with NANBH, 57
developed chronic NANBH. HCV
infection was documented in 53 of
these children.
Italy Resti et al
(1992)
Not reported Children with beta-thalassaemia who
had been transfused (35 followed from
birth, 43 presented at mean age 7.7 y)
78 mean 7.7
s.d. 3.1
mean 158
s.d. 36
No difference was found between
cases of chronic NANBH with respect
to HCV infection status. 30% of
children had cirrhosis
Japan Inui et al (1994) Not reported Children with HCV infection and without
other causes of liver disease
25 mean 9.1 mean 44.2 17 children with malignant disease or
aplastic anaemia had a higher grade
of histological  activity in the liver
compared with 8 children without
malignant disease. However, all
children with malignant disease had
been treated with multiple
transfusions and cytotoxic and
immunosuppressive agents.
Japan Matsuoka et al
(1994a)
From 1991 Children transfused in open heart
surgery
29 mean 10.2
s.d. 4.4
mean 85.2
s.d. 33.6
13 children had chronic HCV
infection (elevated ALT for > 6
months following surgery and
elevated ALT within the last 2 y of
follow-up) and 6 had CAH, 6 had
CPHCountry Reference Year of
enrolment
Sample Number of
children
Age at
enrolment
(years)
Number of
months of
follow up
Outcome
Taiwan M.-H. Chang et
al (1994)
Prior to July
1992
Children at risk of HCV infection due to
blood transfusion for congenital
haemolytic anaemia, blood transfusion
for open heart surgery or children of
women with chronic HCV infection
88 < 18 36 During follow-up, 10 children
acquired HCV infection (5 with
haemolytic anaemia, 2 with open
heart surgery and 3 children of HCV-
infected mothers) and 5 had an
episode of acute hepatitis. 6 children
progressed to chronic HCV infection.Table 50  Effect of interferon treatment in children with chronic infection with hepatitis C virus
Country Reference Year of
enrolment
Sample No. of 
childre
n
Age at
enrolment
(y)
Treatment Outcome
Italy Bortolotti et al
(1995)
Apr 1991-
Jun 1992
Children with chronic HCV infection
without underlying systemic diseases,
metabolic liver disorders, HBV or HIV
infection and without a history of
immuno-suppressive or antiviral therapy
27 2-14 Random assignment to treatment
(5 MU/m
2 recombinant IFN-α2b 3
times weekly for 12 months) or no
treatment
10 children completed therapy. By the
end of therapy, all had normal ALT and
9 had undetectable HCV RNA. Of 9
children followed for 12 months after
therapy, 5 maintained normal ALT and
undetectable HCV RNA. Of 13
untreated children, 1 had ALT
normalisation and none were HCV-
RNA negative.
Japan Komatsu et al
(1996)
Not reported Children with chronic HCV infection who
had completed treatment for acute
leukaemia
13 5-17 Natural IFN-α (0.1 MU/kg) daily
for 2 weeks, then 3 times per
week for an additional 22 weeks
Complete response (normalisation of
ALT and undetectable HCV RNA
within 6 months of cessation of
therapy, with ALT remaining normal for
at least 6 months thereafter) in 38%
(5/13), partial response (ALT
normalisation with detectable HCV
RNA) in 1 case and no response
(persistence of abnormal ALT values
for at least 12 months after cessation
of therapy) in 54% (7/13)
Spain Ruiz-Moreno et al
(1992)
Not reported Children with chronic  HCV infection
and without metabolic liver disorders,
HBV or HIV infection. Source of HCV
infection was unknown in 83%.
12 1.5-15 3 MU/m
2 recombinant IFN-α 3
times per week for 6 months
11 children completed therapy. At the
end of therapy, 36% (4/11) had normal
ALT levels and 8 had undetectable
HCV RNA. At 24 months, 45% (5/11)
had normal ALT levels.147
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